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Abstract 
 
  Cancer is one of the greatest causes of death in modern societies, affecting over 
350,000 new cases every year in the UK. Although there are currently more than 
100 different cancer types, breast and prostate cancer remain the most common 
types for women and men respectively. A number of different cancer types follow, 
with bladder cancer being the ninth most significant type, accounting for 3% of 
the total new cases. 
  The currently employed techniques aim to diagnose the cancer at an early 
stage, where the symptoms are easier to be treated and the disease more likely 
to be cured. A further issue is that many cancers diagnosed will not affect a 
patient in their lifetime. The current gold standard for cancer diagnosis, biopsy 
followed by histopathology, is an invasive, restrictive technique and the screening 
tests suffer from low specificity, the need for a novel diagnostic concept is vital. 
Furthermore, the current clinical approach does not identify those patients most 
at risk of advancing disease. A promising approach consists of molecular 
vibrational spectroscopy techniques, which are based on the interactions of light 
with matter. One of these is Raman spectroscopy, a technique with wide 
applications in research and industry, which has the advantage of being non-
invasive and chemically highly specific.       
  In this thesis we explore the potential of a group of minimally invasive diagnostic 
techniques, based on Raman scattering, for prostate, breast and bladder cancer. 
In the case of the two most prevalent types of cancer, prostate and breast cancer, 
deep Raman spectroscopy has been employed to study the origin of Raman 
scattering (Chapters 5 and 6) in animal tissue and tissue phantoms, containing 
highly scattering materials resembling suspicious features found in tissues 
(calcifications). The spatial distribution of the Raman signal through the sample 
volume has been studied in relation to the optical properties and the composition 
of the sample, showing that a couple of transmission measurements would 
potentially cover the measuring volume of prostate of typical dimensions. Deep 
Raman measurements were also extended to animal and human tissue samples, 
in order to investigate the feasibility of collecting Raman scattering from human 
prostate tissue and its major tissue components (Chapter 6). 
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  Further improvements on these measurements were attempted by introducing 
the ‘’photon diode’’ element (Chapter 7) in order to achieve signal enhancement, 
which proved to be in the range of ×1-2.4, depending on the optical properties of 
the tissue and the depth of the probing element. The same ‘’photon diode’’ 
concept was utilised to attempt depth prediction of a calcification feature in 
sample volume (Chapter 8).  
  Regarding bladder cancer, the minimally invasive approach adopted was 
Raman spectroscopy on urine samples, rather than deep Raman spectroscopy. 
Raman microscopy was employed in order to discriminate pathological features 
of bladder cancer between healthy and malignant urine samples. For that reason, 
the potential differences in urea’s distribution and interactions in urine from 
healthy and patients with bladder cancer were studied, resulting in promising 
diagnostic values (73% sensitivity, 80% specificity). 
  The results presented in this thesis are expected to lead to a better 
understanding of the Raman scattering signals collection through biological 
tissues and help in this way the future design of Raman instruments aiming to 
target disease specific signals. This study shows promise for future application of 
Raman spectroscopy and paves the way towards the future integration of Raman 
spectroscopy in a non-invasive cancer diagnosis. 
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1 Chapter 1: The disease 
 
1.1 Introduction 
 
  Cancer is one of the greatest death causes in modern societies, affecting over 
14 million people worldwide (statistics 2014). There are currently more than 100 
different cancer types, but only four of them (lung, breast, bowel and prostate 
cancer) account for 4 out of 10 cases diagnosed worldwide1.  
  Although mortality for the most common types of cancer has decreased the last 
few years, the number of cancer cases newly diagnosed continues to rise every 
year. Only in 2014 in UK, there were 296,863 cancer cases registered, a number 
which accounts for 813 cases per day2.  
  Between the most common risk factors for cancer is smoking, lack of physical 
activity, alcohol, unhealthy diet, obesity and several infections1. In most cancer 
cases, the combination of genetics, age and risk factors result in an incontrollable 
cell growth. This is initiated with the mechanism of carcinogenesis which is the 
process by which normal cells are transformed into cancer cells. This process is 
characterized by a group of cellular and genetic changes that eventually 
reprogram a cell to undergo uncontrolled cell division and thus forming a 
malignant mass. Many theories about cancer development have been described 
in the latest decades and it applies to all cancer types. 
  As a general concept through the years, more men are diagnosed with cancer 
than women. However, the most frequently diagnosed cancer for men remains 
prostate cancer and for women breast cancer (Fig.1.1). Due to this, prostate and 
breast cancer are the two main types this study aims at. For the needs of our 
study, bladder cancer is mentioned less extensively in the last part of this thesis. 
In this chapter we will provide a theoretical background on the statistics, 
physiology and cancer pathology of all three types of cancers. This knowledge 
will support the comprehension of the results presented in the last few chapters 
of the thesis. 
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Figure 1.1:The number of cancer registrations by the 24 major sites of the 
body, England, 20143. 
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1.2 Prostate cancer  
 
1.2.1 Statistics (incidence, mortality, survival rates) 
 
  Prostate cancer is nowadays the most common male cancer in UK (2010), as a 
quarter of all new cases of cancer diagnosed in UK men are prostate cancers. 
There are more than 40,000 new cases every year (47,000 only in 2013) and 
54% of men who are diagnosed are over 70 years old4. Only 1 in 14 men who 
are diagnosed with prostate cancer die from the disease (10,837 deaths in 2012). 
Over the last 20 years, the number of men who have been diagnosed with 
prostate cancer has increased. However, the mortality only slightly decreased, 
which means that many of those men may not have benefitted from that diagnosis 
(fig. 1.2). 
 
Figure 1.2: Prostate cancer incidence and mortality rates, England, 1971-
20105. 
 
  The prevalence of this disease is so high that it could be considered a normal 
age related phenomenon6. On the whole, 70% of men over 80 years have 
histological evidence of cancer in the prostate7. Therefore, a very high number of 
men diagnosed with prostate cancer die with the disease, but not from it. 
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1.2.2 Anatomy and physiology of prostate gland 
 
Prostate location and function 
In a healthy adult man, the prostate gland has the size of a walnut (weighing 20-
40g) and the shape of an inverted cone. It is located within the pelvis, with its 
base proximally at the bladder neck and its apex distally at the urogenital 
diaphragm. It lies anterior to the rectum, with the urethra running through its 
centre (Fig. 1.3) and serving as an important reference landmark8.  
 
 
Figure 1.3: Side view of the prostate9 
 
  The prostate gland has multiple functions as it helps to control the flow of urine 
and in the same time secretes fluid that nourishes and protects sperm. During 
sexual activity, the seminal vesicles, which are attached to the prostate produce 
a protein that mixes with prostatic fluid which forms semen. The tubes (vasa 
deferentia) from the testicles carry sperm up to the prostate where sperm is mixed 
with the seminal vesicle and prostatic fluids. During ejaculation, the prostate 
squeezes this fluid into the urethra and therefore it is expelled. 
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Physiology of the prostate gland 
 
  In 1930, Lowsley described human prostate gland as a composition of diverse 
lobes: 5 main (posterior, middle, anterior and two lateral) and 2 smaller which do 
not exist in adults10. Although that was a very useful topographic description, the 
specific separation was not consistent histologically. Fifty years later J. E. McNeal 
described a different concept which was based on the separation of prostate into 
zones rather than lobes11-13. This description consists of the most widely 
accepted concept at the moment (Fig. 1.4). 
 
Figure 1.4: Zonal anatomy of the normal prostate as described by McNeal14. 
 
  The peripheral zone comprises all the prostatic glandular tissue at the apex as 
well as all of the tissue located posteriorly near the capsule (Fig. 1.5). The 
transition zone comprises only 5-10% of the glandular tissue in the young male 
and consists of two equal portions of glandular tissue lateral to the urethra in the 
midgland. The central zone, a cone-shaped area of the adult gland, forms part of 
the base of the prostate and it is traversed by the ejaculatory ducts. The anterior 
fibromuscular stroma (AFMS) forms the convexity of the anterior external surface. 
The apical half of this area is rich in striated muscle, which blends into the gland 
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and the muscle of the pelvic diaphragm. Toward the base, smooth muscle cells 
become predominant, blending into the fibers of the bladder neck15. 
 
Figure 1.5: Anatomy of the prostate8. 
 
Cell types in prostatic gland  
 
  At histological level, the two generic categories of prostate cell types are 
epithelial and stromal cells. The stromal to epithelial ratio tends to be higher in 
healthy human prostate compared to cancerous16. The epithelial cell layer forms 
glands which are composed of differentiated basal, secretory luminal, transit-
amplifying and small neuroendocrine cells17. The luminal cells are the major cell 
type in prostate and form a layer over the basal layer (Fig. 1.6). Contrary to basal 
cells, the luminal ones are androgen dependent. They also produce the prostate 
specific antigen (PSA) and are terminally differentiated18. The stroma surrounds 
the epithelial layer forming a boundary on the periphery of the prostate gland. The 
stromal layer contains muscle cells and fibroblasts19. Additional prostate 
elements include vascular cells, nerve cells, basement membrane plus tissue 
matrix. 
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Figure 1.6: Prostatic cellular compartments and different prostatic cells18. 
 
1.2.3 Cancer pathology and grading  
 
  During prostatic carcinogenesis, both prostatic epithelium and smooth muscle 
dedifferentiation is promoted due to androgen-mediated signal loss between the 
two different types of cells19. 
  Most prostate carcinomas are detected in the peripheral (75%), but some of 
them (20%) arise from the transitional zone of prostate gland20-23. Cancer areas 
in the transition zone tend to be characterized by large irregular glands with tall 
columnar cells, pale-to-clear cytoplasm and basally located nuclei, whereas 
prostate cancer in the peripheral zone show small round glands with cuboidal 
cells, amphophillic cytoplasm and nuclei located to the centre24 (Fig. 1.7). On the 
other hand, anterior fibromuscular is not a usual layer for detection of pathological 
lesions mainly due to its lack of glands25. 
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Figure 1.7: Prostatic adenocarcinoma of different zonal origins. (a) Mid-prostate 
transverse section with two separate foci of prostatic adenocarcinoma on 
transition (left) and peripheral (right) zone (b) Prostatic adenocarcinoma in the 
transition zone (c) Prostatic adenocarcinoma in the peripheral zone24. 
 
Prostate calcifications 
  A common finding during histological assessment of prostate gland is the 
presence of calcifications, especially in older ages (over 50). Although the 
mechanism of calcification formation is not fully understood yet, it is believed that 
they are a result of altered secretions of the luminal cells in the gland, leading to 
clogged ducts and inflammation26. These secretions can be either related to the 
production of corpora amylacea27 in benign glands or crystalloids or mucin in 
cancerous glands28. However, some of these processes are pathophysiological 
phenomena occurring during the aging process29.  
  The pathogenesis of prostatic calcifications still remains unclear. Their size, 
number or location does not seem to be related to their malignancy27. Many 
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reports support their association with inflammation of the prostate (prostatitis)30 
or bacterial infection31. Most of the calcifications in prostate are located in the 
transition zone (77.7% of the total calcifications detected)32. This supports their 
relationship to benign prostatic hyperplasia (BPH), since the majority of BPH arise 
from this zone33. However, there is also evidence that prostate calcifications can 
occur in direct association with prostatic adenocarcinoma32, although less 
frequently.  
 
                  
Figure 1.8: Patterns of calcification associated with benign hyperplasia (A, B 
and C left) and prostatic adenocarcinoma (A, B, C and D right)32. 
 
Gleason grading system 
  In order to assess the stage and the progression of prostate cancer, Dr Donald 
F. Gleason developed the Gleason grading system in 1966, based on the study 
of nearly 3,000 patients’ biopsies. Nowadays, it is the strongest prognostic factor 
of a patient’s time to progression. The natural history of the disease correlates 
well with its histological grade, assessed by Gleason score.  
  Gleason grading system is based entirely on the histological pattern of 
arrangement of carcinoma prostate cells in H&E-stained sections, observed 
under low magnification. The Gleason scoring system is defined by a scale of 1 
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to 10. The five basic grade patterns which are used to generate a histological 
score are shown in Figure 1.9. 
 
Figure 1.9: Gleason grades basic patterns34. 
 
 
  The five basic patterns above are used to generate a histological score, which 
can range from 2 to 10, by adding the primary grade pattern and the secondary 
grade pattern. The primary pattern is the one that is predominant in area (most 
common cell pattern), by simple visual inspection. The secondary pattern is the 
second most common cell pattern. In that way, the primary pattern is added to 
the secondary grade to arrive at a Gleason score. Consequently, the Gleason 
score possibilities range from 2 (1 + 1) up to 10 (5 + 5). If only one grade is in the 
tissue sample, that grade is multiplied by two to give the score34, 35.     
  In general, low-grade cancers (Gleason 6 or less) are typically small and slow- 
growing, confined to the prostate gland. High-grade cancers (Gleason 8 or 
more) grow faster and frequently invade through the prostate capsule, can 
directly infiltrate adjacent organs (seminal vesicles, bladder, rectum), and may 
disseminate to regional lymph nodes and by vascular invasion typically to bone, 
but also occasionally to lung and liver36.  
  Although the Gleason system is now widely accepted, there are several issues 
concerning it as a prognostic factor. Most notably Gleason grading has inherent 
sampling errors since it is observer dependent and may vary depending on the 
level of experience15. Other issues that often arise are specimen being 
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undergraded37 or inability of Gleason score to represent efficiently prostate 
cancer heterogeneity38. 
    
1.3 Βreast cancer  
 
1.3.1 Statistics (incidence, mortality, survival rates) 
 
  Breast cancer is the most frequently diagnosed female cancer and the leading 
cause for cancer mortality in women worldwide, accounting for 1.38 million of 
newly diagnosed cancer cases and 14% of the total cancer deaths in 200839. In 
UK, breast cancer is the most common type of cancer, with around 53,400 cases 
diagnosed only in 2013. Almost half (46%) of breast cancer cases are diagnosed 
in females over 65, whereas the disease seems to be less common in the most 
deprived areas40. 
  The risk factors related to breast cancer in developed countries are reproductive 
and hormonal factors, tobacco, alcohol and lack of physical activity41. It has been 
estimated that exposure to modifiable lifestyle and environmental factors 
(alcohol, obesity, physical activity) is linked to at least 17% of female breast 
cancer cases in UK (2010)42. 
  Although the last twenty years, the survival rates have risen by 40% (Fig. 1.10) 
due to early detection and improved treatment, the mortality rates still remain 
high. In 2012, around 11,600 women died from breast cancer. This number 
accounts for 32 women every day40.   
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Figure 1.10: Female breast cancer in England: Incidence and mortality41. 
 
  Male breast cancer is far less common, with 1 in 870 men to be diagnosed with 
the disease during their lifetime (the equivalent frequency for women is 1 in 8)40. 
This accounts for 0.26% of the overall breast cancer cases41. 
 
1.3.2 Anatomy and physiology of breast  
 
Breast location, function and physiology 
  The breast is a gland existing in both men and women, although more dominant 
on the latter. The female breast develops at puberty and changes through life in 
response to hormonal stimulation. Each breast lies over a pectoral muscle and 
consists of glandular, fatty and connective tissue. The anatomical structure of the 
breast reflects its function which is the production of milk. 
  In the adult woman, the mammary gland is composed of approximately 15-20 
lobes43, supported and held together by a loose mesh of fibers, called Cooper’s 
ligaments44. Each lobe is divided into multiple lobules, which consist of clusters 
of alveoli containing mammary secretory epithelial cells45. These cells, under the 
influence of hormone prolactin, are producing milk which is transferred to the 
nipple through small tubes, the lactiferous ducts (Fig.1.11). While the glands are 
dispersed through the adipose tissue, which consists the main volume of the 
breast, a thin layer of connective tissue (or fascia) surrounds it on the outside.   
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Figure 1.11: During lactation, milk moves from the alveoli through the 
lactiferous ducts to the nipple. 
 
  Other structures found in the breast are sensory nerves, blood vessels which 
are connected to the internal mammary artery and lymph vessels. The lymph 
vessels are a part of the lymphatic system, a vital part of the immune system 
useful for fighting infections. The lymph vessels circulate lymph fluid away from 
the breast and they drain it into small masses of lymphatic tissue in the area 
around the breast, the lymph nodes.  
 
Cell types in breast 
  Breast tissue is composed of a number of different cell types. The ductal network 
of the gland is made of epithelial cells, whereas the fat area where the ducts are 
embedded, consists of adipocytes. In the gland, there is also a number of 
vascular epithelial cells, making the blood vessels, stromal cells (including 
fibroblasts) and immune cells46. The main lactiferous ducts are lined by stratified 
squamous epithelium near the nipple and two-layer cuboidal epithelial cells in 
greater depths43. The rest of the duct system consists of two different types of 
epithelium: one layer of luminal epithelial and one layer of basal/myoepithelial 
Connective tissue (fascia) 
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cells47. The luminal epithelium forms the ducts, whereas in the alveoli, the 
myoepithelial cells surrounds the cuboidal (also luminal epithelial) cells in order 
to help them secrete milk by contracting. The two different types of epithelium 
cells form a double layer which is embedded within the fatty stroma46. 
  The mammary stroma consists of a number of components, such as adipocytes, 
pre-adipocytes, fibroblasts, blood vessels, inflammatory cells and extracellular 
matrix (ECM). The ECM contains myoepithelial basement membrane and 
connective tissue and its role is very important since it allows communication 
between stromal and epithelial cells48. Disruption of this communication can 
promote breast cancer as we will see in the following section. 
  
 
1.3.3 Cancer pathology and grading  
 
  Breast cancers can be divided into two groups depending on their origin: 
carcinomas which arise from the epithelial component and the sarcomas that 
originate from the stromal component of the breast. Carcinomas is the most 
frequently diagnosed type of breast cancer, with sarcomas to account for less 
than 1% of the total cases. Carcinoma can be either in situ or invasive, depending 
on if the abnormal cells have expanded outside of the mammary lobules and 
ducts. In situ carcinomas, which have not metastasized outside of the milk ducts 
yet, are believed to be the precursors of the invasive type49. 
  Breast carcinomas can also be classified as ductal and lobular depending on if 
they have developed in the breast ducts or lobules respectively (Fig.1.12). The 
most frequently diagnosed invasive breast carcinoma is the invasive (or 
infiltrating) ductal carcinoma and represents 75-80% of the total invasive breast 
cancer cases. The second most frequently observed type is the infiltrating lobular 
carcinoma (10-15%)50. Although implied by the name, both of the carcinoma 
types have been suggested to originate in the terminal ductal-lobular unit51.  
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Figure 1.12: Types of breast carcinomas: Ductal Carcinoma and Lobular 
Carcinoma52. 
 
  Clinically, human breast cancers are also classified with three markers: estrogen 
receptor (ER+), progesterone receptor (PR+) and human epidermal growth factor 
receptor 2 (HER2+)53. These three markers can classify many breast tumours into 
one of the three molecular categories based on the presence or absence of the 
specific receptors on the breast cells: luminal (ER/PR positive), HER2 (HER2 
positive), or basal-like (ER/PR negative and HER2 negative)54. Depending on the 
different subtype of the cell receptors, the breast tumour can be approached 
using a more specific treatment.  
 
Breast calcifications  
  A number of primary breast cancer cases (30-50%) give evidence of calcified 
formations in the mammary gland, which are detectable with mammography and 
in many cases are the only evidence of malignancy before cancer metastasis55. 
These calcifications are believed to be a product of cell mineralisation 
mechanism56 and appear in different forms (clustered, linear or scattered)57 and 
shapes58. Their chemical composition also varies and can be either calcium 
oxalate (type I) or calcium phosphate (type II)- mainly hydroxyapatite (HAP). 
Calcium phosphate crystals are basophilic, whitish, generally ovoid or fusiform, 
and non-birefringent under polarized light, whereas calcium oxalate crystals are 
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of amber colour, partially transparent and polyhedral in shape59 (Fig. 1.13). The 
different types of crystals found in the breast appear to be directly related to their 
pathology. Calcifications with the colourless structure of calcium oxalate are not 
associated with carcinoma or epithelial hyperplasia but are only found in benign 
cysts or at most in non-invasive lobular carcinomas in situ60, whereas 
calcifications consisting of calcium phosphates and mainly HAP, can indicate 
either benign or malignant lesions and are a result of cellular degeneration or 
necrosis61. Regarding HAP calcifications, it has been also suggested that they 
contain a higher amount of calcium carbonate when they are formed in malignant 
ducts rather than in healthy ones62, 63.   
 
Figure 1.13: Type I (A) and II (B) breast micro-calcifications observed in 
sclerocystic mastopathy and adenocarcinoma respectively59. 
 
 
1.4 Bladder cancer  
 
1.4.1 Statistics (incidence, mortality, survival rates) 
 
  Bladder cancer was the ninth most common diagnosed cancer worldwide in 
2012 with 430,000 new cases diagnosed64. In UK, the disease seems to follow 
the same trend65, rated as the ninth more frequently diagnosed cancer in 2013, 
with 28 newly diagnosed cases per day in 201366. Mortality rates have generally 
decreased the last twenty years in all of the age groups under 8566. This is due 
to reductions in both smoking prevalence and occupational exposures known to 
cause bladder cancer67.  
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  Bladder cancer affects men three to four times more frequently compared to 
females, with a 14-fold variation in incidence internationally39. The disease is both 
sex and age-related (Fig.1.14), but it is also directly linked to many avoidable risk 
factors, such as smoking which is related to 37% of bladder cancer cases in UK66.  
 
 
Figure 1.14: Average Number of New Cases Per Year and Age-Specific 
Incidence Rates per 100,000 Population, UK68. The blue and red curve show 
how the diagnosis rate changes with age for men and women respectively, 
whereas the bars indicate the number of cases for each age group.  
 
   Different types of bladder cancer can be related to different risk factors. Studies 
have shown that the majority of squamous cell carcinomas (2% of total bladder 
cancer cases) are associated with bladder infection specifically caused by the 
parasite Schistosoma69. On the other hand, transitional cell carcinomas (TCC) 
which represent the majority of bladder cancer cases (93%), are associated with 
smoking39. Another major risk factor for bladder cancer is occupation and 
exposure to certain chemicals69. 
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1.4.2 Anatomy and physiology of bladder 
 
  Urinary bladder is a pear shaped organ located in the pelvis, just behind the 
pelvic bone, which stores all the urine produced by the kidneys and transferred 
there via two ureters, one for each kidney. Once the urine is stored there, they 
pass through the urethra, located at the neck of the bladder, and exit the body 
(Fig. 1.15).  
 
Figure 1.15: Bladder location and function70. 
 
  Many tiny folds (rugae) line the inner surface of the bladder when it is empty of 
urine. When the bladder fills up, these folds disappear and the wall expands in 
such a way that it can store up to 500-600 ml of urine in a healthy person.   
  A healthy bladder is composed of multiple layers: urothelium, lamina propria, 
detrusor muscle and perivesical soft tissue (Fig. 1.16). Urothelium is the 
innermost lining of the bladder and consists of transitional epithelial cells which 
provide elasticity and protection from extreme pH urine to the bladder. Below the 
urothelium lies the lamina propria, a layer of connective tissue rich in blood 
vessels and nerves which supports and controls the bladder wall. The next layer 
is detrusor muscle which provides the bladder with the ability of contracting during 
urination in order to expel urine from the body. The detrusor muscle also forms 
the internal urethral sphincter, responsible for keeping the urine into the bladder. 
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The outer layer is perivesical soft tissue and consists of fat, fibrous tissue and 
blood vessels70.   
 
 
Figure 1.16: Bladder wall structure71. 
 
 
  Histologically, there are three distinct layers identified in the bladder wall: the 
mucous membrane (mucosa) which consists of the transitional epithelial cells and 
the submucous coat (lamina propria), the submucosa, the muscular layer 
(detrusor muscle) and the adventitia, which is the outermost loose connective 
tissue72. 
 
1.4.3 Cancer pathology and grading  
 
  Most bladder cancers originate from the cells on the inner layer of the bladder, 
the transitional epithelium. Transitional cell carcinoma (TCC) represents the 90% 
of the total bladder cancer cases diagnosed. Other bladder cancer types are 
squamous cell carcinoma and adenocarcinoma, with the latter to originate from 
cells that make up mucus-secreting glands infections. There is also papilloma, a 
type of benign urothelial neoplasm of low malignant potential.  
  Depending on the aggressiveness of the bladder cancer, it can be in situ or 
invasive. Invasive cancers start by penetrating through the layer of lamina propria 
and in a second stage they become ‘’muscle-invasive’’ by travelling through the 
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detrusor muscle layer. The cancer can also develop outside of the bladder wall, 
invading into lymph channels or blood vessels. In that case we have metastatic 
cancer and it can travel to additional organs throughout the body. The invasive 
nature of the bladder cancer can be assessed more systematically with the TNM 
(tumor-node-metastasis) classification system. This however is out of the scope 
of this chapter. 
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2 Chapter 2: Diagnostic techniques 
 
2.1  Introduction 
 
  A number of techniques are currently employed for cancer diagnosis at an early 
stage, where the symptoms are easier to be treated and the disease more likely 
to be cured. Common diagnostic techniques and treatments for prostate, breast 
and bladder cancer are presented in this chapter. Between several diagnostic 
methods, biopsy followed by histopathology, the gold standard in cancer 
diagnosis, and complementary imaging techniques are explored in terms of 
advantages and limitations. The background information presented in this 
chapter will help us evaluate the results and conclusions drawn in the following 
chapters of the thesis. 
 
2.2 Prostate cancer  
 
2.2.1 Current diagnostic techniques  
 
  Despite its ambiguous nature, the most commonly used method for prostate 
cancer screening is currently the PSA test. Once cancer is suspected, clinical 
examination (DRE) and biopsy, which is currently the gold standard, will be also 
performed. Depending on the cancer stage, imaging techniques might also be 
applied in order to check for metastasis throughout the body. 
 
PSA test: The most common test provided for prostate cancer screening. PSA 
(Prostate Specific Antigen) is a glycoprotein enzyme73 secreted by both normal 
and cancerous prostate cells and the test is measuring the PSA levels in patient’s 
blood. Elevated PSA blood levels are expected to be connected with raised 
prostate cancer risk. However, although raised PSA serum levels (usually above 
4 μg/l) are  an indication for prostatic biopsy, this hypothesis may be misleading 
as they may be also increased in the absence of prostate cancer, due to a non-
cancerous enlarged prostate (benign prostatic hyperplasia-BPH) or prostatitis 
(inflammation of the prostate gland)7. Statistically, in 85% of the cases an 
elevated PSA value is due to BPH and only in 12-15% is due to cancer.  
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  Another limitation of PSA test is that it can be age and ethnicity-dependent and 
also lead to high rate of false positive results, resulting in overdiagnosis and 
overtreatment. Rates of overdiagnosis vary between different studies and have 
been shown to range between 29% and 44% for different ethnicities74. In the past, 
two major landmark trials studying the effect of screening on prostate cancer 
mortality have taken place. European Randomized Study of Screening for 
Prostate Cancer (ERSPC) and US-Based Prostate, Lung, Colorectal and Ovarian 
(PLCO) Cancer Screening Trial have shown that increase of diagnosis with PSA 
screening did not have any important impact on mortality rates in any age group75. 
On the contrary, stress placed on the patients through overdiagnosis and 
overtreatment has increased. 
  Due to all these limitations, the application of PSA test can be controversial in 
some cases and its combination with other techniques is essential in order to 
accurately diagnose the disease. 
 
Digital rectal exam (DRE) and transrectal ultrasound (TRUS): The physician 
uses either a gloved, lubricated finger (Fig. 2.1) or a small probe (Fig. 2.2) 
respectively to examine the lower rectum and check for abnormalities on the 
prostate gland. During digital rectal examination the doctor is looking for 
abnormalities on the prostate through physical examination by assessing the size 
and the texture of the gland, whereas during transrectal ultrasound the probe 
releases sound waves which are used to create a video image of the prostate. 
Because DRE and TRUS are only able to detect gross morphological changes 
on the prostate gland but cannot determine if the changes are due to prostate 
cancer or to a non-cancerous condition, these techniques are prone to false 
positive results (up to 20%)76. It should be noted here that the ultrasound can 
additionally detect calcifications found in the prostate gland77, but without being 
able to confirm their malignancy.     
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Figure 2.1: Digital rectal exam for prostate cancer diagnosis78. 
 
 
Figure 2.2: Transrectal ultrasound (TRUS) for prostate cancer diagnosis79. 
 
Imaging techniques: Other techniques used in prostate cancer diagnosis are 
CT scan (Computed Tomography) and MRI (Magnetic Resonance Imaging). Both 
of them produce very detailed images of lymph nodes or other areas on patient’s 
body with the help of X-rays and strong magnetic field respectively. The images 
allow the doctor to check for swollen or enlarged lymph nodes, which might mean 
that prostate cancer has spread. A most recent advance is multiparametric MRI 
which seems to be a promising technique for detection, localization and 
characterization of prostate cancer, using parameters such as T1- and T2 -
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weighted images, dynamic contrast, diffusion weighting, and proton 
spectroscopy80. 
 
Biopsy followed by histopathology: The definite diagnosis and classification 
of prostate cancer is only confirmed after prostate biopsy (Fig. 2.3), which is 
currently the gold standard for prostate cancer diagnosis. A prostate biopsy may 
be performed at the same time as the ultrasound and most commonly through 
the rectum (transrectal method), through the skin between the scrotum and the 
rectum (perineal method) and through the urethra using a cystoscope 
(transurethral method). During the procedure, prostate gland tissue samples from 
different areas of the gland are removed with a special biopsy needle or during 
surgery to determine if cancer or other abnormal cells are present. The tissue 
samples are looked at under a microscope in order to detect cell differentiation 
assumed that cancerous cells are shaped and arranged differently than healthy 
cells. The samples may also be submitted to staining so that the differences 
between them are more obvious. 
 
 
Figure 2.3: Transrectal ultrasound guided prostate biopsy81. 
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  However, a negative prostate biopsy does not guarantee the existence of a 
healthy prostate gland. During biopsy, multiple samples from different areas of 
the prostate are taken in order to make an accurate diagnosis, but if a tumour is 
small enough, it can be missed during the procedure. Since only a very small 
percentage of the entire gland is sampled every time, there are many chances 
that the biopsy will conclude to a false negative result. This happens for at least 
2-3 in 10 men tested (20–30%)82, 83. If a biopsy is negative it may need to be 
repeated and this may detect a cancer that was missed the first time. 
 
Immunohistochemistry: Even though the diagnosis after biopsy can be usually 
made on cell morphologic features (growth pattern, nuclear atypia, absence of 
basal cells) it is sometimes difficult to reach a firm diagnosis by routine 
histological study84. Therefore, the application of immunohistochemistry to 
distinguish prostate cancer from benign growths and to confirm the diagnosis 
becomes helpful and necessary. 
  The immunohistochemical diagnosis of prostate cancer mainly depends on a 
group of biomarkers because there is not an individual highly specific and 
sensitive enough marker discovered yet. Immunohistochemistry for prostate 
cancer diagnosis usually includes at least one basal cell-specific marker, usually 
high- molecular-weight cytokeratin (HMWCK) and p63, and the prostate cancer-
specific marker, alpha-methyl-CoA-Racemase (AMACR)85. 
 
Nomograms: A predictive approach for prostate cancer diagnosis which takes 
into consideration results from the tests described above (biopsy, DRE, etc.) and 
the patient’s record, is nomograms. Nomograms are graphic representations of 
an algorithm which incorporates several predictors in order to predict a particular 
endpoint and they consist of sets of axes86; each variable is represented by a 
scale, with each value of that variable corresponding to a specific number of 
points according to its prognostic significance87. Nomograms help in assessing 
the nature of the disease and predict the risk and the possible outcomes of the 
treatment. Prostate cancer nomograms are regularly used by physicians to 
decide which treatment approaches will result in the greatest benefit for men at 
different stages of prostate cancer88. 
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2.2.2 Treatment options  
 
  Treatment options for prostate cancer are suggested by the doctor and depend 
on the stage of the disease. In early stages, active surveillance might be the best 
solution for young and old patients and patients with early disease are less likely 
to receive a radical treatment such as surgery and radiotherapy. Different 
parameters such as patient’s life expectancy (age), predicted natural history of 
the prostate cancer and treatment toxicity are usually taken into account before 
making a decision. The most common treatment approaches are: 
 
Radiotherapy: Radiotherapy is a radical approach which uses high-energy rays 
(x-rays, gamma rays) or particles to destroy the cancer cells while damaging the 
nearby healthy tissues as little as possible. Radiation can be emitted either 
externally or internally (brachytherapy) from radioactive pellets inserted inside the 
body. Radiotherapy may be included in the treatment options combined with 
surgery in the case of locally advanced prostate cancer. Common toxicities from 
radiotherapy include urinary problems, tiredness, impotence in 50% of the cases, 
lymphedema and rectal bleeding. 
 
Prostatectomy: Radical prostatectomy is the main type of surgery for prostate 
cancer, where the surgeon removes the entire prostate gland and surrounding 
tissue. Similar to radiotherapy, prostatectomy is usually suggested for cases of 
locally advanced prostate cancer and its potential outcome is directly related to 
the patient age. According to a 10-year randomized study carried out by The 
Scandinavian Prostate Cancer Group comparing watchful waiting versus radical 
prostatectomy, benefits of radical treatment for prostate cancer are only existent 
for patients younger than 65 years89.  
 
  For prostate cancer metastasis, radiotherapy and prostatectomy are not usually 
suggested. In this case, different treatment options could be effective. These 
options might include either hormones or chemotherapy. Hormonal therapy is 
suggested for the majority of patients, whereas chemotherapy may be used if 
hormones fail to confine the cancer. If the prostate cancer has metastasized to 
bones, bisphosphonate (zoledronic acid) therapy has been shown to delay 
symptomatic progression of bone metastases90. 
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Photodynamic therapy (PDT): Photodynamic therapy is a treatment that uses 
a drug (photosensitizing agent) which responds to a particular wavelength of light. 
When photosensitizers are exposed to a specific wavelength of light, they 
produce a form of oxygen, become cytotoxic and kill nearby cells. The 
photodynamic approach has been initially applied to superficial cancer, such as 
skin cancer, where the light is easier to reach. Attempts for application of PDT to 
interstitial cancers, such as prostate cancer, require the development of 
transparent fibers, through which the light will be transmitted and delivered within 
the tumour. 
  In the first step of PDT for prostate cancer treatment, a photosensitizing agent 
is administered to the patient either orally or intravenously. The agent is absorbed 
by cells all over the body but stays in cancer cells longer than it does in normal 
cells. After a certain period of time (usually 24 to 72 hours after injection), most 
of the agent has left normal cells but remains in cancer cells and this is when the 
tumour is exposed to a low power laser light which activates the drug. The light 
is usually delivered to the prostate through hollow plastic needles which fit into a 
perineal template (Fig. 2.4) while the patient is under general anaesthesia. When 
the photosensitizer becomes active due to light, an active cytotoxic form of 
oxygen is produced91. In addition to directly killing cancer cells, PDT can damage 
blood vessels in the tumour, preventing in this way the cancer cells from receiving 
necessary nutrients and also activate the immune system to attack the cancer 
cells92. In terms of side effects, PDT can cause burns, swelling, pain, and scarring 
in nearby healthy tissue. Although these side effects are usually temporary, 
further research and clinical trials are required in order to evaluate the use of PDT 
for prostate cancer treatment.  
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Figure 2.4: Photodynamic therapy procedure for prostate cancer93. 
 
2.3 Breast cancer  
 
2.3.1 Current diagnostic techniques  
 
  The most common technique for breast cancer screening and diagnosis is 
mammography. Currently screening mammography is suggested to every 
woman over 50 who has no symptoms in UK, as a routine procedure whereas 
diagnostic mammograms are used after suspicious signs of breast cancer. For 
younger ages and denser breasts, breast ultrasound scan can also be an option. 
Other techniques such as physical exam and MRI can be complementary to the 
mammography. However, the gold standard for breast cancer diagnosis is biopsy 
followed by histopathological analysis.  
 
Clinical examination: A clinical breast examination is performed by a clinician 
and involves a visual check of any abnormal texture or lumps on the skin and 
breast tissue. Signs such as palpable lumps, skin thickening and nipple discharge 
can be quite significant for an early cancer detection. Clinical examination is 
always combined with imaging diagnostic techniques as it cannot guarantee 
alone an accurate diagnosis due to its very low sensitivity rates94. 
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Mammography: Mammography is a low energy X-ray test of the breast, using 
ionizing radiation to create an image where signs of breast cancer such as 
characteristic masses and micro-calcifications can be early detected. During the 
procedure, the breast is compressed using a mammography unit (Fig. 2.5) in 
order to reduce the tissue thickness that x-rays will penetrate and increase the 
image quality. Mammography can be used for either screening or diagnostic 
purposes, with the latter to be more detailed and with additional views. 
Mammograms are less efficient to high density breast tissue. 
 
Figure 2.5: Illustration of a mammogram95. 
 
  Although mammography is currently considered the standard practice for breast 
cancer screening in many countries, its application is controversial due its low 
specificity and high number of false positives obtained96. Mammography is not 
able to investigate the chemical composition of suspicious elements detected in 
the breast (eg. calcifications) and therefore discriminate between malignant and 
benign ones, just by their morphology or location in the gland97. The 
overdiagnosis of breast cancer results in 21.9% of total women screened for the 
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disease to be treated unnecessarily98, 99. This constitutes not only a psychological 
hardship to women but also to a financial burden to the health service. At the 
same time, mammograms also give a high number of false negative results 
(around 25%), especially in younger ages, where breast density is usually higher. 
As tumours have similar density to fibroglandular rather than fatty tissue, they can 
be harder to detect in women with denser breasts using mammography100. 
Another possible risk of mammography is the radiation exposure which seems to 
be high both in young women, because of radiation’s cumulative effect, and for 
older women, since their breast epithelial cells are more prone to low dose 
radiation damage101. Due to the controversy around mammography application, 
a more individual approach to breast cancer diagnosis has been suggested by 
the scientific community96. 
 
Ultrasound: Ultrasound uses high-frequency sound waves to produce an image 
of the internal structure of the breast tissue. Contrary to ionizing radiation used 
by mammography, these waves are not harmful to the cellular DNA. Ultrasound 
is an inexpensive technique which is more commonly used in combination with 
other techniques, in women where mammography is not applicable due to their 
breast tissue density and has a potential to detect small node negative 
cancers102.  
  An ultrasound examination is usually able to reveal if an abnormal element in 
the breast is a solid lump or a cyst but it cannot identify the malignancy of a 
tumour or detect the presence of calcifications with great accuracy due to lack of 
contrast between normal parenchyma and the calcifications103. Other 
disadvantages of ultrasound application for breast cancer diagnosis include the 
need of highly qualified staff to perform the examination and lack of standardized 
scanning protocols102. 
 
MRI (Magnetic Resonance Imaging): MRI provides an image of the breast 
tissue using magnetic field and radio waves. MRI has been proven to be 
significantly more sensitive compared to mammography and ultrasound104 as it 
is not affected by high breast density105. However, due to its low specificity 
compared to mammography, MRI generates a very high number of false positive 
results106. Its high cost and rates of overdiagnosis do not allow MRI to be the first 
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choice for breast cancer diagnosis. It is still very useful though in collecting 
information about a suspicious area which has already been proved to be 
malignant using other techniques. 
 
Biopsy followed by histopathology: Biopsy is currently the gold standard for 
breast cancer diagnosis. During the procedure, a small amount of breast tissue 
is removed from the gland (Fig. 2.6) and examined in terms of morphology under 
the microscope by a specialized pathologist. There are different types of biopsy: 
fine needle aspiration biopsy (FNAB), open surgical biopsy and core needle 
biopsy which can be assisted by x-ray (stereotactic), MRI or a hollow probe 
communicating with imaging systems (vacuum-assisted).  
 
 
Figure 2.6: Fine needle aspiration biopsy for breast cancer diagnosis107. 
 
  In fine needle aspiration biopsy, a very thin hollow needle is inserted into the 
gland in order to collect a small number of cells or liquid in the case of a cyst. 
Because the biopsy volume is very small (only a few cells) there is a risk of 
missing the cancerous area and conclude to false negative results. The chances 
to detect the malignant area are higher in core needle biopsies, where breast 
tissue is collected from different locations on the gland, with a bigger needle 
compared to FNAB. In certain cases, where open surgical biopsy is required, a 
significant part (incisional) or the entire (excisional) abnormal area may be 
removed and examined under the microscope. In that case, a complementary 
amount of tissue (margin) around the abnormal area may also be excised in order 
to check for cancer cells having metastasized.    
  Another inherent limitation of breast biopsies is the histopathological 
interpretation of the samples excised from the gland. This can lead to a high rate 
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of false negative results especially in the presence of tissue heterogeneity108, 109. 
In order for the biopsy to be as precise as possible, it usually needs to be 
histopathologically assessed by more than one pathologist and combined with 
complementary imaging techniques. 
 
2.3.2 Treatment options  
 
  Different treatment approaches for breast cancer include surgery, radiotherapy, 
chemotherapy, hormone therapy and biological (targeted) therapy. These 
treatments are used individually or in combination, depending on the grade and 
stage of cancer for each case. 
  The most common type of treatment for breast cancer is surgery, which 
involves removing the tumour and nearby margins from the breast tissue. The 
removal of the margins is important so that tissue further away from the tumour 
can be checked for cancer cells and therefore for assessing if the cancer is safely 
removed. The type of surgery for breast cancer can be either lumpectomy or 
different types of mastectomy, depending on the breast tissue amount required 
to be removed. Lymph nodes can also be occasionally removed in order to check 
for possible metastasis. 
  A second common treatment for breast cancer is chemotherapy. 
Chemotherapy uses a combination of anti-cancer drugs to attack the tumour and 
either destroy the cancer cells or slow down their growth rate. Due to the 
pharmacological targets of the drugs used for breast cancer (DNA, RNA), cells 
that multiply fast are affected either if they are cancerous or healthy. Because of 
that, cytotoxic drugs induce a number of side-effects such as hair loss, nausea 
and vomiting, reduction in blood cells, tiredness and weakness. Chemotherapy 
is usually combined with other treatments in order to assist, for example, a tumour 
to shrink just before surgery.  
  When radiotherapy is used for treatment, high-energy radiation is targeted to 
a specific part of the body in order to kill cancer cells by permanently damaging 
their DNA. The main side-effects originate from the damage to adjacent healthy 
tissue, but are only short-term since the healthy cells are able to repair 
themselves easier. The radiation therapy can be delivered to the tumour either 
externally, using a linear accelerator, or internally by inserting a radioactive 
47 
 
 
 
material inside the breast tissue and close to the tumour. Radiotherapy is most 
frequently used in combination with chemotherapy or before and after surgery to 
minimize the tumour size and destroy any cancer cells left behind, respectively.  
  A major part of breast cancer diagnosis relies on the identification of hormones 
receptors on tumour cells and the subsequent treatment with hormone therapy. 
These hormone receptors can be either estrogen (ER) or progesterone (PR) 
receptors and their existence on the cell membrane of tumour cells provides 
potential for the tumour to respond efficiently to hormone therapy. In this case, 
hormone blockers are used in order to inhibit the hormone supply to the cancer 
cells. If no hormone receptors are present on the tumour cells, the cancer is 
‘’hormone-receptor-negative’’ and it is more likely that a hormone therapy will be 
ineffective.   
  A more recent approach to breast cancer treatment is the targeted therapy. 
This type of therapy employs targeted drugs, usually monoclonal antibodies, 
which aim at a specific target on the cancer cells. For example, women who have 
been identified with HER2 (human epidermal growth factor receptor 2) receptors 
on their cancer cells can benefit from trastuzumab, a monoclonal antibody 
specifically targeting this type of receptor. Other targeted therapy drugs include 
bevacizumab, which reduces cancer cells’ blood supply, and lapatinib which 
interrupts both the HER2 and the EGFR (epidermal growth factor receptor) 
pathways.   
 
2.4 Bladder cancer  
 
2.4.1 Current diagnostic techniques  
 
  Similar to breast cancer and prostate, the gold standard for bladder cancer 
diagnosis is biopsy followed by histopathology. Cystoscopy is the main technique 
used for both screening and collection of biopsies, whereas a number of imaging 
techniques are used for assessing the cancer stage. 
 
Cystoscopy: Cystoscopy, the current gold standard for bladder diagnosis, is the 
procedure where the specialist checks for abnormalities on the inner wall lining 
of the bladder using a cystoscope (a thin flexible tube with a light and camera on 
the end). Cystoscopy can be accurate in identifying benign over malignant 
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bladder lesions by their appearance, but if it is not followed up by biopsy, it is less 
precise in discriminating between different grades of malignancy110. The 
procedure is performed under local anaesthesia when the patient is checked for 
the first time and under general anaesthesia when a biopsy collection is 
performed. 
 
Imaging techniques: Techniques such as ultrasound, computerised 
tomography (CT) and intravenous urogram (IVU) are used to check any 
abnormalities in the urinary system (bladder, ureters, kidneys). Other imaging 
techniques such as MRI and bone scans are used to check if the bladder cancer 
has spread to the bones or rest of the body.  
 
Photodynamic diagnosis (PDD): Photodynamic diagnosis is a more advanced 
approach of standard cystoscopy, where a light-sensitive blue dye is added 
beforehand and absorbed by the abnormal cells in the bladder. During the 
procedure, a blue (instead of white) light is shined onto the bladder lining and 
make the cancer cells fluoresce, helping in this way the specialist to detect the 
cancerous areas easier. PDD has been mentioned to be superior to white light 
cystoscopy111, 112 in terms of sensitivity, especially for superficial TCC tumours113 
but it is also characterized by low specificity rates113, 114. 
 
Biopsy followed by histopathology: If during cystoscopy any abnormalities are 
detected in the bladder, a second cystoscopy under general anaesthetic is 
performed. During this procedure, small samples of tissues are taken from areas 
that look abnormal or even some healthy areas in order to ensure an accurate 
diagnosis.  Cystoscopy followed by biopsy can usually result in a high rate of false 
positive, especially when PDD is applied, due to its limited ability of discrimination 
between cancerous and inflamed areas115. 
 
Urine tests: These are non-invasive enzyme immunoassays applied directly to 
patient’s urine in an attempt to detect urinary tumour markers for bladder cancer 
diagnosis. Although these markers show high sensitivity, they lack specificity116, 
117 and a significant positive predictive value118. For example, NMP22 which is a 
type of nuclear matrix protein released in higher amounts in urine of patients with 
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TCC, gives a high rate of false positive results because its expression tends to 
be affected by various pathological conditions118, 119, which leads to low specificity 
rates. Concerning the consistent application of urinary biomarkers, the 
combination of a number of them seems more promising for an accurate bladder 
cancer diagnosis, but cannot replace cystoscopy120, 121.     
 
2.4.2 Treatment options  
 
  Depending on the stage of bladder cancer, different treatment approaches are 
used. The most common treatment involves Transurethral Resection of Bladder 
Tumour (TURBT) for non-muscle invasive cancer and cystectomy for muscle 
invasive bladder cancer. 
  Non-muscle invasive cancers account for the 70% of the total bladder cancer 
cases and is a superficial type of cancer, where the malignancy has not been 
developed through the deeper muscle layers. These types of cancers are initially 
treated with Transurethral Resection of Bladder Tumour (TURBT) which is the 
surgical removal of suspicious or abnormal areas through cystoscopy. TURBT 
can be followed by complementary treatment in order to minimize the chances of 
a recurring cancer. One of these treatments include BCG (Bacille Calmette-
Guerin), a vaccine for tuberculosis, which can stop the bladder cancer from 
spreading. 
  Different approach is adopted for more aggressive types of bladder cancer, 
which start by penetrating through the bladder wall and eventually reaching and 
travelling through the muscle layer (muscle invasive cancer) (see chapter 1). For 
the treatment of this aggressive cancer type, the removal of the bladder 
(cystectomy) and surrounding organs can be suggested and complementary 
treatments such as chemotherapy might follow.   
 
2.5 Discussion 
 
  The current imaging techniques presented above can significantly assist in 
prostate, breast and bladder cancer diagnosis, after having their risks and 
benefits assessed by specialists for each individual case. However, the 
successful treatment of cancer is directly dependent on the detection of the 
disease at its earliest stage and one major limitation of the current imaging 
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methods is the lack of ability to detect an abnormality in an early cancer stage, 
where all of the early changes during tumorigenesis begin. As a result, cancer is 
not treated until cancer cells have intruded to surrounding tissues and 
metastasized122. Additionally, because these techniques have no insight into the 
molecular tissue level, they cannot discriminate benign from malignant cases. 
  The biopsy followed by histopathology is the only currently used diagnostic 
technique which can reveal structural changes on a molecular level during the 
disease progress. However, even if the biopsy is considered to be the gold 
standard for cancer diagnosis, it is an invasive technique linked to false negative 
results108 which can render the method partially unreliable. The false negative 
results derive from the fact that the volume of tissue removed during the biopsy 
is very small compared to the total tissue volume and not always adequate for an 
accurate histological evaluation. As a result, if the tumour is small, there is a 
significant chance of missing it during sampling. Another major limitation of 
histopathology is relatively low inter-observer reproducibility between different 
pathologists who are assessing the biopsies123, 124. The evaluation of the cell 
morphology under the microscope can be quite challenging, especially in 
intermediate cancer stages, and can therefore be subjectively assessed by 
different pathologists resulting in a wide variation of results.  
  Since the current applied techniques do not fully cover the current diagnostic 
needs, we need to consider different diagnostic approaches which will enable the 
specialists to detect molecular changes in the potentially malignant tissue more 
efficiently and in a minimally invasive way. The alternative approach should not 
only be able to assess the tissue content and provide molecular information of 
the area, but also to discriminate malignant from benign tissue.  
  One of the most promising novel diagnostic approaches is comprised of a group 
of optical techniques which take advantage of light-matter interactions in order to 
explore the quality and quantity of molecular components in different tissues. One 
of these techniques is Raman spectroscopy, a promising method which uses 
Raman scattering in order to analyse vibrational modes of molecules inside 
tissues. Due to its ability to provide the molecular fingerprint of the area scanned, 
Raman spectroscopy is able to discriminate between healthy and malignant 
areas, through their different molecular content. The applications and theoretical 
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background of Raman spectroscopy and the rest of the optical techniques are 
described in more detail in the following chapter.   
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3 Chapter 3: Novel optical diagnostic techniques 
   
3.1 Introduction 
 
  In the last chapter we highlighted the disadvantages of the current diagnostic 
techniques for cancer. In this chapter we explore the application of optical and 
more specifically molecular vibrational spectroscopy, and novel approaches for 
cancer diagnosis.  
  A number of optical techniques such as elastic scattering spectroscopy 
(ESS)125, 126, optical coherence tomography (OCT)127, 128, fluorescence 
spectroscopy129, 130, fluorescence lifetime imaging microscopy (FLIM)131 and 
diffuse reflectance spectroscopy (DRS)132, 133 have been studied widely for 
application in cancer diagnosis. However, these have their limitations, often 
associated with the application of these techniques. These include low specificity 
(ESS, fluorescence spectroscopy), low penetration depth and low specificity 
(OCT), low signal-to-noise ratio (FLIM), low accuracy (DRS) and invasive nature 
for most of them. 
  Vibrational spectroscopy, such as Raman and mid-infrared (IR), are strongly 
sensitive to the chemical composition of the sample and have been tested for 
application in the cancer diagnosis routine. Between the two techniques, IR is 
significantly affected by the presence of water in the tissue and therefore cannot 
be used in non-invasive measurements in vivo. In contrast, Raman (near-infrared 
wavelengths) remains largely unaffected by water content and for that reason it 
can be used directly in real-time for non-invasive measurements. Due to its high 
specificity and sensitivity, Raman spectroscopy is currently applied in a number 
of applications including material characterization, security134, pharmaceutical 
industry135, art history136 and geology137. Between the numerous applications, 
here we will focus on how this emerging field can contribute in cancer diagnosis. 
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3.2 Theoretical background  
 
3.2.1 Light propagation in biological samples 
 
  Photons propagate through tissues in a number of different ways. They can 
travel through the sample in a random walk, being scattered from the tissue 
molecules or being absorbed by them. 
  In the case of scattering, light photons interact with matter and change their 
direction, with or without losing energy. The more scattering the medium is, the 
more the photons will deviate from the original forward direction (Fig. 3.1). 
 
 
Figure 3.1: Transmission of light through a non-diffusely scattering (a) and 
diffusely scattering (b) medium. 
 
  In the case of absorption, the photon will be absorbed only when the energy of 
the photon matches the energy gap between the initial and the final energy states 
of the atom or molecule. Energy from the photons which is absorbed, is often 
dissipated in the tissue as thermal energy. If the energy gap between energy 
levels in the molecule, is substantially different to the photon energy, then the 
photon will not be absorbed.  
  How efficiently the photon will travel through the tissue, depends on the fraction 
of light which will be absorbed or scattered by it, which is described principally by 
the scattering and absorption coefficients. The scattering coefficient (μs) 
depends on the probability of the medium per unit length to redirect the incident 
photons into new directions and therefore prevent the forward on-axis 
transmission of light. The average distance that a photon travels between 
scattering events is called mean free path length. Similarly, the absorption 
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coefficient (μa) describes the probability of the medium per unit length (μα) to 
absorb the photons138.   
  Because in biological tissues the light is not scattered in all possible directions 
but is mainly forward directed (anisotropic scattering)139, 140, it is convenient to 
define a mean scattering angle which is described by the value of anisotropy 
(g)141. In order to be more precise in the description of scattering in biological 
tissues, scattering coefficient and anisotropy are combined into the expression of 
reduced scattering coefficient which is defined as: 
 
𝜇′𝑠 = 𝜇𝑠(1 − 𝑔)    (3.1) 
 
  The optical properties described above (μa, μs, μ’s and g) are characteristic of 
tissue in general and range much for different types of human tissue. These can 
provide useful information on each tissue. For example, absorption coefficient is 
related to the concentration of various chromophores inside the tissue, whereas 
scattering coefficient describes the form, size and concentration of the scattering 
components in the tissue142.         
 
3.2.2 The Raman effect 
 
  Raman scattering is a specific case of photon scattering, where the photon is 
scattered in a medium with a change in its energy (inelastic scattering). When 
incident light falls onto a material surface, it will be typically scattered in random 
directions. The vast majority of the light will be elastically scattered, maintaining 
the same energy (i.e. frequency). A very tiny amount of the light (less than 
0.001%)143 will be scattered with slightly different frequency from the incident light 
(inelastic scattering). The difference in the frequency is characteristic of the bond 
vibrations of the molecules and provides important chemical and structural 
information on the material. 
  The Raman effect was first discovered while C.V. Raman in India was trying to 
explain the blue colour of the sea in 1921. Since then, the effect was studied and 
finally established in 1928 in liquids by C.V. Raman and K.S. Krishnan and 
independently in crystals by G. Landsberg and L. Mandelstam a few years later. 
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For the discovery of the Raman effect, C.V. Raman was awarded with the first 
ever Nobel prize to an Asian scientist in 1930.  
  As light can be both a wave and a particle in nature, the Raman effect can be 
interpreted in two ways: the wave interpretation and the quantum particle 
interpretation. In the first case, light is considered to be a wave with an oscillating 
electric field which interacts with a molecule through its electron cloud. When the 
light interacts with a molecule, vibrating at a frequency given by its bond strength, 
it induces a dipole moment (μind) which is equal to the product of the electric field 
of the incident light (E) and the polarizability α’ (how easily distorted the 
molecule’s electron cloud is by an electric field). The polarizability of the molecule 
depends on the number of the electrons, their distance from the nucleus and how 
strongly attracted they are to it. The Raman effect depends on polarizability 
change of molecule during its vibration.  
  In the quantum mechanics interpretation, light is considered to be a photon 
which interacts with a molecule and loses or gains energy (inelastic scattering). 
The possible outcomes from an incident photon hitting a molecule are described 
in Figure 3.2. Initially the molecule is excited to a virtual state and at a second 
stage there are three possible outcomes. Most frequently, the molecule will relax 
back down to the initial ground state, scattering a photon of equal energy to that 
of the incident photon (Rayleigh scattering) (Fig. 3.3). More rarely, the molecule 
will either relax to a real vibrational state and emit a photon with less energy than 
the incident photon (Stokes) or emit back a photon with higher energy after having 
already been in an excited vibrational state in the first place (anti-Stokes). As 
most of the molecules are initially found in the ground state at room temperature, 
it is more likely for a photon to be Stokes rather than anti-Stokes.  
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Figure 3.2: Three of the ways in which the first electronic excited state can 
return to the ground state: vibrational relaxation, fluorescence (short-lived 
photon emission) and phosphorescence (long lived photon emission)144. 
 
 
Figure 3.3: Jablonski diagram representing quantum energy transitions for 
Rayleigh, Raman scattering and IR absorption145. 
57 
 
 
 
 
  The intensity of the Raman scattered light is proportional to the Raman cross-
section of the material (σj), which describes the efficiency of the molecule to 
scatter an incident photon as a Raman-shifted photon with a particular Raman 
shift146. The Raman scattering intensity is related to the Raman cross-section and 
laser intensity (I0) by the following formula: 
 
𝐼𝑅 = 𝐼0𝜎𝑗𝐷𝑑𝑧    (3.2) 
 
Where D is the number density of scatterers and dz is the path length of the laser 
in the sample146. 
The power of Raman scattering is also linearly related to the intensity of the 
incident photons and inverse of the photon wavelength to the fourth power: 
 
𝑃𝑠  ∝  𝐼0/𝜆
4    (3.3) 
 
  Unfortunately, as the fluorescence process increases with shorter wavelengths, 
it is not always possible to achieve the best result as the measurement can be 
inhibited by fluorescence. The process of fluorescence involves the emission of 
a photon from an electronically excited state, after absorption of an incident laser 
photon, after having lost typically some of the (excess) energy through vibrational 
relaxation144, as shown in Figure 3.2. This process is likely to occur with shorter 
wavelengths as it necessitates the presence of electronic absorption which are 
more likely to be present in visible/UV region of the optical spectrum. The emitted 
fluorescence photons can create excessive background which can swamp weak 
Raman signals. Another two mechanisms by which an electron in an excited state 
can return to the ground electronic state are the vibrational relaxation, where the 
energy of the electron is given away to other vibrational modes as kinetic energy, 
and the intersystem crossing, where the electron changes spin multiplicity from 
an excited singlet state to an excited triplet state with the possibility to lead to 
phosphorescence (Fig. 3.2).    
  Another type of molecular process, where electrons do not possess enough 
energy to jump to the first excited state, include Raman scattering, Rayleigh 
scattering and absorption. Whereas Raman and Rayleigh scattering have been 
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explained earlier, infrared (IR) absorption process consists of absorption and 
emission of photons on the vibrational levels of the electronic ground state,(Fig. 
3.3). Raman and IR spectra consist of characteristic ‘’fingerprints’’ for the 
chemical molecules and can complement one another because different bond 
vibrations can have different IR and Raman activity. The main difference is that 
in order for a bond to be IR active, a change in the dipole moment is required. On 
the other hand, in order for a bond to be Raman active, a change in polarizability 
is required, as described earlier. Both of the cases usually depend on the 
elements of symmetry of the molecule. Raman active bonds tend to be symmetric 
vibrations, whereas IR activity is usually observed with polar bonds and 
asymmetric vibrations. 
  The basic bond vibrations that one can find in the molecules can be of two types: 
stretching vibrations where the bond atoms are successively approaching and 
moving apart so that the distance between them changes along the axis of the 
bond and bending vibrations where the angle changes between two bonds. 
Bending vibrations can be scissoring, rocking, wagging or twisting (Fig. 3.4). 
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Figure 3.4: Basic molecular vibration modes. 
 
  
3.3 Instrumentation 
 
  After the discovery of Raman scattering, the scientific community took benefit of 
the new knowledge so fast that Raman spectroscopy was being applied since 
1930 and flourished around late 1960s when laser sources became available. 
Today the principal on which Raman spectrometers operate remains the same 
(Fig. 3.5) and it is mainly the illumination of the sample and the collection of the 
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Raman scattering that varies in configuration between the different Raman 
techniques.   
 
 
Figure 3.5: Simplified diagram of a Raman spectrometer’s operation147. 
 
  Most of the modern compact Raman spectrometers are either dispersive or non-
dispersive depending on if they use a prism/grating or an interferometer (Fourier 
transform based spectrometers) respectively. Both the types comprise of: a 
monochromatic light source (laser), a sample area with collection optics, spectral 
analyser unit and a detector.  
   
Light sources 
  In Raman spectroscopy, any kind of electromagnetic radiation can be used as 
a light source, including filtered sun light, which was at the core of the discovery 
of the Raman effect148. Currently, the main light sources used are lasers because 
they can provide intensity high enough to produce a sufficient amount of Raman 
scattering. Laser wavelength used in Raman spectroscopy can typically range 
from UV (<300 nm) to near-infrared (NIR) (1064-1700 nm) (Table I). Lasers of 
wavelength less than 900 nm are commonly used in Raman dispersive systems, 
whereas those with 1064 nm and above are usually nondispersive Fourier 
transform (FT)-Raman systems146. Shorter wavelengths in near-infrared (NIR) 
region are generally more efficient since Raman intensity is inversely proportional 
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to the fourth power of the laser wavelength and also more effective detectors can 
be used (CCD’s). However, as the laser wavelength decreases, the risk of 
fluorescence increases. This is why for measuring biological samples an 
intermediate laser wavelength (usually between 532 and 830 nm) is selected as 
a compromise, depending on the nature of the sample.   
 
Laser Type Wavelength (nm) 
Doubled Ar+ 244 
Ar+ (air cooled) 488 
Ar- (water cooled) 351-528 
He-Ne 632 
Kr+ 413 
Nd:YAG 1064 
Doubled Nd:YAG 532 
Diode 670-865 
Ti:saphire 700-1100 
 
Table I: Commonly available continuous lasers for Raman spectroscopy146. 
 
  The most commonly used laser sources for biological samples are the semi-
conductor diode lasers. These lasers use electric current to excite the active 
medium and amplify the light. Because diode lasers can be very small in size, 
power efficient and inexpensive, they are quite attractive for Raman 
spectroscopy. They also operate in a range of wavelengths in NIR, an area 
suitable to avoid fluorescence and still achieve high CCD detector performance.  
  Another type of light source are tunable lasers, which can be, for example, 
pumped by another laser and their wavelength can be selected by the user (e.g. 
Ti:sapphire laser). Laser light can be brought to the sample either through a 
microscope objective (Raman microscopy) or directly, e.g. in a 90º or 180º 
scattering geometry.  
 
Sample area with collection optics 
  Once the sample is placed on sample stage, the light has to be transferred from 
the source to the sample. For that reason, optics relaying the laser line onto the 
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sample and filters rejecting the laser spectral ‘’wings’’ (amplified spontaneous 
emission, ASE) are located before the sample holder. In order to achieve this, a 
bandpass filter transmitting only a narrow range of wavelengths around the laser 
line, would be typically used.  
 The light scattered from the sample has to be then collected from the sample. 
Again depending on the different Raman technique, the Raman scattered light 
can be collected in different configurations. In any case though, there are filters 
which are used for rejecting the intense elastically scattered light (Rayleigh) and 
allowing the relatively weak inelastic Raman scattered light to reach the detector. 
The above filters used are either notch or edge filters.     
  An edge filter is a long pass optical filter which rejects wavelengths up to a 
certain point, and then transmits with high efficiency wavelengths above this 
point. As a result, an edge filter could block Rayleigh (and anti-Stokes) scattered 
light and allow Stokes to reach the detector. The notch filters have sharp, discrete 
absorption which can be chosen to coincide with a specific laser wavelength and 
is typically a few nanometres wide. As a result, the laser line is reflected but the 
Raman spectrum (Stokes and anti-Stokes) will be transmitted. The great 
advantage of notch over edge filter is that it allows both Stokes and anti-Stokes 
Raman scattered light to pass and reach the detector. 
 
Light dispersing unit  
  In dispersive Raman spectrometers the scattered Raman light is projected and 
separated into different wavelength components on the detector using a 
dispersion grating. For example, gratings can be fabricated using densely 
engraved or imprinted lines or grooves into the surface, which then disperse the 
incoming light. The higher the number of grating lines per unit length, the higher 
the dispersion and the higher the spectral resolution achievable. 
 
Detector 
  Dispersive and Fourier transform Raman instruments are using different types 
of detectors in Raman spectroscopy. Whereas FT spectrometers use liquid 
nitrogen cooled sensor, the current detectors for dispersive Raman 
spectrometers typically use Charged-Coupled Devices (CCD). These detectors 
are often in a form of a two-dimensional arrays of elements (typically < 30μm) 
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made of semi-conductive material (silicon). When the detector is exposed to light, 
electron-hole pairs are created in the silicon. The number of photo-electrons 
(charge) acquired is directly proportional to the number of photons falling on each 
element. At the end of the measurement, the charge is quantified in an analogue-
to-digital convertor. In this way, each pixel acts as an individual detector, so each 
dispersed wavelength is detected by a different pixel (or closely spaced group of 
pixels). CCD detectors commonly have a large wavelength response region, 
routinely extending from 400nm up to approximately 1000nm.  
  The CCD detector performance can be characterised by generated noise which 
consists of pixel noise and fixed pattern noise. Pixel noise is the variation in the 
values of a charge read on a pixel and has three main constituents: readout noise, 
‘dark’ noise from the dark signal and photon shot noise from the light signal itself. 
The readout noise is due to the amplifier and electronics and is present on every 
read out. The ‘dark’ noise depends on the exposure time of the measurement 
and is due to basic physical laws of charge migration in and out of the 
measurement region. This noise is dependent on the temperature of the detector 
which is confronted by cooling of the sensor (e.g. to -75°C). The fixed pattern 
noise is a constant noise which is due to the variation in the dark signal produced 
by each individual pixel and also small irregularities during the fabrication of CCD. 
These variations remain stable from measurement to measurement and as such 
can be subtracted away if accurately measured. 
  Another important characteristic of CCD detectors is the quantum efficiency 
which is directly related to the spectral response of CCD. The quantum efficiency 
describes the probability of a photon of a certain frequency to excite a photo-
electron in the silicon, i.e. to be detected. The quantum efficiency of a detector 
depends both on the wavelength of the photons and on the absorption coefficient 
of the silicon.  
  Three types of CCD technology are widely used: front-illuminated, back-
illuminated and back-illuminated deep depletion. Deep depletion CCDs, 
fabricated from thick silicon substrate of high resistivity, are the ones which offer 
a maximum efficiency to NIR scattered radiation and are usually an optimum 
solution for NIR dispersive Raman systems.  
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3.3.1 Raman microscopy  
 
  Raman microscopes are currently the most common configuration of Raman 
spectroscopy employed in research. A Raman microscope is an optical 
microscope combined with an excitation laser, laser rejection filters, a 
spectrometer or monochromator and an optical sensitive detector (usually CCD). 
 
 
Figure 3.6: Schematic drawing of a Raman microscope. 
 
  In a Raman microscope, a laser beam is focused on the sample through lenses  
(Fig. 3.6). The scattered light is collected typically in a back-scattering geometry 
using the same objective that directs the light onto the sample. The scattered light 
travels through filters in order for the weak Raman light to be isolated from the 
Rayleigh (elastic) scattering. The collected Raman scattering is then focused on 
a dispersion grating which separates it into single wavelength components. After 
the scattering light has been separated into individual spectral components, it is 
projected onto the detector (usually CCD), which then generates the measured 
Raman spectrum.      
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3.3.2 Deep Raman spectroscopy 
 
  The conventional Raman microscopy is only able to collect Raman scattering 
up to a depth of a few hundred micrometres from tissue (depending on the 
sample). Deep Raman spectroscopy, an emerging set of techniques, is employed 
for collecting the mean Raman signal from diffusely scattering samples of 
significant volume and depth (up to several centimetres)149. 
  Deep Raman spectroscopy can be either of temporal or spatial approach. In 
the first case, scattered Raman light is being collected from subsurface sample 
depths (Fig. 3.7) using temporal gating, by taking advantage of a medium which 
causes light to rotate its polarisation transiently (several picoseconds) by 90o in a 
nonlinear optical medium (Kerr medium). Kerr gated spectroscopy enables to 
collect the weak Raman scattering from sublayers, by rejecting the strong surface 
signal. The Kerr gate setup can be also used to reject sample fluorescence (Fig. 
3.8), which usually has a longer lifetime compared to Raman scattering. Because 
of that, Raman light can change polarization while passing through the active Kerr 
medium and be detected as soon as the laser pulse strikes the Kerr medium. 
However, since the Kerr gate anisotropy is only short lived, any fluorescence 
arriving after the Raman light is not subjected to polarization change and is 
prevented from going through the second polarizer. 
 
Figure 3.7: Schematic diagram of the 4 ps Raman Kerr-gated setup for the 
discrimination of sub-surface layers150. 
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Figure 3.8: Schematic diagram of the Kerr gate used in the fluorescence 
rejection system151. 
 
  Unfortunately, Kerr-gating Raman spectroscopy has limited use in medical 
applications due to high instrumental complexity, cost and safety limits. For this 
reason, a range of geometrical optical approaches of deep Raman spectroscopy 
have been developed152, 153, including: spatially offset Raman spectroscopy 
(SORS), inverse spatially offset Raman spectroscopy (i-SORS) and transmission 
Raman spectroscopy (TRS). This group of techniques benefits from both 
fluorescence suppression (where fluorescence is located near surface) and 
collecting weak Raman signals from deeper sample layers. 
  The setup configuration of these techniques is different from Raman microscopy 
in terms of illumination and collection geometry. In a basic SORS configuration, 
the laser light is brought onto the sample surface in the centre of a ring and the 
scattered radiation is collected from a ring or point zone (Fig. 3.9a). In i-SORS 
case, the sample surface is illuminated in a ring pattern with different diameters 
and Raman light is collected through a disk within the centre of the ring (Fig. 
3.9b). The collection of Raman light can be facilitated using optical fibres or via 
free-space optical relay system. The ring-shape laser beam can be generated 
using a conical lens with an adjustable radius of the ring. In the case of 
transmission Raman spectroscopy, the laser beam illuminates the sample from 
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the one side and the mean volume Raman signal is collected on the other side of 
the sample (Fig.3.10b).  
 
 
Figure 3.9: Schematic diagram of conventional SORS and inverse SORS 
(iSORS) showing Raman collection and beam delivery geometries. 
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Figure 3.10: Basic implementations of the (a) SORS and (b) transmission 
Raman concepts154. 
 
  SORS technique relies on the optical properties of the diffusely scattering 
material and it is most efficient on samples with low absorption, such as at NIR 
with the majority of biological tissues. In a turbid medium, as excitation photons 
reach the sample surface, they are diffusely scattered and travel to deeper 
sample layers (Fig. 3.11). When the collection area is located in a distance from 
the excitation one on sample surface, the weak Raman photons from deeper 
layers can be collected. In SORS, the measurement is performed by collecting 
the Raman scattering from a spatially offset area to avoid the dominating 
excitation surface region signals. As the random photon diffusion takes place in 
the sample, greater depths correspond to a wider spread of photons around the 
illumination point on the sample surface155. In this way, the greater the ring 
diameter is, the deeper the Raman photons are collected from.  
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Figure 3.11: Diagram of most probable photon trajectories and detection points 
during spatially offset Raman measurements. 
 
  Lasers commonly used in SORS systems are diode lasers with stabilized 
wavelength. Typical excitation wavelengths for biological tissues are within NIR 
region of the spectrum in order to minimize absorption and interfering 
fluorescence whilst staying within the detection range of CCD.  
  Conventional SORS technique can be limited in sensitive applications (e.g. in 
vivo measurements) by concentrating all light into one zone. The inverse SORS 
(iSORS) variant, can comply better with safety limits since it distributes the same 
light over a wider sample area. For this reason, iSORS is a useful approach that 
improves certain measurements such as analysis of tissue in vivo. In this case, 
as abovementioned, rather than using a spot collection geometry and a central 
collection spot for illumination, the collection offset is maintained by illuminating 
the sample with a ring of light and collecting the Raman signal from a central 
point. 
  The ring shaped laser beam can be generated using a conical lens (axicon) 
where the ring radius can be adjusted by changing the distance between the 
axicon and the sample153, or by changing the magnification of lenses inserted 
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between the sample and the axicon156. The radius of the ring defines the spatial 
offset and can be adjusted to the dimensions and scattering properties of the 
sample. 
  SORS techniques can currently achieve depths of many millimetres (~10 
mm)157. However, they are generally limited in samples with high absorption 
coefficients, since this leads to the reduction of photon migration distances and 
consequently achievable penetration depths. SORS is also limited in the case 
that the fluorescence from the sample is too high, as the weak Raman scattering 
cannot stand out and be detected. However, if the fluorescence originates from 
the sample surface, SORS can effectively avoid measuring it155. 
  The third variant of deep Raman spectroscopy is transmission Raman. In that 
case the sample needs to be accessible from both sides, since the laser is shone 
upon it from one side and the Raman scattering is collected from the opposite 
side (Fig. 3.10b). During the measurement, the light is diffusely scattered through 
the sample randomly and as Raman photons can be created at all points that the 
light passes through, the total Raman signal measured on the opposite side is 
highly representative of the bulk sample volume. Transmission Raman can be 
considered as an extreme case of SORS, where the laser beam and the Raman 
collection zone are completely separated to the extreme (180º) as being on the 
opposite sides of the sample. 
  Contrary to SORS techniques, transmission Raman is unable to provide pure 
signatures of individual layers within a sample, since it mainly offers bulk 
averaged compositional information for the whole sampling volume within a 
single spectrum. Because of the bulk information that transmission Raman 
provides, surface signals can be suppressed158. Up to now, transmission Raman 
has achieved sampling depths of up to 27 mm149. 
  A number of different approaches have been applied to transmission Raman 
setups in order to enhance the signal to noise ratio (SNR) and therefore achieve 
higher measurement sensitivity and penetration depths. One way of achieving 
this is to use a ‘’photon diode’’ which acts as a beam enhancing element. This 
unidirectional mirror allows laser photons to be transmitted through it on one side 
whilst laser and Raman photons re-emitted from the diffusely scattering sample 
to be reflected from it back into the sample due to the angular dependence of its 
reflectance properties159. In this way, the ‘’photon-diode’’ prevents the loss of 
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diffusely scattered photons which re-emerge from the sample at the point where 
the laser beam enters the sample, and enhances the Raman signal of it160. 
Additional ways to improve the SNR in deep Raman measurements is the 
increase of the laser power, the collection time or even the optimization of the 
collection system efficiency, by using for example wider slit spectrographs in 
conjunction with high dispersion gratings161.    
 
3.3.3 Fibre optic probes 
 
  A number of Raman spectroscopy variations which have also been developed 
the last few years include: Surface-enhanced Raman spectroscopy (SERS), fibre 
optic probes, Resonance Raman spectroscopy, Spontaneous Raman 
spectroscopy (SRS), Optical tweezers Raman spectroscopy (OTRS), Stimulated 
Raman spectroscopy, Coherent anti-Stokes Raman spectroscopy (CARS), 
Raman optical activity (ROA) and Tip-enhanced Raman spectroscopy (TERS). 
In the context of this thesis, it is worth elaborating on fibre optic probes.  
  Fibre optic probes coupled to a Raman spectrometer have been developed for 
real-time, non-invasive, in vivo Raman measurements as they are more flexible 
in application and can improve tissue access. Raman probes have been adopted 
for a number of studies in different configurations and have found application in 
needle probes162 and endoscopes163-165. However, the basic concept remains the 
same, as they mostly consist of one excitation fibre and one or more collection 
fibres, in different geometry and proximity to each other. Depending on the probe 
design, it can also entail a certain level of confocality166 or not. 
  Fibre optic Raman probes can be employed to perform measurements in 
different modalities, as it has been demonstrated through a number of studies. 
They usually emit a near-infrared laser (750-850 nm) and they contain filters to 
suppress fluorescence, reflected excitation light and background signal from the 
fibres. One of the most common Raman probe designs consists of a silicon fibre 
bundle where the excitation light is emitted to the sample through a central 
delivery fibre and collected through a number of collection fibres surrounding the 
central one (Fig. 3.12). The number of collection fibres can vary in a great 
range167-171, with one to be the minimum 1172, 173 and 50 the maximum number 
demonstrated174.  
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Figure 3.12: Schematic of a typical Raman probe tip in a longitudinal view and 
a transverse cross-section at the fibre–filter interface171. 
 
  Fibre optic technology can also be coupled with iSORS153 and SORS modality, 
providing a subsurface signal 174, by employing an annular probe where the 
excitation fibre is spatially separated from the collection ones152, 175, 176. The 
extreme case of SORS, transmission Raman spectroscopy, can be also 
performed by employing a collection fibre bundle158, 161. 
 
 
Figure 3.13: Fibre optic probes employed in a conventional configuration (a), 
SORS (b) and transmission mode (c). 
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  Raman fibre optic probes have been employed in a number of measurements 
on skin surface166, 177-179. However, the Raman probe application is more 
challenging when it comes to accessing and measurement of remote organs, 
since more flexibility is required. These measurements usually require short 
acquisition time (less than 1 s), high signal to noise ratio and a limited probe 
diameter (up to 2 mm)171. Despite their limitations, Raman probes have been 
employed in a number of studies during the last decade as described in the next 
section157. 
 
3.4 Novel vibrational spectroscopy in cancer 
diagnosis 
 
  A number of vibrational spectroscopy techniques have shown great potential for 
cancer diagnosis over the last decade. This is reflected on the literature with 
studies employing IR180, 181 and Raman spectroscopy for the detection of cancer 
on tissue samples, body fluids and cell cultures182-184. Due to its water content 
dependence, IR spectroscopy has been mainly used on dried histopathological 
sections for the detection of several types of cancer such as oesophageal185, 
gastric186, colorectal187 and breast cancer188.   
  Contrary to IR, Raman spectroscopy is not affected largely by water content 
since the –OH vibrational modes of water molecules produce weak Raman 
signals189. Consequently, Raman spectroscopy can be employed for real-time 
and non-invasive measurements on fresh samples without the need for fixation. 
Raman scattering is suitable for both qualitative, since it provides a chemical 
‘’fingerprint’’ of the sample, and quantitative tissue analysis, since the Raman 
scattering intensity is proportional to the concentration of the sample molecules. 
  Different modes of Raman spectroscopy have been employed for different types 
of samples. Conventional Raman spectroscopy, usually coupled with a 
microscope, is the most common approach to measure tissue sections and 
biological fluids and has been employed in a number of studies in order to 
discriminate between pathologies in different cancer types such as 
oesophagus190, laryngeal191, bladder192 and prostate193 lymph nodes194, 195, 
breast196, 197, skin198, 199 and liver200. Raman spectroscopy has also shown 
potential in assessing tumour margins during surgery201, 202, in order to ensure 
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complete removal of malignant cells and in this way reduce the tumour recurrence 
risk. 
  Raman fibre optic probes have been employed for real-time measurements of 
tissues, inserted through endoscopes or in the form of needle probes. The 
feasibility of routine clinical endoscopy combined with Raman probe has been 
demonstrated multiple times for scanning gastrointestinal tract170, 203 for Barrett’s 
oesophagus neoplasia204 and colon cancer205. Raman fibre optic probe have also 
been used for discrimination between benign and malignant samples in 
prostate168 and bladder cancer206, skin cancer207, cervical cancer208 and brain 
cancer209, 210. 
  However, the need for real time, non-invasive, in vivo measurements of 
significant tissue volumes has led to the application of deep Raman 
spectroscopy, which includes transmission and spatially offset (SORS) Raman. 
Up to date, deep Raman includes clinical applications in breast cancer for the 
detection of calcifications157, 161 and assessment of tumour margins211, 212 as well 
as urology213. This promising field of emerging techniques has been employed to 
conduct the experimental part of this thesis.  
  
 
 
 
3.5 Purpose of experiments 
 
  As described in the previous three chapters, application of vibrational 
spectroscopy for cancer diagnosis and disease monitoring exhibit a number of 
advantages over conventional spectroscopy. 
  As the thesis mainly focuses on breast, prostate and bladder cancer, a less 
invasive approach for each one of the cases was explored. In the case of prostate 
and breast cancer, the transmission Raman mode is most applicable, benefitting 
from its high penetration depth, as both of the organs can be accessed from 
opposite sides (Chapter 10- Fig. 10.2). That would include the illumination of the 
tissue with a laser source on the one side and the collection of Raman scattering 
from the other side of the tissue. The deployment of transmission Raman 
geometry might be obvious for the breast cancer screening (Chapter 10- Fig. 
10.2a), but less so for the prostate gland analysis, as it is an internal and less 
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accessible organ. In the latter case, the illumination fibre could be inserted 
transurethrally and the collection fibre transrectally or the other way round 
(Chapter 10- Fig. 10.2b). 
  To assess the feasibility of such potential measurements, Chapter 5 describes 
transmission Raman measurements of liquid tissue phantoms similar in size and 
comparable in optical properties to breast and prostate gland. As calcifications 
are common features found both in breast and prostate and indicating potential 
malignancy, the phantoms fabricated contained a calcification-like compound, but 
of higher Raman cross-section, representing a malignant element in a block of 
tissue. By studying the magnitude and origin of Raman signal distribution in 
relation to the calcification position, we explored the possibility of malignancies 
being detected through the sample volume, in different depths and off the beam 
axis positions. Fabrication of different phantoms also allowed us to assess the 
Raman photon migration in relation to the tissue optical properties. This is a 
necessary step since different optical properties are not only observed between 
different types of tissues, but also in a single tissue of different malignancy 
stages. In chapter 6, the measurements are extended to animal samples and 
their different components as well as human prostate tissue in different modes of 
deep Raman, in order to assess the feasibility of such a concept. 
  In an attempt to improve the tissue phantom measurements in transmission 
Raman geometry, the promising approach of enhancing the Raman signal using 
the ‘’photon diode’’ is explored in chapter 7. The signal enhancement is studied 
in relation to the tissue optical properties and depth of the signal origin in the 
sample. The same signal enhancement concept is employed in chapter 8 to 
predict the depth of a potential malignant element in the sample volume. 
  In the case of bladder cancer (chapter 9), the feasibility of diagnosing the 
disease in urine samples using Raman microscopy was assessed. In that case, 
the urine samples were studied in terms of spectral features and their spatial 
distribution and the results were related to the presence of bladder cancer. 
Multivariate analysis was also used in order to determine the most significant 
discriminant features between healthy and malignant group. 
  The general objective of this thesis is to improve the future design of an in vivo, 
real-time and non-invasive cancer diagnosis by means of transmission and back-
scattering Raman spectroscopy. During our study, we assessed the feasibility of 
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a non-invasive diagnosis for breast and prostate cancer on tissue samples and 
phantoms and for bladder cancer on urine samples. In the case of breast and 
prostate cancer, we assessed the limits of detection of Raman signals from a 
potential malignancy in simulated in vivo measurement conditions. We also 
explored in which way parameters such as the optical properties and ‘’photon 
diode’’ enhancement are contributing to such an application as well as advance 
the understanding of how the distribution of collected Raman scattering signals 
change in relation to these parameters.  
  This study is intended to be a contribution to the future design of Raman 
instruments targeting disease specific signals within particular regions of the 
sample, and pave the way towards a real-time, non-invasive cancer diagnosis. 
The benefits of such an application could involve increased accuracy during 
cancer diagnosis, improved biopsy targeting and treatment monitoring. 
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4 Chapter 4: Materials and methodology 
 
  In this chapter the samples employed for measurements with deep Raman 
setup and Raman microscopy as well as the apparatus characteristics are 
described. The samples include a number of liquid tissue phantoms, human and 
animal tissue. The documents submitted for acquiring ethical approval for the 
human samples can be found attached in the end of the thesis (appendices). 
 
4.1 Sample collection and preparation 
 
4.1.1 Tissue phantoms 
 
  Inclusion-containing tissue phantoms with various optical properties are 
commonly used to simulate tissues in deep Raman spectroscopy214-216. During 
the experimental part of this thesis, a number of liquid tissue phantoms were 
fabricated and measured. 
 
4.1.2 Phantom design 
 
  The liquid phantoms employed in the study, consisted of a quartz cell (45 mm 
width × 30 mm length (26 mm internal cell optical path length) × 45 mm height) 
(ramé-hart instrument co., USA) containing aqueous solutions of Intralipid and 
Indian ink in various concentrations (Figure 4.1(i)). Intralipid (Fresenius Kabi Ltd, 
United Kingdom and 20% emulsion, Sigma), a dilute mixture of emulsified fatty 
acids, served as a scattering medium whereas Indian ink (Histology Stain, 
American MasterTech), a dispersion of carbon particles, acted as a broad band 
absorbing agent. The combination of water, Intralipid and Indian ink has been 
shown not to change the microphysical and optical properties of the constituents 
when mixed217.    
  The preservation of Intralipid’s quality over time was assured by recording the 
stability of its UV/Vis absorption at 830 nm before each experiment. The UV 
measurements were performed using a Thermo Scientific Evolution Array UV-Vis 
Spectrophotometer with a range of 185-1100 nm, 30 scans and a 1000 ms 
integration time. A volume of 0.75 ml Intralipid stock solution was diluted down to 
a 0.15% aqueous solution to avoid saturation in measurements. Since the 
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Intralipid as a fat emulsion tends to form aggregates which can precipitate over 
time, recording its absorption frequently reveals any changes in its consistency. 
 
 
Figure 4.1: (i) Liquid tissue phantoms components. (ii) The quartz cell and the 
vial which were used in our measurements.  
 
  Whenever Indian ink was used, it was first subjected to ultrasound in an 
ultrasonic water bath for 30 minutes. This was necessary in order to prevent 
suspended carbon particles from forming clusters in the aqueous solution and 
maintain reproducible ink optical properties218, 219. 
  In order to simulate a pathobiological formation in the tissue, an inclusion 
consisting of a thin vial (12 mm width, 4 mm length (2 mm optical path length)) 
containing hydroxyapatite (HAP) or trans-stilbene, was placed inside the quartz 
cell (see Fig. 4.1 (ii)). HAP was selected for these experiments in order to 
represent a calcified formation (calcification) which can usually be found in both 
breast220 and prostate tissues63, 221. Another important feature of HAP is that it 
provides a distinct Raman signal from the surrounding phantom (representing the 
soft tissues here) and therefore the signal distribution in relation to the phantom 
properties can be better studied. In some cases trans-stilbene was used as an 
inclusion material instead for its high Raman cross-section properties. By 
replacing HAP with trans-stilbene it was possible to probe higher optical 
properties phantoms with the existing Raman apparatus, while having the same 
expected behaviour as HAP and therefore assess the detection limits of our 
system.   
  During the mapping experiments in chapters 5, 6, 7 and 8, the vial was attached 
to a computer-controlled motorized translation stage (Standa Ltd, Lithuania) in 
order to move it to different positions inside the liquid phantom. 
 
(i) 
(ii) 
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4.1.2.1 Phantom stability assessment 
 
  In order to assess liquid tissue phantom consistency and stability during 2D 
mapping over time, a series of measurements were recorded for a number of 
phantoms. Measurements were recorded while the trans-stilbene vial was moved 
in different positions inside the quartz cell, in a snake-like pattern (Fig. 4.2). After 
the measurements have been pre-processed as described later in 4.3.1 section, 
the mean trans-stilbene Raman signal intensity has been calculated on the y axis, 
in order to plot the intensity as a function of the phantom depth. 
 
 
Figure 4.2: Recorded measurements while the trans-stilbene vial was moved in 
a snake-like pattern into the quartz cell. 
 
  The movements were realized in a normal (snake-like) pattern and reversed 
sequence using the motorized x-y translation stage, over different measurement 
points. 
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Figure 4.3: Stability measurements in liquid tissue phantom with scattering (1% 
IL) and no absorption. 
 
Figure 4.4: Stability measurements in liquid tissue phantom with scattering (1% 
IL) and absorption (0.2μl/ml ink). 
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Figure 4.5: Stability measurements in liquid tissue phantom with scattering (2% 
IL) and absorption (0.2μl/ml ink). 
 
  The trans-stilbene Raman signal height for 1192 cm-1 band was measured and 
compared for each phantom in one normal and two reversed sequences with 30 
minutes time gap between them. For the only scattering phantom (Fig. 4.3), the 
trans-stilbene Raman signal between the two time points are identical and the 
measurements are highly reproducible and accurate. When absorption is 
introduced in lower (Fig. 4.4) and higher levels (Fig.4.5), the values seem to follow 
the same trend with an extra variation of less than 10%. This variation is possibly 
due to the liquid nature of the tissue phantoms, but it is not high enough to affect 
significantly the experimental results. However, in order to achieve high 
repeatability between the different measurements, the liquid phantom solution 
was transferred to a 50 ml falcon tube and mixed by shaking, before the start of 
every mapping.  
 
4.1.2.2 Correlating phantoms with human tissue 
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  The liquid tissue phantoms employed for this study were fabricated to mimic 
mainly human breast and prostate tissue both in size and optical properties. In 
terms of dimensions, the quartz cell was chosen in order to provide an 
approximation to breast volumes in mammographic screening (1.9–7.2 cm 
compressed breast thickness)222 and human prostate gland (4–4.5 cm length, 2–
3.5 cm width, 1.7–2.5 cm thickness)223. 
  In terms of optical properties, the Indian ink and Intralipid concentrations in 
phantoms were determined to match those for human prostate and breast tissue 
optical properties of absorbance and reduced scattering in 830nm, as found in 
the literature. The reduced scattering (μ′s) and absorption (μa) coefficient values, 
for normal and cancerous prostate glands, have been calculated through optical 
extinction and diffusion reflectance measurements. The values reported in the 
literature for μ′s at 830 nm are 4 cm−1 for healthy and 6 cm−1 for cancerous 
prostate glands, whereas the values for μa are 0.027 cm−1 for healthy and 0.002 
cm−1 for cancerous prostate respectively224. Svensson et al. used NIR time-
resolved spectroscopy to estimate the reduced scattering coefficient between 5.5 
and 9.5 cm−1 and absorption coefficient between 0.3 and 0.7 cm−1 for malignant 
prostate glands with untreated cancer.225. Regarding breast tissue, the reduced 
scattering coefficient has been calculated for 830 nm wavelength to be μ′s = 9.84 
cm−1 226. Breast tissue absorption coefficients are not available in the literature 
for the exact wavelength of 830 nm, but a value of μa between 0.068 and 0.102 
cm−1 in papillary breast cancer is estimated for a very close wavelength of 825 
nm226, 227. 
  Based on the literature values for reduced scattering and absorption coefficients 
of human prostate and breast tissues, liquid tissue phantoms were built around 
clinically relevant values of μ′s and μa, using appropriate Intralipid and Indian ink 
concentrations. In order to calculate the appropriate component concentration 
required for the phantoms, our stock Intralipid and Indian ink needed to be 
characterized in terms of reduced scattering coefficient and absorption coefficient 
respectively. For simplicity reasons we assumed that Intralipid has no absorption 
and Indian ink no reduced scattering properties. 
  For the characterization of Intralipid, the fitting parameters for 10%, 20% and 
30% Intralipid provided by Michels et al228 were used in order to calculate the 
Intralipid reduced scattering coefficient and converted to our wavelength. From 
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the fit, we extracted the Intralipid concentrations equivalent to the required 
reduced scattering coefficient values (Fig. 4.6). Using these values, liquid tissue 
phantoms with reduced scattering coefficients in a range of 2.3 to 36.9 cm−1 were 
fabricated, using Intralipid concentrations calculated based on the calibration line 
expression 𝑦 = 92.17𝑥.  
 
 
Figure 4.6: Percentage Intralipid concentration versus reduced scattering 
coefficient (cm−1). 
 
  It should be mentioned here that the Intralipid concentration may not be 
correlated linearly with the reduced scattering coefficient values in the whole 
concentration range as assumed from Michels’ paper. However, there is 
evidence that in low Intralipid concentrations (0.5-1.3%) at 830 nm, there is a 
fairly linear correlation between the two values229, 230 231. 
  In terms of absorption properties, different concentrations of Indian ink were 
used to achieve different absorption coefficients in the phantom. Indian ink from 
different manufacturers has been widely employed and characterized in various 
studies232. In this study we measured the absorption coefficient of our specific 
stock volume of Indian ink.  
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  UV/Vis absorption spectra of different ink concentrations were recorded similarly 
to Intralipid UV measurements earlier.  
 
 
Figure 4. 7: Absorbance spectra for different concentrations of Indian ink. (laser 
and Raman photons wavelengths are indicated for citing reasons in Chapter 5). 
 
  Data from these measurements were curve fitted for the appropriate wavelength 
(830 nm) and the ink concentrations required for the human tissue absorption 
were calculated233 as below: 
 
  If during an absorption measurement we consider an ink aqueous solution with 
C concentration, absorption cross-section σ in a cuvette of x thickness, then from 
Beer-Lambert Law:  
 
𝐼 = 𝐼0𝑒
−𝜎𝐶𝑥 = 𝐼0𝑒
−𝜇𝑥    (4.1) 
 
  Where 𝜇 = 𝜎𝐶 is the linear attenuation coefficient which we can equate with the 
linear absorption coefficient in the case of ink where there are no scattering 
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events present. Because μ is a function of wavelength, Beer-Lambert Law will 
also be a function of wavelength: 
 
𝐼(𝜆) = 𝐼0(𝜆)𝑒
−𝜇(𝜆)𝑥    (4.2) 
 
As absorbance is defined: 
 
𝐴 = log(
𝐼0(𝜆)
𝐼(𝜆)
)    (4.3) 
 
From (1): 𝐴 = log(
𝐼0(𝜆)
𝐼(𝜆)
)  log(𝐼0(𝜆)/𝐼0(𝜆)𝑒
−𝜇𝑥) = log(𝑒𝜇𝑥) 
𝑨 = 𝜇𝑥 log(𝑒) = 𝟎. 𝟒𝟑𝟒𝟑𝝁𝒙    (4.4) 
 
Where: μ= absorption coefficient depending on the wavelength 
A= absorbance value at a specific wavelength 
x= cuvette path length (here in cm) 
 
  Using the measured absorbance for each ink concentration at 830nm, we 
plotted the two values against each other in a calibration curve: 
 
 
Figure 4.8: Indian ink calibration curve: ink absorbance versus ink 
concentrations in aqueous solution (μl/ml). 
y = 0.5567x + 0.0056
0
0.2
0.4
0.6
0.8
1
1.2
0 0.2 0.4 0.6 0.8 1 1.2 1.4 1.6 1.8 2
In
k 
co
n
ce
n
tr
at
io
n
 (
m
ic
ro
lit
re
s/
m
l)
Absorbance
Ink calibration curve
86 
 
 
 
 
  Since the cuvette path length was 1 cm in these measurements, we can 
calculate the respective absorption coefficient for each concentration using (4.3).  
  Based on the calculations above, a number of liquid phantoms were produced 
with absorption coefficients in a range from 0 to 2.26 cm−1. Our data were in a 
very good agreement with the literature in the range of concentrations 
mentioned224.  
  In order to simulate the optical properties of prostate and breast tissues, the 
scattering and absorption agents were combined in the same sample. The 
phantoms were made by combining an Intralipid range of 0-4% (corresponding 
to reduced scattering coefficient: μ’s= 0-36.9 cm-1) and an Indian ink range of 0-
0.5μl/ml (corresponding to an absorption coefficient: μa= 0-2.26 cm-1). 
  Finally, the absorbance spectra of water, a main phantom component, has also 
been recorded (Fig. 4.9). 
 
 
Figure 4.9: Absorbance spectrum of water in the range of 400-1100 nm. 
Negative absorption values are due to the difference in refractive index between 
air (used as a blank in the cuvette) and water. The cuvette path length in the 
measurements is 1 mm. 
 
87 
 
 
 
 
4.1.3 Tissue samples 
 
4.1.3.1 Animal tissue samples 
 
  Animal tissue which has been used in this thesis included chicken breast, beef 
shin and pork fat, all purchased from a local shop. 
 
4.1.3.2 Human tissue samples 
 
  The human samples used in this study were prostate tissue and urine samples 
and were acquired following fully informed consent of the patients and ethical 
approval from the Royal Devon & Exeter Tissue Bank. The documents related to 
this procedure can be found in Appendix 1. 
 
4.1.3.2.1 Prostate tissue 
 
  Nineteen tissue sections of prostate biopsies and 9 TURPs have been acquired 
for the study through biopsy and transurethral resection of prostate, respectively. 
TURP chips were around 20 mm long and 2.5 mm thick and the biopsies 10 mm 
long and less than 1 mm thick (Fig. 4.10).  
 
 
Figure 4.10: (a) TURP chip and (b), (c) prostate biopsies measured in the deep 
Raman system. 
 
  Once the samples were removed from the patient, they were transferred into 
cryovials, snapped frozen in liquid nitrogen and stored in an -80°C freezer in 
Royal Devon and Exeter Hospital. The samples were put into polystyrene boxes 
filled with dry ice and transferred to Physics School in Exeter University. In the 
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labs of Exeter University, they were also stored in an -80°C freezer until being 
measured. The Raman measurements were followed by staining the edge of the 
sample for orientation reasons. The samples were stained using the following 
procedure: 
a) the end of a dry TURP chip was dipped in ink and let to dry 
b) acetic alcohol (100 parts of ethanol mixed with 3 parts of glacial acetic 
acid) was added on the top of the inked edge 
c) the TURP chip was let to dry and then dropped into a formalin pot. 
 
  The stained samples were moved into formalin pots and transferred back to the 
hospital for histopathological analysis. Both the TURP chips and the prostate 
biopsies were subjected to the same procedure, except that the biopsies were 
transferred to acetate paper right after the collection, in order to facilitate the 
sample handling, while their volume remained intact despite their small size. 
 
 
Figure 4.11: Protocol followed during the collection of prostate samples from 
the hospital. 
  For certain measurements described in chapter 6 the TURP chips were 
cryosectioned while frozen using a freezing- microtome (Fig. 4.11). The sample 
was kept frozen in ice rather than OCT in order to avoid signal contamination of 
the tissue. The thickness of the sections was 20 μm.  
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Figure 4. 12: Sectioning TURP chips using a microtome before recording 
Raman measurements. 
 
  It should be mentioned that due to the limitations identified while measuring the 
prostate samples in the deep Raman setup (not sufficient sample size, sample 
fluorescence induced by the surgical procedure), it was not eventually possible 
to correlate our results with the histopathological analysis.  
 
4.1.3.2.2 Urine samples 
 
  Urine samples from 11 healthy and 11 patients with bladder cancer were 
acquired from the Royal Devon & Exeter Tissue Bank. One of the patients did not 
have TCC bladder cancer and so the specific urine sample was excluded from 
the study. All of the samples were provided in 4 ml tubes, flash frozen in liquid 
nitrogen and stored at -80°C until required for analysis. Part of the samples was 
initially studied with Mass Spectrometry in Biosciences department of Exeter 
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University. As a following step, the remaining urine aliquots were transferred to 
Biophysics’ lab and studied with Raman spectroscopy. The urine samples used 
for Raman analysis had not been subjected to any protein removal. During the 
Raman measurements, the urine samples were measured in drops of 1μl laid on 
calcium fluoride (CaF2) substrates (Fig. 4.13). 
 
 
Figure 4.13: Urine drops measured with Raman microscopy. 
 
 
4.2 Experimental setups  
 
4.2.1 Deep Raman spectroscopy 
 
  The deep Raman setup employed for the measurements at the University of 
Exeter is a flexible setup which can be easily changed between transmission and 
iSORS modes. Before the start of the experiments, two different back illuminating 
CCD cameras were tested and compared in terms of performance, in order to 
identify the most appropriate one for the deep Raman setup. 
 
4.2.1.1 Camera evaluation 
 
  Two CCD detectors with different pixel array configuration, Andor iDus 416 
(2000256) and Andor iDus 420 (1024255), were compared in terms of fixed 
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pattern noise. The performance of the two cameras was assessed in terms of 
stability, oscillations and pattern of dark signal, by acquiring measurements in 
complete darkness.  
  Andor iDus 416 model has a greater number of pixels horizontally. In Figure 
4.14b the spectral range was adjusted in order to overlap Neon Argon Raman 
peak positions. 
 
 
Figure 4.14: Neon Argon measured with Andor iDus 420 (green) and 416 (red) 
detector before (a) and after (b) adjusted spectral range. 
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  The two cameras were also compared in terms of the standard deviation of their 
dark noise, which was lower for iDus 416 in counts, but higher when calculated 
in the ultimately relevant photoelectrons (i.e. detected photons) (in iDus 420 the 
number of photoelectrons per count (2.5) were higher compared with the iDus 
416 (0.7)). 
  Signal to noise ratio was another feature assessed between the two cameras. 
This is due to photon shot-noise (random and independent of CCD) stemming 
from the particle-like nature of light and other (fixed) instrumental influences such 
as etaloning effect (Fabry-Perot) which takes place between the two silicon 
surfaces of a back illuminating CCD due to the interference of light waves in a 
constructive or a destructive way (or also present due to laser-blocking filter 
residual etaloning effect). The etaloning was assessed by calculating the range 
of regular oscillations divided by the signal, on the white light spectrum measured 
by each camera (Fig. 4.15). Both cameras exhibit a range of oscillations divided 
by the signal being around 5%, which is acceptable for our measurements. More 
specifically, the oscillations for iDus 416 were calculated to be 5.7%, whereas for 
iDus 420 4.5%. 
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Figure 4.15: Room light spectrum (acquisition time: 1 s) as measured with 
Andor iDus 420 (green) and 416 (red). 
 
  Another characteristic assessed was the pattern of dark signal which should 
normally be stable and independent of wavelength. Although, for iDus 416 that 
was the case, for iDus 420 an uneven elevated background signal was observed 
when not at fully cooled state (e.g. at ~ -70 oC and higher temperatures) (Fig. 
4.16). For that reason, before every measurement it was ensured the CCD 
camera was cooled fully down to -75 ºC in order to minimize the thermal noise. 
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Figure 4.16: Dark noise pattern as measured in complete darkness (acquisition 
time: 1s) with Andor iDus 420 (blue and red) and 416 (yellow) at different 
temperatures (-70 ºC and -80 ºC) at the lowest charge shift speed (16.25 μs). 
 
  Since the two cameras exhibited very similar performance, Andor iDus 420 was 
eventually chosen for its more suitable pixel configuration for our applications (i.e. 
it could capture more light in the vertical direction, matching better the fibre bundle 
slit in our system). 
 
4.2.1.2 Setup description (transmission, iSORS) 
 
  The deep Raman system at Exeter University is a flexible setup which can be 
changed between transmission and iSORS configuration (Fig. 4.17). The setup 
consisted of a spectrum-stabilized laser (Innovative Photonics Solutions: 
Innovative Photonic Solutions: I0830MM0350MF-EM) with laser emission at 830 
nm and an output power of ∼300 mW. The laser was coupled to a Thorlabs 400 
μm diameter multimode optical fibre and at the output collimated and filtered by 
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passing through a pair bandpass laser line filters (FL830-10, Thorlabs) in order 
to suppress the spectral wings.  
 
 
Figure 4.17: Deep Raman flexible setup for transmission and iSORS 
measurements in Exeter University. 
 
  When the setup was used in a transmission mode, which is the case for most of 
the measurements described in the experimental section, the laser was directed 
towards the sample with a mirror and brought onto it with a 25 mm diameter, 70 
mm focal length lens (Fig. 4.18a). The sample was illuminated with 280 mW of 
light in a 3–4 mm diameter spot.  
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Figure 4.18: Deep Raman setup configuration in (a) transmission and (b) 
iSORS mode. 
 
  When the setup was used in an iSORS mode, the laser beam was passed 
through an axicon (conical lens), illuminating the sample in a ring shape, on the 
same side where the Raman light was being collected (Fig. 4.18b). The size of 
the ring was adjusted by moving the axicon to different distances from the 
sample. In this way, different translational positions of the axicon on the rail (0 to 
9 cm) correspond to different radii of the illumination ring (1.5 to 7.5 mm), or 
spatial offsets from the collection centre (Fig. 4.19).  
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Figure 4. 19: Different axicon distances from the sample correspond to different 
spatial offsets from the collection centre (indicated at the top). 
 
  In both transmission and iSORS configuration, the light passing through the 
sample is either scattered or absorbed by the molecules present. The Raman 
photons were collected using an AR coated lens (f = 60 mm, dia. = 50 mm, 
INGCRYS Laser systems). The collimated light was passed through a 
holographic super notch filter (HSPF-830.0 AR-2.0, Kaiser Optical Systems) to 
remove the elastically scattered light (laser photons) and imaged onto a fibre 
probe bundle by a second lens of the identical parameters to the collection lens 
(i.e. the collection system exhibited no magnification). The fibre bundle 
(CeramOptec, ‘spot to slit line’ type bundle assembly, active area spot diameter 
approximately 2.2 mm, slit line 0.2 mm × 14.95 mm) was connected to the 
entrance port of a Holospec VPH system spectrograph (Kaiser Optical systems 
Inc, HSG-917.4 custom). Measurements were recorded using a deep depletion 
CCD camera cooled down to −75 °C (Andor Technology, iDus 420, DU420A-BR-
DD, 1024 × 255 pixels). Only a part of the input fibres aligned in the vertical line 
pattern (around ~6 mm) were imaged onto the CCD. The overall spectral 
resolution of the detection system was ∼8 cm−1.  
  Through both transmission and iSORS measurements, the shift speed and the 
readout rate applied on the camera settings were set to the lowest value (16.25 
μs and 33 kHz respectively) in order to introduce the least noise possible to the 
spectra acquired. In the case of accumulated measurements, the cosmic ray 
removal option in the detector software (Andor Solis) was applied. The system 
was always calibrated using an aspirin tablet (acetylsalicylic acid) and HAP 
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(hydroxyapatite) powder (Fig. 4.20). Their Raman signal was also recorded over 
a specific acquisition time (3 s for ASA and 1 s for HAP) in order to compare the 
peak height levels from day to day.   
 
 
Figure 4.20: Aspirin (ASA) and hydroxyapatite (HAP) spectra from calibration 
standards during the deep Raman measurements. Acquisition time: 3 s for ASA 
and 1 s for HAP. The spectral offset has been adjusted for clarity. 
 
4.2.1.3 Automated stage and mappings 
 
  For the recording of the phantom mappings described in the experimental part, 
a motorized translation stage (8MTF-102LS05, Standa Ltd, Lithuania) was 
employed. During the mappings, the probing vial was suspended from the 
motorized stage and moved to different positions. The vial width (12 mm) was 
always aligned with the y-axis and the 4 mm length was aligned with the optical 
axis of the system (x-axis). In this way, the vial was moved in a two-dimensional 
horizontal grid (Fig. 4.21).  
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Figure 4.21: Vial attached to the translation stage and moved in different 
positions of a 2-D grid during the phantom mappings. 
  During the mappings, the vial was moved in a ‘snake’-like pattern, starting from 
the laser entrance side and moving towards the exit side of the cell. At each step, 
a Raman spectrum was recorded and the stage was moved to the next position.  
 
4.2.1.4 ‘’Photon diode’’ element and reflective filters 
   
  The ‘’photon diode’’ element used in Chapter 7 and 8, is an unmounted 830 nm 
bandpass filter with 25 mm diameter and 3.5 mm thickness (Semrock, FWHM 
bandwidth measured as 9.5 nm, BrightLine® singleband bandpass filter) (Fig. 
4.22a). 
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Figure 4.22: (a) Semrock photon diode mounted at the centre of a metal plate 
wrapped with aluminium for optimum reflectivity and (b) signal enhancement 
mechanism of photon diode. 
 
  The photon diode is a dielectric bandpass filter which increases the collected 
Raman signal from a highly scattering sample when it is placed in close proximity 
to the sample surface, at the point where the illumination beam enters the sample. 
The photon diode is essentially a unidirectional mirror which allows photons of a 
specific wavelength (in our case: >90% 829-831nm) and angle of incidence (0 ± 
5 degrees) to be transmitted. For photons with a different angle of incidence, as 
the deviation from the right angle increases, the wavelength transmittance 
distribution is moving to lower wavelengths (Fig. 4.23). Due to this angular 
dependence, the majority of the photons of a collimated laser beam will enter the 
sample but will not escape from it backwards once they are scattered or 
converted to Raman photons, due to the change of angle of incidence and 
wavelength respectively (Fig. 4.22b). Minimizing the photon loss in the air-sample 
interface is critical, since more than 90% of the photons can escape typically from 
the sample by this mechanism234. As the laser and Raman photons are forced to 
remain inside the sample, they have more chances to interact with the Raman 
a 
b 
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scatterer and travel deeper inside the phantom, towards the collection system. In 
this way, the sensitivity, penetration depth and overall detectable Raman signal 
of the experiment are improved.  
 
 
Figure 4.23: Schematic illustration of the shift of the design wavelength with the 
angle of incidence for a dielectric bandpass filter used for the enhancement of 
the coupling of laser radiation into a turbid sample235. 
 
  During the measurements, the photon diode was mounted at the centre of a 
metal plate which was then placed at the front of the quartz cell against its internal 
wall (Fig. 4.24i). The metal plate outside the active area of the photon diode was 
covered with an aluminium reflecting foil, in order to achieve the maximum 
reflectance of re-emerging photons back to the phantom also outside the filter 
(Fig. 4.24ii).  
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Figure 4.24: Photon diode (i) introduced in the setup and (ii) inserted inside a 
metal plate on the front of the phantom while undertaking deep Raman 
measurements. 
 
  In order to identify the side of the diode with the effective layer, we recorded a 
series of measurements from an identical trans-stilbene vial, testing the two 
different diode sides (A and B) which were facing the laser beam each time. For 
the test measurements, a combined tissue phantom (1%IL + 0.2 μl/ml ink) was 
employed and the longitudinal plots of generated Raman signal along the optical 
axis are presented in Figure 4.25. 
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Figure 4.25: Raman intensity of trans-stilbene (1192 cm-1) as a function of 
distance from the illumination side. 
 
  From the plot above it is obvious that when side A of the photon diode faces the 
laser beam, there is a greater transmittance and signal enhancement. This is why 
in the following experiments the diode was used in this specific orientation.  
 
  During the control (no photon diode) measurements in chapter 7 and 8, a quartz 
window of identical dimensions was placed at the same location in order to make 
up for the loss of liquid phantom volume and to retain the identical mapping 
pattern. Additionally, a calcium fluoride disc (20 mm diameter, 1 mm thickness) 
was placed between the diode/quartz and the cell wall during every 
measurement, in order to minimize the solution volume trapped in the front 
interface which would potentially lead to disruption of the incident collimated laser 
beam. 
104 
 
 
 
  Both the diode and the quartz layers were cleaned thoroughly before every 
measurement, using a lens tissue wrapped around a tip and moistened by 
acetone, as suggested by the manufacturer.   
  Since a major part of the analysis in Chapters 7 and 8 involves comparison of 
measurements using different elements (photon diode, quartz layer), it was 
considered necessary to measure the transmittance of the elements separately 
on the deep Raman setup using a power meter with no solution and no vial 
present in the cell (Fig. 4.26).  
 
 
Figure 4.26: Transmittance of photon diode and quartz layer used in the 
experiments, as power meter is set in different distances from them. 
 
  The transmitted power though quartz layer and diode individually (without the 
quartz cell on the sample holder), only shows a significant difference when the 
power meter is placed closest to the illumination side. However, when the quartz 
cell was introduced to the measurements (Fig. 4.27), we observed a considerable 
difference in the power which drops from 275 mW (quartz layer) to 254 mW 
(photon diode). This reduction of power by ~8% (due to the different 
transmittance of materials) is affecting signal comparisons between the two of 
them, as described in chapter 7. 
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Figure 4.27: Measuring photon diode and quartz layer transmittance on deep 
Raman setup. 
 
4.2.2 Raman microscopy 
 
4.2.2.1 InVia Raman spectrometer 
 
  For the Raman microscopy measurements in chapter 9, we used a Renishaw 
inVia spectrometer (Renishaw plc, New Mills, Wotton-under-Edge, 
Gloucestershire, GL12 8JR), with near-infrared diode excitation lasers (785 nm 
and 830 nm). The system is equipped with reflected light white light imaging and 
generates 300 mW of power. The laser light is initially focused through the 
microscope lens (×50 objective) onto the sample on a motorized XYZ stage. 
Following interaction with the sample, the Raman back-scattered light is collected 
through the collection optics and focused onto the grating, whereas Rayleigh light 
is rejected away through filters. The dispersion grating then splits the beam into 
its constituent wavelengths which are directed onto a CCD detector. The CCD 
used for converting the photons to electrical signal, is a deep depletion charge-
coupled-device detector that comprises an array of 1024 × 256 pixels. Similar 
schematic overview of a Raman microscope can be found in chapter 3 (Fig. 3.6). 
  InVia Raman spectrometer can operate in both traditional point Raman mode 
and StreamLine Raman imaging mode, which is a fast mapping method for data 
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collection236. In Streamline mode, a laser line is employed to scan a sample area 
and produce a spectrum which is made of an accumulation of 6 point spectra. 
Whenever Streamline was used, Slalom mode was also activated. Slalom mode 
ensures that data from the whole of the area defined for analysis is sampled, 
since it zigzags StreamLine’s laser line. The single point measurements 
presented in chapter 9 were recorded with traditional Raman mode, whereas the 
mappings were recorded with the Streamline mode.  
  Renishaw InVia microscope is equipped with three different gratings (300, 600 
and 1200 lines/cm). For the measurements recorded in this thesis, we used the 
1200 l/cm grating centred at 1300 cm-1. The spectral resolution for 1200 l/cm 
grating and 785 nm excitation laser was calculated to be 2.5-3 cm-1. 
  Although the system is equipped with internal calibration routines, both internal 
and external standards (Si, NeAr) were measured prior to each measurement in 
order to ensure optimum conditions for reproducibility and comparison between 
the samples. 
 
4.2.2.2 Other Raman systems 
   
  For the urine maps analysed with multivariate analysis in Chapter 9, 
measurements were recorded on a Renishaw System 1000 using 830 nm as the 
excitation wavelength. This is operating in a similar way as InVia237. 
  For the polarization measurements described in Chapter 9, polarizers were 
added in the path between the laser light and the sample on Renishaw System 
1000, in a parallel and perpendicular orientation. 
  For a single measurement of urine samples with 532 nm excitation laser in 
Chapter 9 (Fig. 9.1), confocal Raman microscope (Witec alpha300) has also been 
used. 
 
 
Raman spectroscopy substrates 
  Irrespective of Raman systems employed, urine samples were always 
measured in drops of 1 μl laid on calcium fluoride (CaF2) substrates (Fig. 4.13). 
Calcium fluoride has been shown to be a suitable substrate for Raman 
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measurements, as it only exhibits a peak at 321 cm-1 (Fig. 4.28), lacking 
significant background in the rest of the fingerprint region. 
 
 
Figure 4.28: Raman spectrum of CaF2 discs, used as substrates in Raman 
microscopy measurements. The peak at 1540 cm-1 corresponds to atmospheric 
oxygen. 
 
4.3 Data processing and analysis 
 
4.3.1 Spectral analysis 
 
  Single Raman measurements shown for comparison reasons in this thesis, are 
plotted using Origin8 (OriginLab, Northampton, MA, USA).  
  For deep Raman data analysis (Chapter 5, 6, 7, 8), the maps recorded on the 
deep Raman system, were loaded into Matlab R2013a (The Mathworks Inc., 
Natick, Massachussetts, USA) for data pre-processing. The spectra were 
subjected to baseline correction using asymmetric least squares smoothing238, 
principal component (PC) noise reduction and subsequent reconstruction from 
the first seven principal components into 1D and 2D images. The noise in the 
principal components were assessed individually by eye. PC noise reduction is a 
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useful method for minimizing the noise in a set of spectra by reconstructing it only 
from the significant noise-free principal components. In this way, all of the 
important spectral information is retained, whereas the background noise is being 
removed239, 240. For the 1D plots only, following pre-processing, the mean 
intensity on the y-axis was calculated in order to directly compare the values 
between the different maps. 
  For urine analysis (Chapter 9), the maps data were also processed using 
Matlab. The set of spectra for each map were subjected to baseline correction 
with asymmetric least squares smoothing and cosmic ray removal241. The mean 
spectra for each sample were calculated from the processed individual spectra 
and scaled to a 0 to 1 scale. The 1542 cm-1 band attributed to the atmospheric 
oxygen has been removed from the spectra which were finally normalized, mean 
centred and analysed with multivariate techniques.   
 
4.3.2 Multivariate analysis 
 
  Multivariate analysis is a very useful tool for data analysis in spectroscopy 
commonly used for data reduction and quality improvement (signal-to-noise ratio, 
resolution), classification of information of the data and appropriate display of 
information (visualization of information content and its statistical validity)242. In 
this thesis, Principal component analysis (PCA) and partial linear discriminant 
analysis (LDA) were performed over the pre-processed Raman spectra. In the 
deep Raman data PCA was employed for noise reduction in the spectra, whereas 
in the urine sample PCA and LDA have been used for revealing the discriminant 
features between the two pathology groups.  
 
4.3.2.1 Principal Component Analysis (PCA) 
 
  PCA is an unsupervised multivariate technique, as it ‘’ignores’’ the pathology 
class of each sample. PCA is used to explore the inherent structure of the data 
and involves a mathematical procedure which uses an orthogonal transformation 
in order to reduce the dimensionality of a dataset with possibly correlated 
observations (e.g. Raman shifts) and converts it into linearly uncorrelated 
(orthogonal) components which are called principal components243, 244. The first 
principal component (PC1) accounts for the greatest data variance from the mean 
and each succeeding component accounts for as much of the remaining spectral 
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variability as possible in a descending order. The original matrix is decomposed 
by PCA into two smaller matrices, one of scores and another of loadings245. 
  The loadings describe decreasing amounts of variance present in the dataset246 
and when they are plotted as a function of the variables, the plot reveals the most 
important diagnostic features related to the differences in the dataset. When 
loadings are multiplied by their corresponding scores and summed, the original 
spectra can be reconstructed. When scores are plotted against each other, they 
reveal relationships between the groups of observations. In that way PCA allows 
the identification of groups of variables that are correlated via underlying 
phenomena that cannot be observed directly247.      
  In the deep Raman data, PCA was used for noise reduction in the spectra, by 
analysing the principal components of the dataset and reconstructing them by 
only combining the limited noise components.   
 
4.3.2.2 Linear Discriminant Analysis (LDA) 
 
  Contrary to PCA, LDA is a supervised technique which tries to maximize the 
separation between multiple classes, by identifying the optimum linear 
combination of features (vectors) that characterize/discriminate the classes. LDA 
results in linear discriminant functions that maximize the variance in the data 
between separate pathological groups and minimize the variance between the 
members of the same pathological group.  
  While analysing urine samples in Chapter 9, PCA was initially performed to 
obtain the first 15 principal components and the PC scores were then used to 
perform LDA on the dataset. During LDA, each principal component was 
assessed in terms of ability to provide an optimum separation of the pathology 
classes. Once the optimum combination is identified, the model can be tested by 
the ‘’leave-one-out’’ cross-validation method. This method involves leaving a 
sample from a group out of the dataset, performing PCA followed by LDA on the 
dataset and then test the resulting model with the sample which has been left out 
initially246. In this way a confusion matrix is being created to describe the 
performance of the classification model, from where the sensitivity and specificity 
of the diagnostic algorithm can be calculated.     
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5 Chapter 5: Deep Raman spectroscopy on 
tissue phantoms for cancer diagnosis 
 
5.1 Introduction 
 
  Deep Raman spectroscopy (Spatially Offset Raman Spectroscopy (SORS) and 
Transmission Raman Spectroscopy (TRS)) is a group of techniques developed 
for biomedical, pharmaceutical and security applications152, 161 and which in the 
last decade have found application also in cancer diagnostics154.  
  In this chapter we are exploring the potential of transmission Raman in the 
diagnosis of two of the most prevalent types of cancer, prostate and breast 
cancer, using equivalent tissue phantoms. As previously mentioned in Chapter 3, 
the potential clinical application of transmission Raman for cancer scanning of 
breast and prostate glands would include the illumination of the tissue with a laser 
source and the collection of Raman scattering from the other side of sample. The 
deployment of transmission Raman geometry might be obvious for the breast 
cancer screening, but less so for the prostate gland analysis, which is an internal 
and less accessible organ. In the latter case, the illumination fibre could be 
inserted transurethrally and the collection fibre transrectally or the other way 
round as shown in Figure 5.1. 
 
Figure 5.1: Potential transmission Raman geometry applied to prostate cancer 
detection (the peripheral zone is marked in blue) (recreated from248). 
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  A first step in order to assess the potential of this approach is to test its feasibility 
with transmission Raman measurements on tissue phantoms with similar size 
and comparable optical properties to breast and prostate. Similar studies on 
tissue and phantoms for diagnosis149, 155, 214, 249, 250 and surgical margins 
assessment212 have been reported in the literature. However, in these studies the 
Raman signal was only explored in terms of sample thickness, whereas aspects 
such as its spatial distribution throughout the sample volume and its dependence 
on the optical properties, still remain unexplored. 
  In this study, in order to assess these parameters, we are recording the Raman 
scattering of calcification-like inclusions (often found in cancerous tissues) while 
its position inside the phantoms is changing and their optical properties vary. In 
this way we can explore the origin of Raman signal currently in our phantoms and 
in a later stage in tissue areas of different consistency, understanding the relative 
signals measured from lesions (calcifications) buried in different depths in real 
tissues. With these measurements we assess the feasibility and the limits of 
detection of Raman signals from a calcification in simulated in vivo measurement 
conditions in order to help the future design of optical sampling methods to 
maximise the excitation and collection of these signals. 
 
5.2 Development of liquid tissue phantoms 
 
  In order to test the feasibility of measuring liquid tissue phantoms in a 
transmission mode of the deep Raman setup, their development had to be 
assessed step by step. 
 
Proof of principle:  
  First, the capability of the system to collect Raman photons emerging from 
deeper layers of the sample was tested. For that reason, Raman measurements 
were recorded from individual and overlaid vials (Fig. 5.2) containing different 
materials with high Raman cross-section such as calcium hydroxyapatite (HAP), 
calcium oxalate monohydrate (COM) and polytetrafluoroethylene (PTFE) (Fig. 
5.3).  
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Figure 5.2: Transmission Raman measurement of two overlaid vials containing 
two different materials. 
 
 
Figure 5.3: Raman signal from individual and overlaid vials containing different 
materials, in a transmission setup. The spectral offset has been adjusted for 
clarity. 
 
  The two layer measurements show that even if the sample is opaque, it is still 
possible for the laser photons to pass through the first layer via diffuse light 
scattering and interact with the second layer, generating in this way Raman 
photons which can be detected on the other side of the sample. In all of the 
overlaid measurements (COM in front of HAP, HAP in front of COM, HAP in front 
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of PTFE), the Raman peaks of the individual materials can be observed in Figure 
5.3. These peaks are more intense or weaker depending on the Raman cross-
section of each individual material.  
  To extend our hypothesis, a plastic container filled with amino acid (L-
methionine) was measured on a transmission mode on the deep Raman setup 
(transmission mode). The plastic container and its content (amino acid in powder) 
were also measured separately on a conventional reflectance Raman 
microscope (Renishaw System 1000- Chapter 4).  
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Figure 5.4: Amino acid powder and plastic container measured on transmission 
deep Raman instrument (photo) and Raman microscope for an acquisition time 
of 30 s x 3 accumulations and 10 s x 3 accumulations respectively. The spectral 
offset has been adjusted for clarity. 
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  We can observe that in both cases, the Raman signal acquired from deep 
Raman configuration is a composite signal from both the plastic container and 
the amino acid powder. Contrary to this, the measurements acquired on a 
conventional Raman microscope are single point spectra of either the plastic 
container or the amino acid powder.  
  This proves the ability of deep Raman to acquire signal from deep layers. This 
is in contrast with the capability of Raman microscopy that only collects effectively 
Raman photons typically from a few hundred micrometres depth, depending on 
the sample optical properties and exact optical configuration of the microscope.   
  
Zero diffuse scattering and zero absorption measurements: 
 
  In order to develop and spectroscopically assess the liquid tissue phantoms 
(Chapter 4), we started by testing the Raman signal of the HAP (hydroxyapatite) 
vial in different positions inside the quartz cell filled with water (26 mm optical 
path) and no diffuse scattering present. The specifications of the vial and cell are 
described in Chapter 4. No added absorbent was present although water itself 
induced notable absorption at different laser and Raman detection wavelengths. 
  The HAP was placed in three different positions (front, middle, back) on the laser 
beam axis (Fig. 5.5). The Raman signal acquired from these positions is 
presented in Fig. 5.6.  
 
Figure 5.5: A schematic diagram of the different positions of the HAP vial inside 
the quartz cell. 
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Figure 5.6: Raman signal acquired from HAP vial in three different positions of 
the beam axis (middle, front, back) in a quartz cell filled with water (transparent 
sample). The values indicate the heights of the phosphate peak (959 cm-1). 
Acquisition time: 1 s x 30 accumulations. The spectral offset has been adjusted 
for clarity. 
 
  We notice that the HAP vial has the maximum signal at the back of the cell, 
where the focusing point of the laser beam is and the majority of the Raman 
photons generated are collected by the fibre bundle. The second higher HAP 
signal is observed when the HAP vial is in the middle of the cell, followed by the 
position at the front as expected. The change of HAP intensity in different 
positions in the quartz cell when the medium lacks any scatterer or absorber 
(plain water), is due to the change of the solid angle of collection. When the HAP 
vial is closer to the collection side, the collection angle is the largest possible and 
more of the scattered photons are collected.  
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Introducing scattering (Intralipid): 
 
  To bring the tissue phantoms closer to the real tissue properties, scattering and 
absorption agents had to be introduced in the model. For that reason, Intralipid, 
a scattering medium of emulsified fatty acids which is described in Chapter 4, 
was added into the quartz cell surrounding the HAP vial. In order to explore the 
effect of scattering on the Raman signal, measurements were recorded with the 
HAP vial in different positions (front, middle, back) in the same way as in Fig. 5.5 
and in a solution of fixed scattering concentration (0.3%). 
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Figure 5.7: Raman signal before (blue line) and after spectral denoising (red 
line) acquired from HAP vial (960 cm-1) in positions front (a), middle (b) and 
back (c) on the beam axis and while the quartz cell was filled with 0.3% 
Intralipid solution. Acquisition time: 10 s x 10 accumulations. 
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  We notice that the behaviour of Raman signal changes compared to the water 
measurements earlier (Fig. 5.6). The maximum signal is still observed when the 
HAP vial is at the back of the cell, but the second maximum is now at front, and 
they have both comparable values. The minimum was absent when the vial is in 
the middle of the quartz cell, where no HAP peak is observed. 
  In the next step we explored how the concentration of the scatterer affects the 
Raman signal of HAP. A series of measurements were recorded for different 
concentrations of Intralipid while the HAP vial was in a fixed position (back). 
Background measurements were also recorded for the same concentrations of 
Intralipid in the absence of a HAP vial and were subtracted afterwards from the 
initial measurements (Figure 5.8). No absorber was added to the solution at this 
stage.  
 
 
Figure 5.8: Raman signal acquired from HAP vial at the back of the cell while 
the concentration of the Intralipid (IL) in the aqueous solution was increased 
gradually (from 0.05% to 0.3% IL). Acquisition time: 10 s. 
 
  It is important to observe here how the intensity of HAP decreases as the 
scatterer concentration and therefore the diffuse scattering are increasing. It is 
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obvious that the more Intralipid molecules there are in the phantom, the more 
difficult it is for the laser photons to reach the HAP vial and for the generated 
Raman photons to reach the collection optical fibres. In even higher IL 
concentrations, the transmittance of the sample would be so low that almost no 
laser photons would reach the HAP vial to generate Raman signal (which would 
presumably drop to zero).  
 
Introducing absorption (Nigrosin, haemoglobin, Indian ink): 
 
  In order to simulate real tissue optical properties, absorption also needed to be 
introduced in the phantoms. Since many different absorbing agents have been 
used for phantom fabrication in various studies, it was useful to characterise 
spectroscopically our potential absorbers first, in order to identify the most 
suitable one for our purposes. For that reason, Raman spectra were recorded 
from nigrosin, haemoglobin and Indian ink in the deep Raman setup (Fig. 5.9). 
 
 
Figure 5.9: Raman spectra of HAP vial in an aqueous phantom of (a) Nigrosin 
(10 s x 10 accumulations), (b) haemoglobin (10 s x 10 accumulations) and (c) 
Indian Ink (6 s x 5 accumulations) on a transmission mode. No scatterer is 
present. The spectral offset has been adjusted for clarity. 
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  From Figure 5.9 shows that Nigrosin exhibits a high fluorescence background. 
Since the absorber would be chosen in order to provide broad band absorption 
without fluorescence contributions, Nigrosin was not suitable as an absorbing 
agent for measurements in this range of wavelength. The second option was 
haemoglobin (Hb) which has a suitable Raman spectrum but it is also linked to 
stability issues when mixed with Intralipid. Indeed, the integrity of haemoglobin in 
an Intralipid aqueous solution was observed over time, showing a formation of 
aggregates on the solution surface (Fig. 5.10c) and a subsequent change in 
clarity of the initial solution (Fig.5.10a-b). For all these reasons Indian ink was 
chosen as an absorbing agent in the tissue phantoms.  
 
 
Figure 5.10: Observation of haemoglobin stability in an Intralipid aqueous 
solution over time. The solution before (a) and after (b) a set of measurements 
that lasted 3 hours. Formation of aggregations can also be observed on the 
surface of the solution (c) after a long interaction time between Intralipid and 
haemoglobin. 
 
  We can now explore how the concentration of Indian ink affects the Raman 
signal of HAP when HAP vial is in a fixed position (back). Measurements of 
phantoms of different absorber concentrations in absence of Intralipid were 
recorded in the transmission deep Raman setup. 
a b c 
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Figure 5.11: Raman signal acquired from HAP vial on the back of the cell while 
the Indian ink concentration in an aqueous solution was increasing gradually 
(from 0.1 μl/ml to 0.8 μl/ml). The values indicate the heights of the phosphate 
peak (959 cm-1) in a.u. Acquisition time: 0.25 s x 120 accumulations. The 
spectral offset has been adjusted for clarity. 
 
  The intensity of HAP decreases as the Indian ink concentration increases, 
because both of the laser and the generated Raman photons are being absorbed 
and therefore fewer photons reach the collection fibre optics. 
 
On and off the beam axis measurements: 
 
  The effect of the HAP position on the collected Raman signal has only been 
explored in terms of the vial position when this is aligned with the beam axis. 
However, due to the diffuse scattering we expect the Raman signal to be 
detectable outside the beam limits. In order to explore the spatial detection limits 
and the Raman scattering distribution more consistently and in greater detail, the 
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phantom transmission signal was recorded while the HAP vial was at 300 
different positions on a grid inside the quartz cell (Fig. 5.12) as described in 
Chapter 4.  
 
Figure 5.12: The top view of the phantom with the HAP vial inside the quartz 
cell, in a 300 position grid (less positions are shown here for simplicity 
purposes). 
 
  The measurements took place in a set of phantoms with varying optical 
properties, in order to simulate the range of clinically relevant optical properties 
of prostate and breast tissue (Chapter 4 and Chapter 7- Table II). The results of 
these measurements are presented below.  
 
5.3 Individual maps of scattering and absorption in 
transmission mode using HAP  
 
  Raman scattering mappings were first recorded in scatterer (Intralipid) only 
phantoms, in order to assess the effect of scattering alone on the signal 
distribution of the maps. The amount of scattering was defined by the 
concentration of the Intralipid added to each phantom, which was in turn related 
to the scattering coefficient of the phantom (see Chapter 4 for calculations).  
  Initially, a plain water mapping was recorded for each one of the two sides of 
HAP vial (Fig. 5.13), in order to check that the orientation of the vial does not 
have any effect on the signal distribution throughout the phantom.    
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Figure 5.13: The two different sides of HAP vial and their corresponding 2D 
plots in a water solution where laser photons are injected on the left of the 
image and Raman signal is collected on the right. Every pixel represents a 
different location of the HAP vial in the cell whereas the colour of the pixel 
indicates the intensity of ~960 cm-1 phosphate Raman band of HAP. 
 
  Between the two different sides of the HAP vial, no significant difference in 
Raman signal intensity or distribution is observed. This means that any 
differences on spatial signal distribution between the phantoms, cannot be 
attributed to the orientation of the vial enhancing in this way the reproducibility of 
the measurements. 
1a: HAP vial side 1 
2a: HAP vial side 2 
1b: plain water  
2b: plain water 
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  In a next step, Raman scattering maps for tissue phantoms with increasing 
Intralipid (IL) concentrations and in the absence of absorption were recorded. 
Both 1D and 2D plots of the mappings were reconstructed (Fig. 5.14). In the 2D 
plots, every pixel represents a different location of the HAP vial in the cell whereas 
the colour of the pixel indicates the intensity of ~960 cm-1 phosphate Raman band 
of HAP for this position. The 1D plots represent the generated Raman signal 
along the optical axis (‘on axis’ Raman intensity).  
 
2D Raman Intensity of HAP 1D Raman Intensity of HAP 
c: 0.5% IL (μs’= 4.6 cm-1) 
b: 0.25% IL (μs’= 2.3 cm-1) 
Distance from the illumination side in mm 
a: 0% IL (μs’= 0cm-1) 
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2D Raman Intensity of HAP 1D Raman Intensity of HAP 
d: 1% IL (μs’= 9.2 cm-1) 
e: 2% IL (μs’= 18.4 cm-1) 
f: 3% IL (μs’= 27.7 cm-1) 
g: 4% IL (μs’= 36.9 cm-1) 
Distance from the illumination side in mm 
Figure 5.14: The origin of Raman signal in different Intralipid 
concentration tissue phantoms when no absorber is present. The 
Intralipid concentration and the equivalent scatterer coefficient (μ’s) of 
each phantom is indicated on the 2D plots. The intensity scales of the 
1D plots have been chosen to highlight the change of HAP intensity 
across the phantom depth. 
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  In the plain water mapping (Fig. 5.14a) significant Raman signal is only 
observed on the beam axis positions and not outside of the laser beam 
boundaries, therefore no diffuse scattering is present as expected. Once the 
scattering agent of Intralipid is introduced into the system (Fig. 5.14b), laser 
photons are elastically scattered between its suspended lipid droplets and 
therefore they are able to reach the HAP vial and interact with it in more distant 
off axis positions compared to the plain water mapping. This is why Raman 
photons can be detected outside of the boundaries of the illuminating beam axis, 
with detection limits that depend on the reduced scattering coefficient (Intralipid 
concentration) of the tissue phantom.    
  As the concentration of the scatterer in the phantom increase (moving from Fig. 
5.14a–g), the scattering distribution pattern changes. In phantoms with low 
reduced scattering coefficients (Fig. 5.14b) we observe a form of symmetry in the 
Raman signal between the illumination (left) and the collection (right) side. It 
should be considered here that most of the Raman photons in the phantom are 
expected to be generated on the illumination side because this is where most of 
the laser photons are entering the cell without having being scattered by the 
medium yet and as a result they interact with the HAP vial with the greatest 
probability of inducing Raman events. However, the Raman photons which are 
generated on the illumination side, need to propagate across the entire width of 
the cell through the turbid medium to the right side in order to be detected; 
undergoing loss due to scattering and absorption. On the other hand, when the 
HAP vial is on the collection side of the phantom, the Raman photons generated 
there are most efficiently collected, since this is where they have the least 
distance to travel in order to reach and be detected by the collection optics.  
  The Raman scattering distribution through the phantom volume will always be 
a balance between these two phenomena. As Intralipid molecules in the tissue 
phantom increase in concentration (Fig. 5.14c and d), it is progressively less likely 
for the Raman photons generated at the illumination side to pass through the 
phantom volume and be detected on the other side of the cell prior to being 
absorbed or scattered out of the sample (signal balance moves to the collection 
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(right) side). As Intralipid concentration rises further (Fig. 5.14e–g), the diffuse 
scattering and therefore the path lengths for both laser and Raman photons 
increase considerably. Because of the water presence in the phantoms, as the 
photon path length increases, its absorption will have a more significant impact 
on the Raman signal distribution pattern. As mentioned in the literature251 and 
also confirmed with our measurements (Chapter 4- Fig. 4.9), water absorbs the 
Raman photons generated in our setup (at 902 nm) more than the laser photons 
(830 nm). This may explain why the signal balance moves to the collection 
surface (right), as it is easier for laser photons to traverse diffusely the cell than 
Raman photons, when the scattering increases. 
  Another important feature evidenced by the maps is that the higher the Intralipid 
concentration is, the broader the measurable signal region becomes. This means 
that a lesion located off the illumination–collection axis would be more likely to be 
detected in tissues with higher turbidity (modelled with higher Intralipid 
concentrations) than a lower one. This becomes clear if we compare maps with 
low Intralipid concentrations (Fig. 5.14b and c) with the ones with increased 
Intralipid (Fig. 5.14d–g). 
 
Ink maps 
  Raman scattering mappings were also recorded in absorber only phantoms in 
order to observe the individual influence of absorption on the map signal 
distribution. The absorber of our choice was Indian ink for the reasons described 
earlier. Three different concentrations of Indian ink, which correspond to different 
absorption coefficients calculated in Chapter 4, were explored (Fig.5.15).  
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Figure 5.15: The origin of Raman signal in different Indian ink concentration 
tissue phantoms when no scatterer is present. The Indian ink concentration and 
the equivalent absorption coefficient (μa) of each phantom is indicated on the 
2D plots. The intensity scales of the 1D plots have been chosen to highlight the 
change of HAP intensity across the phantom depth. 
 
  In the ink mappings above, we observe that no Raman signal is recorded 
outside of the boundaries of the laser beam because of the lack of diffuse 
2D Raman Intensity of HAP 1D Raman Intensity of HAP 
Distance from the illumination side in mm 
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scattering. However, when the ink concentration is doubled, the signal intensity 
drops by at least half. The ink absorbs both laser and Raman photons and the 
higher its concentration is, the less signal is recorded. In higher concentrations 
(Fig. 5.15c), we observe a maximum signal on the collection side which is a result 
of the laser focus on the system. 
  The maps above support our understanding of Raman scattering distribution 
throughout the phantom volume, when absorber and scatterer are added 
individually. In the next step, we explore how this distribution changes under the 
influence of both scattering and elevated absorption, which is the case of real 
tissue. 
 
5.4 Combined scattering and absorption maps in 
transmission mode using HAP 
 
  In this section, both scattering (Intralipid) and absorbing (Indian ink) agents were 
combined in liquid tissue phantoms in order to simulate the real tissue optical 
properties of breast and prostate (Chapter 4 and Chapter 7- Table II). Similar to 
the previous measurements, the recovered Raman signals from various locations 
of the HAP vial inside the phantom, were explored in terms of its optical properties 
(Fig. 5.16). 
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Figure 5.16: Raman scattering 2D(i) and 1D(ii) spatial distribution plots of HAP 
in phantoms with different Intralipid/ink concentrations. The intensity scales of 
the 1D plots have been chosen to highlight the change of HAP intensity across 
the phantom depth. 
 
  In the combined scattering and absorption maps, when scattering and 
absorption agents are both present at low concentrations (Fig. 5.16a), we 
observe a strong Raman signal from both the illumination and the collection sides. 
Distance from the illumination side in mm 
  (c) Phantom 3: 0.5% IL and 0.2 μl/ml ink (μs’=4.6 cm-1, μa=0.8 cm-1) 
(b) Phantom 2: 1% IL and 0.1 μl/ml ink (μs’=9.2 cm-1, μa=0.37 cm-1) 
(a) Phantom 1: 0.5% IL and 0.1 μl/ml ink (μs’=4.6 cm-1, μa=0.37 cm-1) 
1D Raman Intensity of HAP 2D Raman Intensity of HAP 
(ii) 
(ii) 
(i) 
(i) 
(i) (ii) 
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As explained earlier this is because of the balance between the most efficient 
Raman photon generation on the illumination side and the most efficient photon 
detection on the collection side. If we double the density of scatterer but maintain 
the absorber concentration constant (Fig. 5.16b), the signal on the collection side 
is being significantly suppressed. This is due to the impact of the ink absorption 
in the phantom. Indian ink in aqueous solution has been shown through UV/Vis 
absorbance measurements (Chapter 4 - Fig. 4.7) to absorb the laser photons 
(830 nm) more than the generated Raman ones (902 nm), i.e. the opposite net 
effect to that induced by water alone (Chapter 4 - Fig. 4.9). Consequently, the 
detected signal is much less likely to originate from the collection side of the 
phantom, as there are relatively less laser photons reaching it.  
  As a matter of fact, when we increase the scattered concentration, the photon 
path length is significantly increased and in the presence of ink this directly 
increases the chances of the laser and Raman photons being absorbed by it. For 
the same reason, when we increase the ink concentration, we expect a similar 
effect on the mapping pattern (Fig. 5.16c) where IL concentration was kept 
constant as in (a) but the concentration of the ink was increased. 
  The significant impact of absorption on the phantoms is also demonstrated by 
the fact that in similar experimental252 and theoretical measurements253, 254 of 
samples with no or minimal absorption, such as pharmaceutical tablets, the 
Raman scattering distribution is quite different. Indeed in these experiments the 
maximum Raman signal originates from objects buried in the middle of the tablets 
rather than towards its edges. Overall because of the size (extended/infinite 
lateral dimensions) and optical properties (absence of significant absorption in 
tablets) differences between maps in biological tissue and pharmaceutical 
formulations are expected to be significant.  
 
5.5 Scattering and absorption maps in transmission 
mode using trans-stilbene  
 
  In order to characterise the system at the maximum range of prostate tissue 
relevant absorption and scattering conditions, which are higher than those used 
in the phantoms earlier, we had to resort to a stronger Raman scatterer, trans-
stilbene. By replacing HAP with trans-stilbene it was possible to probe higher 
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IL/ink concentration solutions with the existing Raman apparatus and while 
recording trans-stilbene’s peak at 1192 cm−1 (921 nm).  
 
 
Figure 5.17: Raman scattering 2D(i) and 1D(ii) spatial distribution plots of trans-
stilbene in phantoms with different Intralipid/ink concentrations. The intensity 
scales of the 1D plots have been chosen to highlight the change of HAP 
intensity across the phantom depth. 
 
  In the figures above, we can still observe the same distribution pattern with the 
two signal maxima on the illumination and collection side. However, when we 
increase the absorption by more than twice (Fig. 5.17b), the collection side 
becomes more dominant. We should mention here that the absorption coefficient 
in Fig. 5.17b is well above the absorption range of human prostate and breast 
(a) Phantom 4: 1% IL and 0.2 μl/ml ink (μs’=9.2 cm-1, μa=0.8 cm-1) 
1D Raman Intensity of trans-
stilbene 
2D Raman Intensity of trans-
stilbene 
  (b) Phantom 5: 1% IL and 0.5 μl/ml ink (μs’=9.2 cm-1, μa=2.26cm-1) 
Distance from the illumination side in mm 
(ii) 
(i) (ii) 
(i) 
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tissue (Chapter 4 and Chapter 7- Table II) and was only tested to assess the 
detection limits of our system. Additionally, with this level of absorber present, the 
Raman signal measured was of the order of the noise, which makes the data 
processing prone to errors.  
  Another reason why we might observe this artefact is the liquid phase of tissue 
phantoms. As the particles in the solution are suspended rather than immobilized 
in the phantom phase, their position is changing during the mapping, potentially 
resulting in precipitation of ink and Intralipid molecules with time. Given that the 
measurements are recorded starting from the illumination (left hand) side and the 
solution is not stirred during the mapping, by the time that the measurements on 
the collection side have finished, many of the particles in the solution will have 
precipitated from the surface to the bottom of the phantom, leaving an optically 
clearer solution behind, with less absorption and scattering on its main volume. 
However, after the assessment of the phantom stability (Chapter 4 - 4.1.2.1), the 
Raman signal variation due to the liquid nature of the phantoms was found to be 
present only in combined (scattering + absorption) phantoms and in a range of 
less than 10%. This variation is high enough to affect the experimental results 
only when the signal to noise ratio is really low and the recorded Raman peak is 
close to noise levels, as in Fig. 5.17b. As a conclusion, although this solution 
instability exists in all of the phantoms recorded, it only makes a difference here, 
where the absorption and scattering is quite high and hence the HAP Raman 
signal is very low in intensity and barely visible above the background baseline.    
 
5.6 Scattering and absorption maps in an iSORS 
mode using trans- stilbene 
   
  Similar mappings were also recorded in an iSORS mode and in different offsets 
with approximate radius of 1.5 mm (minimum), 4.5 mm (middle) and 7.5 mm 
(maximum). The phantom used had a reduced scattering coefficient of 4.6 cm-1 
and absorption coefficient of 0.37 cm-1 (Figure 5.18).   
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Figure 5.18: Raman scattering 2D(i) and 1D(ii) plots of one trans-stilbene 
phantom (μ’s: 4.6 cm-1 and μa: 0.37 cm-1) in three different offsets (minimum, 
middle and maximum) on an iSORS mode. The intensity scales of the 1D plots 
have been chosen to highlight the change of HAP intensity across the phantom 
depth. 
 
  From the maps above we observe that the distribution of the Raman signal is 
higher in the centre of the ring as expected, and lower as the distance from the 
1D Raman Intensity of trans-stilbene 2D Raman Intensity of trans-stilbene 
Distance from the illumination side in mm 
(i) 
(i) 
(i) 
(ii) 
(ii) 
(ii) 
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centre increases. In minimum offset, where the radius of the collection circle is 
minimized, the depth of recovered Raman signal seems to be smaller compared 
to the maximum offset (7.5 mm), where it is possible to recover signal from a 
bigger area of the phantom. We can also observe that the maximum signal in 
iSORS is orders of magnitude higher compared to similar phantoms recorded in 
transmission (Fig. 5.14). This is because the phantom volume through which the 
photons have to travel in iSORS is much smaller compared to the full phantom 
length in transmission mode. 
 
5.7 Discussion  
 
  In order to assess the potential of measuring the Raman scattering of breast 
and prostate gland in vivo in a transmission mode, we fabricated and measured 
the transmitted Raman scattering from liquid tissue phantoms that mimic human 
prostate and breast tissue. To achieve maximum efficiency of the phantoms and 
similarity to the human tissue, all of the separate components had to be chosen 
and assessed spectroscopically, a procedure which is described in the start of 
the chapter.   
  As the phantom design was established and assessed with preliminary 
measurements, detailed Raman scattering maps were recorded for the 
equivalent in size and optical properties tissue phantoms, when a calcification 
vial was moved inside them in 300 different positions. In this way we explored the 
spatial distribution of the Raman signal over the phantom area, not only in a 
variety of optical properties, but also when the calcification was out of the beam 
axis and on different distances from it.  
  In the clinical arena, these measurements can be of importance in assessing 
the origin and detection limits of Raman scattering of a malignant area when 
scanning for prostate or breast cancer. The malignant area can be either a group 
of calcified formations, as it is very often observed in breast cancer255, or simply 
an area with a different Raman signal from the surrounding normal tissue which 
would in this way stand out from the total volume Raman signal.  
  In terms of the detection limits, which are different for each system and tissue 
environment, it was shown that if the measurement parameters (tissue optical 
properties, Raman profile of the malignant area/lesion, laser spot diameter) are 
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known, it is possible to assess the minimum distance from the beam axis in which 
the signal can be detected. In the case of our study the effective measurement 
area would be around 30 mm x 30 mm for both prostate and breast tissue. 
Assuming a 45 mm x 30 mm mean dimension human prostate gland, it would be 
possible to cover its measuring volume using only a couple of transmission 
measurements in a potential scanning for prostate cancer (Fig. 5.19).  
 
Figure 5.19: Spatial distribution of Raman scattering intensity of a potential 
calcification (HAP) throughout the prostate gland. 
 
  In terms of the Raman signal origin, it has been clearly shown how the 
distribution of the collected Raman scattering signals changes under different 
values of absorption and scattering coefficients of the phantom and hence in 
different types of tissues. It has been demonstrated that the highest signals are 
likely to be obtained from nearer surface lesions (either on collection or 
illumination side) than those at depth using transmission Raman. Even in this 
case though, relative signals are likely to be as high as 40–60% for ‘lesions’ found 
in the centre of organs compared to those found towards the edges.  
  In conclusion, this chapter demonstrates the potential for future applications of 
transmission Raman, either in the breast or applied through fibre probes, to the 
prostate. The tissue phantom measurements have expanded our understanding 
of how the distribution of collected Raman scattering signals change in relation 
to a range of expected optical properties of tissues. This is expected to support 
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the future design of instruments which will target the disease specific signals 
within particular regions of the sample and pave the way towards the ultimate 
application of non-invasive deep Raman diagnosis of prostate and breast cancer. 
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6 Chapter 6: Deep Raman spectroscopy on 
prostate tissue 
 
6.1 Introduction 
  
  A significant amount of research has been conducted on the study of prostate 
tissue using Raman spectroscopy. Different modalities of Raman spectroscopy 
have been used in the past to acquire Raman signal from different depths of 
prostate samples (TURPs)213 and discriminate between benign and malignant 
(adenocarcinoma) human prostate tissue168, 193, 256, 257. Prostate cell lines of 
different aggressiveness have also been assessed in terms of aggressiveness by 
means of Raman spectroscopy258. 
  The molecular differences between different pathologies of tissue show reduced 
concentration of glycogen and increased concentration of nucleic acids in 
malignant tissue compared to benign hyperplasia193. Similar studies on healthy 
and different pathologies of prostate tissue have revealed that DNA content 
increases as the tissue progresses from normal to malignant259, as the nuclear to 
cytoplasm (actin) ratio increases. The collagen amount which is abundant in 
extracellular matrix can either increase or reduce, depending on the tumour size. 
On the other hand, choline which has been identified as a malignant disease 
marker before, and cholesterol are both increasing with disease progression 
probably as a response to increased cell necrosis and membrane synthesis due 
to increased proliferation respectively. The same study also provides evidence 
on more components, such as oleic acid, cholesterol, triolein and actin192.  
  However, transmission and iSORS Raman spectroscopy, which can be used 
more easily as minimally invasive and real-time tools, have never been used for 
prostate tissue studies. Having already set the basis for measuring tissue 
phantoms of similar size and optical properties on the same setup (Chapter 5), in 
this chapter human prostate tissue is explored.  
  For this reason, we first assess the feasibility of measuring animal tissue 
individually and then layered with a stronger Raman scatterer (HAP vial). At a 
later stage, we approach the study of TURPs and prostate biopsies with both 
conventional and deep Raman spectroscopy.  
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6.2 Measuring animal tissue 
 
  The Raman signal of three major tissue components (protein, fat and muscle) 
were assessed on the deep Raman setup by measuring chicken breast, pork fat 
and beef shin respectively. Animal tissue blocks were cut in thickness of 0.5 and 
1 cm and measured in a transmission mode. The results are presented in Fig. 
6.2. 
 
 
Figure 6.1: Three different types of animal tissue: chicken breast (a), pork fat 
(b) and beef shin (c), on the sample holder of the deep Raman setup. 
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Figure 6. 2: Transmission Raman spectra of 1 cm pork fat (blue), 0.5 cm beef 
shin (red) and 0.5 cm chicken breast (green). The measurements were 
recorded using 830 nm laser and 2 s x 20 accumulations acquisition time. The 
spectral offset has been adjusted for clarity. 
 
 
  In the measurements outlined above we can observe characteristic peaks from 
main components of chicken, pork fat and beef shin. More specifically, peaks 
observed in the chicken spectrum such as 1657 cm-1, 1450 cm-1, 1003 cm-1 and 
875 cm-1 are representative of protein and correspond to ν(C=O) of α-helix 
conformations, CH2/CH3 bending and amino acids phenylalanine and hydroxyl-
proline respectively260. In beef shin we can notice a peak at 477 cm-1 which 
corresponds to the muscle glycogen due to the glycogen skeletal deformation 
vibration261. This peak is more obvious in chicken spectrum which also contains 
an amount of muscle tissue. In the pork fat Raman spectrum, peaks at 1063 cm-
1 (out-of-phase aliphatic C–C stretch), 1124 cm-1 (in-phase aliphatic C–C stretch), 
1265 cm-1 (in-plane cis olefinic hydrogen bend), 1298 cm-1 (δ(CH2)tw methylene 
twisting deformations), 1448 cm-1 (δ(CH2)sc methylene scissor deformations), 
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1657 cm-1 (cis ν(C=C) olefinic stretch)  and 1745 cm-1 (ν(C=O) carbonyl stretch) 
were observed and assigned to vibrations of adipose tissue262. 
   
  In a next stage, we assessed the signal from the animal tissue above, layered 
with hydroxyl-apatite (HAP), a material of high cross-section and biological affinity 
to the tissues due to the presence of calcifications in some of them. A HAP vial 
of dimensions described in Chapter 4, was layered with beef shin (Fig. 6.3), 
chicken breast (Fig. 6.4) and pork fat (Fig. 6.5) of 0.5 and 1 cm. 
 
 
Figure 6.3: Transmission Raman spectra of beef shin tissue with and without 
an extra layer of the HAP behind the tissue section. The spectral offset has 
been adjusted for clarity. 
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Figure 6.4: Transmission Raman spectra of chicken breast tissue with and 
without an extra layer of the HAP behind the tissue section. The spectral offset 
has been adjusted for clarity. 
 
 
144 
 
 
 
 
Figure 6.5: Transmission Raman spectra of pork fat tissue with and without an 
extra layer of the HAP behind the tissue section. Their baselined difference has 
been also plotted (blue line) in order to confirm the presence of 959 cm-1 peak. 
The spectral offset has been adjusted for clarity. 
 
 
  The results show that for the same tissue thickness, chicken breast and beef 
shin allow the HAP signal to be detected more easily. In the case of the pork fat, 
the Raman signal of the HAP is still barely detectable, only after the subtraction 
of the two spectra (pork fat with and without HAP). This is because adipose tissue 
has a larger Raman scattering cross-section relative to protein (chicken)196. 
Indeed, higher peak intensity is observed in pork fat spectrum, although the 
measurements were recorded for the same acquisition time and the thickness of 
the tissue was the same.  
  Smaller pieces of animal tissue were also measured on both transmission and 
inverse SORS (iSORS) mode of the deep Raman setup, in order to simulate 
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dimensions similar to prostate tissue samples (20 mm length x 2.5-3 mm width) 
and compare the performance of the two modes. 
 
Figure 6.6: Measurements from chicken breast and bacon on transmission and 
iSORS mode of deep Raman setup (The acquisition time for transmission and 
iSORS mode is 1 s and 60 s respectively, however the Raman intensity of the 
measurements has been adjusted for comparison reasons). The spectral offset 
has been adjusted for clarity. 
 
 
  Measurements with both transmission and iSORS show that the Raman signal 
for the same tissues is reproducible between the two modes. The collected 
Raman scattering on iSORS tends to be weaker compared to the transmission 
one. On the other hand, longer acquisition times and hence better signal quality 
can be applied here due to lack of CCD saturation issues.  
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6.3 Measuring TURPs  
 
Transmission Raman: After the signal from the various biological tissues had 
been assessed on the deep Raman setup, we recorded measurements of 
prostate samples collected with the procedure of transurethral resection of the 
prostate (TURP), a surgical procedure commonly used to treat benign prostate 
hyperplasia (BPH). 
 
 
Figure 6.7: One of the TURP chips and its dimensions measured on a 
transmission deep Raman mode. 
  For the transmission mode, the laser spot size (3-4 mm diameter) was bigger 
than most of the TURP chips width (3-5 mm) at many points across their length. 
Although a considerable amount of light was being transmitted through the tissue 
sample, no Raman photons were successfully collected, whereas a CCD 
saturation issue was present in transmission measurements for different 
acquisition times and powers. That would be attributed either to laser light not 
interacting (scattered or absorbed) with the sample or high fluorescence levels 
generated from the laser-sample interaction, or both. In order to explore further, 
the same TURP chips were also measured in an iSORS mode of the deep Raman 
setup.    
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iSORS mode: A number of TURP chips which were measured in an iSORS 
mode, have shown that the Raman signal was dominated by a fluorescence 
background in these measurements (Fig. 6.8).  
 
Figure 6.8: Fluorescence background from TURP chips from 4 different 
patients during 1 s acquisition time on iSORS mode. 
 
  The presence of fluorescence while measuring TURP chips has been confirmed 
by M. Prieto before263. Different positions measured on the same TURP chip, 
using different acquisition times (Fig. 6.9), also did not change the fluorescence 
background emerging from the sample. 
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Figure 6.9: Fluorescence background from the same TURP chip during 
different acquisition times on iSORS mode. Acquisition time: 10 min, 5 min and 
2 min for pink, green and red plot respectively. The spectral offset has been 
adjusted for clarity. 
 
 
  The presence of fluorescence can be attributed to the procedure which is 
followed for the TURP sample collection. These samples are collected during 
transurethral resection of the prostate (TURP), a surgical procedure where tissue 
is being resected with a hot electrical wire loop that cuts through it. Hence we 
expect the tissue to be burnt and as such exhibiting high absorbance followed by 
fluorescence/luminescence.  
 
Raman microscopy: In order to explore the origin and distribution of 
fluorescence on the TURP chips, the samples were also measured with 
conventional Raman microscopy on a Renishaw System 1000 (Chapter 4).  
  Measurements were first recorded from random points on the surface of a TURP 
chip (PC006), giving the same fluorescence background as deep Raman (Fig. 
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6.8). In order to check the tissue inside the TURP for fluorescence, a couple of 
TURP chips (PC005, PC007) were sectioned in the middle and measured on the 
Raman microscope. Raman spectra from different areas on the tissue of the chips 
are presented in Fig. 6.10. 
 
 
Figure 6.10: Raman spectra and characteristic white light images from (i) not 
burnt and (ii) burnt areas on TURP chips from 3 different patients. Acquisition 
time: (i) 15 s, 2 s x 5 and 2 s x 5 for PC007, PC005 and PC012 respectively, (ii) 
3 s, 3 s and 1 s for PC007, PC005 and PC012 respectively. The spectral offset 
has been adjusted for clarity. 
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  Two types of areas were observed on the TURP chips: (i) burnt areas exhibiting 
fluorescence and (ii) non-burnt areas with a clear Raman signal and biologically 
relevant peak positions. Both of the areas and their Raman spectra are shown in 
Figure 6.10. Peaks observed in areas free of fluorescence, have been assigned 
to protein bond vibrations (1251 cm-1, 1651 cm-1)264. 
  In order to study in greater detail the location of the burnt locations over the 
sample area, two of the TURPs (PC011, PC014) were cryosectioned, and 
sections from the middle of the TURP chip volume were laid onto calcium fluoride 
substrates and mapped using 830 nm wavelength on a Renishaw inVia Raman 
spectrometer (procedure in Chapter 4).   
  The measurements from Raman microscopy mapping were preprocessed as 
described in Chapter 4 and analyzed using Matlab (Fig. 6.11). 
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Figure 6.11: White light images (A) and Raman microscopy maps (B) of 
cryosectioned TURP chips (PC011, PC014). The maps (1200 l/mm grating 
centered at 1300 cm-1, 6 s/line acquisition time, 50 μm step, Streamline mode) 
show the distribution of saturated spectra which correspond to burnt areas over 
the chip surface. For PC014, a higher resolution smaller map (red line square) 
was recorded to assess the fluorescence limits in detail. 
 
  Results from Raman microscopy measurements locate the saturated spectra, 
characteristic of the fluorescence background, on the periphery of the sample 
section. This shows that only the outside surface of the TURP is affected by the 
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surgical procedure for the TURP collection. We should also observe the lack of 
fluorescence spots on the top side of PC014 on the Raman map (Fig. 6.11). This 
is because PC014 was the first chip to be collected from the patient during the 
TURP procedure and hence only the one side of it was cut with the hot wire, 
leading to the burnt area.   
 
6.4 Measuring prostate biopsies 
 
  Prostate tissue samples collected through Trans-Rectal Ultrasound guided 
biopsy were measured on deep Raman setup in a transmission and iSORS 
mode. Once the biopsies were collected, they were laid on acetate paper which, 
although not an ideal substrate for Raman spectroscopy, it is frequently used in 
pathology for sample orientation and microtome sectioning.  
  Initially, measurements were recorded from a biopsy (TB1335 L) on acetate 
paper (Fig. 6.12-A) as the biopsy was too thin to be removed onto a different 
substrate. The sample was measured on deep Raman setup and in conventional 
Raman (Fig. 6.13), on successive points across its length. 
 
Figure 6.12: Prostate biopsies laid on (A) acetate paper and (B) calcium 
fluoride substrate. 
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Figure 6.13: Raman measurements of the biopsy on acetate paper on 
transmission, iSORS and conventional Raman microscopy. Acquisition time: 15 
s, 15 s, 2 s x 4 and 3 s for brown, blue, red and green plot respectively. The 
spectral offset has been adjusted for clarity. 
 
 
  The Raman measurements on the first biopsy show that it is not possible to 
collect sufficient Raman scattering signal in deep Raman configuration, 
potentially due to the very small amount of tissue that the biopsy contains and 
does not allow sufficient photon propagation. Most of the signal in both 
transmission and iSORS mode seems to derive from the acetate paper. In 
contrary, Raman microscopy, provides a mixture of Raman signal from both the 
biopsy tissue and the acetate paper as it is strongly biased towards imaged 
biopsy layer.   
 
  A following attempt has been made to measure a second prostate biopsy on a 
calcium fluoride (CaF2) substrate (Fig. 6.12-B), in order to avoid any additional 
Raman signal. CaF2 substrates are commonly used in Raman spectroscopy as 
they are free of Raman signal in the main fingerprint region265. The biopsy has 
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been measured both in deep Raman setup and in conventional Raman across its 
length (Fig. 6.14).      
 
 
Figure 6.14: Raman measurements of the biopsy on calcium fluoride substrate 
in transmission, iSORS and conventional Raman microscopy. Acquisition time: 
1 s, 15 s and 2 s x 4 for transmission, iSORS and inVia modes respectively. 
The spectral offset has been adjusted for clarity. 
 
   
  The results of Raman measurements from the second biopsy samples are 
similar to the previous one, as deep Raman configuration again fails to collect 
any Raman scattering. On the other hand, the confocality of Raman microscopy 
provides well-shaped Raman spectra lacking any signal from the substrate. 
  The peaks observed in the Raman microscopy spectra from both of the biopsies 
correspond to peaks characteristic to prostate tissue as described in literature264 
with proteins (854 cm-1, 937 cm-1, 1003 cm-1, 1033 cm-1, 1450 cm-1, 1659 cm-1), 
DNA (1337 cm-1) and lipids (1450 cm-1, 1659 cm-1) to be prevalent.   
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  We should also notice the difference between the Raman microscopy signals 
from the two biopsies. The biopsy laid on the acetate paper seems to provide a 
stronger Raman signal compared to the one laid on the calcium fluoride 
substrate. This is largely because in the case of the transparent and minimally 
scattering substrate (CaF2), the photons will escape the sample easier by 
travelling across the other side of the substrate. In the case of the acetate paper, 
the photons travelling through the biopsy will be scattered partially back by the 
diffusely scattering acetate paper on the other side of it. This would enforce both 
laser and Raman photons to change their direction towards the collection side, 
with the first ones to be given higher chances to interact with the sample and 
generate Raman scattering – both processes leading to the enhanced detection 
of Raman signal at the collection biopsy surface. 
 
6.5 Discussion   
 
  In this chapter we investigated the feasibility of collecting Raman scattering from 
different types of prostate tissue. In order to assess the spectral response of 
major tissue components (protein, fat, muscle), we first started by measuring 
animal tissue (chicken breast, pork fat and beef shin) in both transmission and 
iSORS modes, confirming fat yields stronger Raman signal due to its higher 
Raman cross-section. The different types of animal tissue were also overlaid with 
a component biologically similar to tissue calcifications (HAP), proving that it is 
more detectable under muscle and protein compared to fat.   
  Moving over to prostate samples, the first measurements were attempted on 
TURP chips which usually consist of benign tissue derived from prostate 
hyperplasia. Measurements on both modes of deep Raman setup (transmission 
and iSORS) were dominated by fluorescence. This is a consequence of the 
transurethral resection of prostate, the surgical procedure where a hot electrical 
wire is used to collect the samples. In this way, the surface of the chip results in 
being burnt and exhibiting fluorescence255. 
  This was further confirmed by measuring the same samples with Raman 
microscopy, where single and map measurements were recorded on the outer 
and interior tissue of the TURP chips. White light images and single Raman 
spectra showed a morphological and spectral difference between outer (burnt) 
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and inner (not burnt) areas of sectioned chips. Mapping measurements on TURP 
cryosections proved that the saturated spectra which correspond to burnt tissue 
are distributed on the outline of the TURP section, leaving all of the inner prostate 
tissue fluorescence free. 
  Prostate biopsies collected were also measured on deep Raman setup, failing 
to provide any sufficient Raman signal. This is due to the very low thickness of 
the specific biopsy. As the prostate biopsies are collected with TRUS biopsy, from 
12 different locations of the human prostate, they tend to be very limited in 
dimensions (around 12 mm long266, 267 × 1 mm thickness268). As a result, the 
technique used for the measurements needs to be able to focus and collect the 
Raman scattering from small areas near the surface on the sample (confocality), 
rather than acquiring a volume signal as in deep Raman mode. This was 
confirmed by the measurements recorded using Raman microscopy on the same 
biopsies.   
  The results of this chapter highlight the limitations of the deep Raman 
spectroscopy, which include the presence of significant absorption and 
fluorescence as well as the need for a sufficient sample volume for the laser 
photons to efficiently propagate through sample and produce Raman scattering 
which can be effectively collected in deep Raman setups. At the same time, we 
demonstrate the efficiency of deep Raman on samples which lack the limitations 
above, as was shown with the initial measurements on animal tissue. The deep 
Raman study proved the feasibility of collecting Raman signal from the prostate 
gland which contains similar major tissue components (fat, protein, muscle) found 
also in the measured animal tissue, whereas Raman microscopy demonstrated 
that prostate gland is not intrinsically fluorescent and hence deep Raman 
measurements will not be inhibited by this issue.  
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7 Chapter 7: Signal enhancement in deep Raman 
scattering measurements in tissue phantoms 
using photon diode 
 
7.1 Introduction 
  
  In previous chapters we explored the origin, distribution and quality of Raman 
signals through liquid tissue phantoms and mammary tissue respectively. In this 
chapter, we are looking into the enhancement of this signal as a function of both 
sample depth and optical properties, using a ‘’photon diode’’ element159 
(described in chapter 4- section 4.2.1.4).  
 
  The photon diode has been applied in deep Raman spectroscopy, enhancing 
the weak Raman signals present with these techniques. As the photons 
propagate through a sample of considerable volume, they can be either diffusely 
scattered or absorbed. Collecting these photons and eventually recovering the 
Raman signal from large depths can be quite challenging. Different approaches 
such as the increase of laser power, collection time, improvement of collection 
efficiency, etc.149, can improve the Raman photon collection and hence the signal 
to noise ratio. An alternative passive approach is the use of a signal enhancing 
‘’photon diode’’ element, which has already been shown to provide a multifold 
enhancement of Raman signal. 
  The photon diode element has been used in a number of deep Raman studies 
in the past, mainly in order to improve the signal to noise ratio in pharmaceutical 
tablets. Literature studies involving a signal enhancement with photon diode are 
presented in Table I below. 
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Signal 
enhance
ment 
Type of 
demonstration 
Modality 
Sample 
thickness 
(mm) 
Sample Probing 
Stu
dy 
x8.5 experimental transmission 6-7 
Paracetamol 
powder 
bulk 269 
x9.9 experimental transmission 3.3 
paracetamol 
tablets 
bulk 234 
x3.8 experimental transmission 3.9 
paracetamol 
tablet 
bulk 
235 
x3-5 
numerical 
simulations 
transmission <20 
tissue (no 
absorption) 
bulk 
x6 
numerical 
simulations 
transmission >20 
tissue (no 
absorption) 
bulk 
x7 
numerical 
simulations 
transmission 4-6 
pharmaceutical 
tablets 
bulk 
x3-7 
numerical 
simulations 
transmission 1-4 
pharmaceutical 
tablets 
bulk 
x6.3 experimental  
transmission 4 
segmented 
tablet with PET-
TiO2 layer in 
different depths 
bulk 270 
x4.3 
numerical 
simulations 
x6.5 experimental transmission 4 paracetamol bulk 
159 
x8.3 experimental transmission 
5.8 (2 
trans-
stilbene + 
3.8 
paracetam
ol) 
paracetamol + 
trans-stilbene 
trans-
stilbene 
(front 
layer) 
x9.4 
numerical 
simulations 
transmission 4 paracetamol  bulk 
x6.7 experimental SORS 4 paracetamol  bulk 
x4.4 - 4.5  experimental SORS 4.2 
paracetamol 
overlaid with 
trans-stilbene 
bulk  271 
x1.5 experimental transmission 27 
Breast phantom 
(porcine tissue) 
trans-
stilbene 
149 
x1.6 experimental transmission 14 chicken breast bulk 235 
  
Table I: Use of photon diode and enhancement factors achieved through the 
literature. 
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  As transpires from the table above, the photon diode has been mainly used with 
pharmaceutical tablets. The concept has also been explored with biological tissue 
samples149, 235 but not as a function of the depth of the signal origin. Because of 
important differences in the optical properties between tablets and tissues, such 
as the lack of significant absorption in tablets and considerably longer mean free 
scattering path lengths in tissues (at least by an order of magnitude) due to the 
difference in spatial scales, we cannot assume identical behavior and 
enhancement. 
  In this chapter, we will explore the photon diode signal enhancement on 
phantoms and its dependence on both the depth of the signal origin and the 
sample optical properties. The phantoms which were employed simulate various 
human tissues in optical properties and particularly breast and prostate in size, 
due to the prevalence of the corresponding types of cancer. Apart from absorption 
and scattering agents, the phantoms also consisted of a high Raman cross-
section compound representing a malignant element found in many cancerous 
conditions (e.g. calcifications). Since this element was located at different depths, 
we were able to explore the enhancement effect of the photon diode as a function 
of the inclusion depth inside each phantom and also relate it to the range of optical 
properties (absorption and scattering) of the tissue matrix.  
 
7.2 Optical properties of various tissue types and 
phantoms 
 
  The tissue phantoms employed in this chapter were fabricated and measured 
similarly to the ones described in Chapter 4 and 5 respectively. The optical 
properties of the phantoms were adjusted to a clinically relevant range of human 
tissue. For this reason, a number of different types of tissue were studied in terms 
of optical properties (absorption and reduced scattering coefficient) through 
literature.  
  The optical property values that we took into consideration are presented in the 
table below and their relative distribution and relation to the phantom properties 
in Fig. 7.1. The reduced scattering coefficients were calculated as a function of 
the excitation wavelength226, whereas the absorption coefficients are based on 
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literature values for skin272, dermis273, brain274, white matter275, breast226, 227, 
fat276, bone277, liver278- at 850 nm, muscle276, small bowel279, aorta280, stomach 
wall281. For prostate tissue both the reduced scattering and absorption 
coefficients were extracted from separate studies224, 225. 
 
 
Figure 7. 1: Reduced scattering and absorption coefficient for different types of 
mammalian tissues obtained from literature data. Each sphere represents the 
range of optical properties for each individual type of tissue. The cross (shown 
with labels in Fig. 7.2) indicates the range of optical properties of the phantoms 
in the current study. 
 
Tissue 
Reduced scattering 
coefficient (cm-1)226 
Absorption 
coefficient (cm-1) 
Liver 6.58 0.6- 1278 
Prostate 4-9.5224, 225 0.002- 0.7224, 225 
Aorta 7.07 3.16280 
Muscle 8.13 0.2- 0.3276 
Small bowel 8.80 0.05- 0.2279 
White matter brain 9.41 0.75- 1.15275 
Breast 9.84 0.068- 0.102227 
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Brain (mean) 10.7 0.4274 
Stomach wall 11.7 2281 
Fat (mean) 13.1 0.02276 
Bone 15.9 0.2277 
Skin (mean) 22.4 0.25272 
Dermis 23.5 3273 
 
Table II: Optical properties of the different types of mammalian tissue as found 
in the literature. The reduced scattering coefficient values are presented in 
ascending order. 
 
  In order to cover most of the optical properties of different tissues (Fig. 7.1), the 
phantoms employed for this set of experiments were selected to cover the tissue 
range in both absorption and scattering. More specifically, the tissue phantoms 
fabricated ranged from 0- 1.63 cm-1 in absorption and 6.4- 23.04 cm-1 in reduced 
scattering coefficient (Fig. 7.2). More details on phantom fabrication can be found 
in Chapter 4.  
 
 
Figure 7.2: Scatterer and absorber concentrations (a) and optical properties (b) 
of the liquid tissue phantoms prepared and measured with transmission Raman 
spectroscopy. 
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7.3 Effect of photon diode on the origin of Raman 
signal within phantom 
 
  In order to evaluate the impact of the photon diode on the signal enhancement 
and the origin of Raman scattering, the Raman signal was recorded while the 
high Raman cross-section inclusion (HAP or trans-stilbene vial) was in several 
different positions inside each phantom. For this reason, a number of 
representative tissue phantoms with different optical properties were measured 
and the results are presented below.  
163 
 
 
 
 
Figure 7.3: Transmission Raman scattering 2D plots of Phantom A (μ’s= 4.6 
cm-1, μa= 0.37 cm-1), B (μ’s= 6.9 cm-1, μa= 0.37 cm-1) and C (μ’s= 13.82 cm-1, μa= 
0.8 cm-1) with (i) and without (ii) the photon diode in a transmission mode. Laser 
photons are injected on the left of the image and Raman signal is collected on 
the right. The plots depict the intensity of ~1193 cm-1 Raman band of trans-
stilbene for phantom C and 959 cm-1 phosphate peak of hydroxyapatite for 
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phantoms A and B, as the vial moves to different positions in the phantom. The 
2D plots without photon diode (ii) have been normalized against the maximum 
intensity of the diode maps (i). 
 
  In the 2D maps above, as the amount of scatterer in the quartz phantoms (ii 
series) increases from 4.6 cm-1 to 13.82 cm-1, the signal in the middle area 
becomes stronger and can be detected in more distant positions outside of the 
illumination beam (Chapter 5). When the ‘’photon diode’’ element is introduced, 
all of the phantoms exhibit a signal enhancement throughout their volume. This 
enhancement is stronger when the vial is at the closest proximity with the diode, 
as expected, since this is the area benefitting the most due to the great photon 
loss on the air/ sample interface. The factor of the signal enhancement depends 
on the optical properties of the phantom and will be explored in the next section. 
The general distribution pattern does not change after the photon diode 
application. The front and the back of the phantoms still exhibit the maximum 
intensity, whereas the middle phantom area is where the minimum Raman 
scattering is collected. 
 
7.4 Diode enhancement in phantoms with varying 
optical properties  
 
  In a second set of experiments, in order to evaluate the diode signal 
enhancement as a function of the tissue optical properties and phantom depth in 
a quantitative way, measurements were recorded for a wide range of absorption 
and scattering, as described in Figure 7.2. In order to make most efficient use of 
the experimental time, Raman signal was recorded from a trans-stilbene vial only 
on the main beam area of the phantoms. The 1D maps reconstructed from the 
measurements reveal the exact range of enhancement that a probed object can 
benefit from, depending on the optical properties of the surrounding medium and 
its depth in the sample.  
  First, the diode signal enhancement was studied in phantoms with varying 
reduced scattering coefficient (Fig. 7.4) and absorption coefficient (Fig. 7.5). For 
clarity and brevity, the ratio of the trans-stilbene signal with the diode over the 
signal without the diode, was plotted against the phantom depth of the trans-
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stilbene vial, for phantoms with different optical properties, in the same plot. 
Additionally, in order to provide confidence in the results, each phantom was 
mapped three times at the same locations. The mean and the standard deviation 
were calculated and displayed as error bars in the plots. 
 
 
Figure 7.4: Ratio of trans-stilbene Raman signal intensity with diode over 
signals without the diode versus the trans-stilbene vial position along the x-axis 
in the phantom (mm), for phantoms with the same absorption but different 
scattering coefficients. The coefficients are presented in cm-1. 
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Figure 7.5: Ratio of trans-stilbene Raman signal intensity with diode over 
signals without the diode versus the trans-stilbene vial position along the x-axis 
in the phantom (mm), for phantoms with the same reduced scattering but 
different absorption coefficients. The coefficients are presented in cm-1. 
 
  In the plots above we notice that the ratio of trans-stilbene Raman signal is 
dropping below one in certain positions (especially at the back) of high optical 
properties phantoms. That would mean that the signal intensity with the diode is 
lower than 1 without the diode (quartz), which is not justifiable to such an extent. 
Further investigation of this issue revealed that a significant volume of solution 
was trapped at the front of the photon diode, between the diode and the cell wall- 
(see Chapter 4), resulting in a disruption of the laser beam collimation before it 
incidents on the photon diode. Because of this, the laser output through the diode 
was gradually reduced with increasing concentration compared to the quartz 
layer as only collimated light can pass through. In high scattering and absorption 
phantoms this issue was more severe, resulting in enhancement ratios 
considerably below 1. 
    This issue has been addressed by adding a calcium fluoride disc between the 
cell wall and the diode, with size big enough (20 mm diameter, 1 mm thickness) 
to cover the laser illumination area and most of the diode area, in order to 
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minimize the solution volume trapped in the front of the diode / sample interface. 
This resulted in improvement of the enhancement ratios in the whole depth of the 
phantoms apart from the positions on the back (closer to the collection side) (Fig. 
7.6, Fig. 7.7) where the Raman signal does not benefit from any diode 
enhancement (enhancement ratios below 1).  
The updated results are presented below.  
 
Diode enhancement in phantoms with varying reduced scattering 
coefficient 
 
  After the introduction of a calcium fluoride disc, the trans- stilbene generated 
Raman scattering has been recorded along the optical axis in phantoms with 
varying reduced scattering and a constant concentration of Indian ink. 
 
 
Figure 7.6: Ratio of trans-stilbene Raman signal intensity with diode over 
signals without the diode versus the trans-stilbene vial position along the x-axis 
in the phantom (mm), for phantoms with the same absorption but different 
scattering coefficients. The coefficients are presented in cm-1. 
 
  In the plot above, the reduced scattering coefficient values explored are in the 
range of 4.6 – 23.04 cm-1. The greatest enhancement factor for all of the 
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phantoms with varying scattering except for the extreme scattering one (μ’s= 
23.04 cm-1), is observed on the measurement points with the closest proximity to 
the diode (0 mm). At this depth, phantoms with lower absorption or scattering 
coefficients exhibit higher Raman signal with the diode, as the generated Raman 
photons cross the phantom bulk on the other side of the vial and are collected 
from the optics more efficiently in low scattering values. When the vial is 
positioned in a certain distance from the diode, the phantoms with the higher 
scattering benefit from the photon diode the most, with enhancement factors 
ranging between 1.17 and 1.83. The reason for this is that the lower scattering 
phantoms do not benefit as much from the back-scattering enhancement 
mechanism of the diode. As a result, in a higher scattering environment, there is 
greater enhancement from the photon diode as the photons which re-enter the 
phantom volume reach the vial more easily due to diffuse scattering. In this way, 
in an extremely high scattering environment, the bulk volume of the phantom is 
the zone benefiting most from the presence of the photon diode. The signal 
enhancement decreases as we move away from the photon diode (0-4 mm) and 
it seems to plateau when the trans-stilbene vial is located around the middle of 
the phantom (4-16 mm). The enhancement factors in this area appear to fall to a 
similar range (1.0-1.2) for most of the phantoms. Towards the back of the 
phantom and closer to the collection side (16-20 mm), the diode enhancement of 
the signal seems to be decreasing even more. This drop is in some cases so 
sharp (e.g. Phantom 8: μs’= 23.04 cm-1 and μa= 0.8 cm-1) that the diode might not 
be beneficial for signal enhancement at all. It should be noted that at high 
scattering coefficient values (18.4 cm-1 and 23.04 cm-1), the enhancement at the 
back of the phantom does not follow the same trend as at the front. The drop is 
most likely due to the overall lower transmittance of the diode compared to quartz 
layer (by around 10%). 
 
Diode enhancement in phantoms with varying absorption coefficient 
 
  Similar trends are observed in phantoms with varying absorption coefficients 
and constant reduced scattering coefficient (concentration of Intralipid) (Fig. 7.7). 
The signal enhancement from the diode here seems to be almost constant 
through many vial depths in each of the different phantoms. The absorption 
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appears to affect the diode enhancement to a greater extent compared to the 
scattering case in our ranges, since the enhancement ratio drops quicker when 
we increase the absorption coefficient (ink concentration) rather than the 
scattering coefficient. Comparing the two plots (Fig.7.6 and Fig. 7.7), it seems 
that a middle value of absorption (μa= 0.8 cm-1) inhibits the signal enhancement 
in the middle of the phantom more compared to a middle scatterer value (μs’= 
13.82 cm-1). This means that it is less likely for the ‘enhanced’ laser photons to 
generate a Raman photon which will get detected on the collection side in the 
presence of ink. On the other hand, when only Intralipid concentration is 
increased, the absorption increases indirectly due to the path length change too, 
but not to such an extent. 
 
 
Figure 7.7: Ratio of trans-stilbene Raman signal intensity with diode over 
signals without the diode versus the trans-stilbene vial position along the x-axis 
in the phantom (mm), for phantoms with the same reduced scattering but 
different absorption coefficients. 
 
  In terms of the enhancement factor in the varying absorption phantoms, it takes 
a wide range of values through the entire phantom depth as the vial is moved 
across towards the collection side. The highest enhancement factor is again 
observed at the point closest to the diode (0 mm) and it takes different values 
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between 0.95 and 2.34, depending on the absorber concentration introduced in 
each phantom. As expected, the highest signal enhancement is observed in the 
phantom with no absorption and as soon as 0.1 μl/ml of ink (equivalent to μa of 
0.37 cm-1) is present, the signal enhancement drops from 2.34 to 2.21. In the 
middle area of the phantom (4-16 mm), the signal enhancement has gradually 
decreased and reached a plateau. Towards the back of the phantom (16-20 mm), 
the signal enhancement seems to be decreasing even more and for the extreme 
ink concentration (Phantom 5: μa= 0.8 cm-1 and μs’= 13.82 cm-1), the benefit of 
using a photon diode is limited, as the signal enhancement ratio constantly 
remains close or under 1. As mentioned before, the values below 1 can be 
attributed to the reduced transmittance of photon diode which becomes 
especially significant in high optical properties phantoms with low signal to noise 
ratios.  
  It should be noted that a reduced signal on the edge of the sample is less 
detrimental to the detection sensitivity than it would be in the centre of the sample, 
as signals tend to be 10-50% higher at the edges than in the centre for tissue 
optical properties282. 
 
7.5 Discussion  
 
  In this chapter we were able to relate the diode signal enhancement with both 
the tissue optical properties and the probing depth of the sample, for the first time. 
The enhancement factors observed through the measurements are in the range 
of 1- 2.4. Studies on samples with similar optical properties (e.g. lack of 
absorption) and thickness, such as chicken and porcine tissue, simulating breast 
phantoms, have exhibited a signal enhancement of 1.6 235 and 1.5 149 
respectively. These observations are in broad agreement with our results but they 
do not assess the signal enhancement in terms of specific tissue optical 
properties.  
  In our study, it was also demonstrated that the gradual introduction of increasing 
absorber agent affects the signal enhancement more strongly compared to a 
scatterer increase in our ranges. In terms of enhancement in different sample 
depths, the overall signal through the sample seems to decrease as the 
absorption goes up. In contrast, an opposite relation is observed when scattering 
171 
 
 
 
is introduced, as the signal enhancement in the bulk sample volume increases 
with the scattering agent concentration. This is attributed to the fact that the 
diffuse scattering is reinforcing the backscattering enhancement mechanism of 
the diode to a greater extent. With this observation it is useful to observe that 
tissues with higher scattering and less absorption are expected to benefit the 
most from a photon diode for the signal enhancement in their bulk volume.   
  Indeed, from figure 7.1 we can conclude that the tissues which benefit the most 
in terms of signal enhancement are generally the ones with high scattering and 
low absorption coefficients as fat, bone and whole skin. In these types of tissues, 
a signal enhancement of at least 1.4- 2.2 at the front and 1.2-1.7 in the bulk 
volume can be achieved. Tissues with lower scattering and moderate absorption, 
such as breast, brain, muscle and small bowel can also benefit from a significant 
diode signal enhancement of 1.8-2.2 at the front and 1-1.5 at the middle of the 
sample. Tissues with even lower scattering but considerable absorption, such as 
prostate, white matter brain and liver would still benefit from a photon diode but 
mainly in regions of interest near the illumination side, with a signal enhancement 
of around 1.8. There are finally certain types of tissues such as stomach wall 
and aorta which would not see any benefit due to their both high optical 
absorption and scattering properties. 
  However, even in the case where certain types of tissue do not seem to benefit 
from a diode signal enhancement, there is still potential for signal to noise ratio 
improvement, with the use of additional filters/mirrors on the remaining 
tissue/phantom sides (right, left, top, bottom and the collection sides), as has 
been proven in the past159. In conclusion, when traditional setup parameters 
(laser power, collection time, collection efficiency) have been maximized, the 
photon diode approach can contribute with a passive enhancement of a 
considerable factor, leading to further enhanced detection sensitivity and 
penetration depth for transmission Raman measurements. This can be proved 
quite beneficial in the case of an in vivo real time measurement with a Raman 
probe, where after an assessment of the optical properties of the tissue 
measured, a simple introduction of a photon diode filter at the front of the Raman 
probe can enhance the signal by a considerable amount in order to increase the 
sensitivity in the measurements.   
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8 Chapter 8: Depth prediction of an inclusion 
buried in turbid media using a photon diode 
 
8.1 Introduction 
 
 
  As described previously, deep Raman spectroscopy is capable of providing 
information on the chemical composition of distinct layers and inclusions at 
different depths of a sample. However, measuring the depth of the detected 
inclusion can also be important, for example in the case of breast cancer 
diagnosis where calcifications are an important diagnostic factor.  
  Of the deep Raman techniques, only SORS has been studied extensively for 
depth prediction of layers283 or inclusions in animal tissue and tissue phantoms216. 
Raman tomography with SORS has also been employed in the past in a series 
of studies in order to assess the location of an inclusion inside tissue phantoms. 
This concept however involves a large number of collection fibres in different 
orientations around the sample, and in some modalities additional use of an 
imaging technique (e.g. MRI, CT) and complex algorithms in order to reconstruct 
the 3D image214, 284, 285.    
  In this study, we are using a simple concept of determining the depth of a single 
inclusion or ‘’calcification’’ in transmission Raman geometry which in itself does 
not render depth specific information in its basic form. To provide depth sensing 
capability we take advantage of photon diode signal enhancement. The photon 
diode has been predominantly used to achieve signal enhancement in 
pharmaceutical tablets235 and tissue samples149 as described in Chapter 7. In this 
chapter, the photon diode is employed to assess if the depth of signal origin within 
the sample can be ascertained, since it has been shown that the signal 
enhancement it provides is a function of depth160. In this way, we explore the 
potential of predicting the depth of a chemically distinct object (inclusion) buried 
within a turbid matrix by performing only two measurements in an identical 
sample orientation, with and without a beam enhancing element, ‘photon diode’. 
The measurements were carried out in animal tissue samples and liquid tissue 
phantoms with and without absorption. Wherever both absorption and scattering 
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were introduced, the optical properties were in the range of those in human breast 
tissue. 
 
8.2 Depth prediction in liquid tissue phantoms with 
no absorption 
 
 
  In order to assess the depth of the signal origin inside the phantom, 
measurements were carried out using the deep Raman system in a transmission 
mode, with and without the photon diode, configured as described in Chapter 7. 
The tissue phantoms employed were fabricated as described in Chapter 4, in 
order to achieve desirable values of optical properties.  
  The phantoms studied initially were free of absorption but were characterized 
by a reduced scattering coefficient of μ’s= 13.82 cm-1, as this is a middle range 
value of the reduced scattering coefficient in biological tissues. Sets of repeated 
runs were performed in three different phantoms with the same optical properties, 
while the depth was varied with and without the photon diode. In the latter case, 
a quartz window replaced the photon diode in order to make up for the volume 
loss in the phantom. The intensity of the trans-stilbene Raman band at 1193 cm-
1 was derived from each measurement and used in analysis below.  
  Three independent measurement replicates with the photon diode element have 
been plotted versus phantom depth (Fig.8.1). Each replicate involved the full 
replacement of the liquid phantom with a freshly made one and re-setting up the 
experiment. 
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Figure 8.1: Raman signal intensity of trans-stilbene vial in photon diode 
measurements, as a function of its depth inside the liquid phantom. 
 
  In order to make up for the errors acquired from resetting the experiment in a 
repeat and for the power differences in the setup, the intensity values from the 
photon diode measurements in each data set have been normalized to the 
intensity recorded from trans-stilbene when it was located at the back of the cell 
and while using the quartz window (Fig.8.2). 
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Figure 8.2: Normalized Raman signal intensity of trans-stilbene vial in photon 
diode measurements as a function of the phantom depth. 
 
  A calibration curve has been created using the mean values from the first two 
data sets (Phantom 1 and Phantom 2) and an exponential line was fitted to the 
data (Figure 8.3).  
 
Figure 8.3: Mean Raman signal intensity of trans-stilbene in the photon diode 
data sets of the first two phantoms with exponential fitting (𝑦 = 0.2418𝑒0.1037𝑥) 
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  Using the equation of the calibration curve (𝑓(𝑥) = 0.2418𝑒0.1037𝑥), the depth 
values of the third set were predicted by using the correspondent normalized 
photon diode intensity. The predicted versus the actual depth values were plotted 
against each other, showing a very high correlation and a great potential for depth 
prediction (Fig. 8.4), with a root mean square error of prediction (RMSEP) of 0.7 
mm. The value of the RMSEP (3.5%) is justified by the error margin of the 
experimental procedure, such as the preparation of the solutions (±6.25%). The 
fact that the predicted depth values are so close to the actual depth values across 
the whole phantom depth is very promising for the application of the depth 
prediction concept in phantoms/ samples exhibiting mainly scattering. 
 
 
Figure 8.4: Prediction of depth derived from the normalized Raman intensity 
values with photon diode. The dotted line represents a 100% accurate depth 
prediction. 
 
8.3 Depth prediction in combined liquid tissue 
phantoms  
 
  In a next stage, depth prediction was attempted in combined phantoms with both 
absorption and reduced scattering agents added. Four different liquid tissue 
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phantoms of identical optical properties (μ’s= 9.2 cm-1 and μa= 0.8 cm-1) were 
measured with and without the photon diode in transmission mode, while the 
trans-stilbene vial was in different positions inside the phantom volume. The 
intensity of the trans-stilbene Raman has been determined for each 
measurement and the ratio of signal intensity with photon diode over the one 
without the photon diode was calculated for each depth (Fig. 8.5). The values 
were then normalized to the signal derived from the quartz set when the vial was 
at the back of the phantom (Fig. 8.6).  
 
 
Figure 8.5: Ratio of trans-stilbene Raman signal intensity with diode over signal 
without the diode versus the phantom depth of the vial. 
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Figure 8.6: Normalized ratio of trans-stilbene Raman signal intensity with diode 
over signal without the diode, as a function of the phantom depth. 
 
  From the first three independent data sets, a calibration curve has been drawn 
using the mean values of Raman intensity. The data points were then fitted with 
an exponential line 𝑓(𝑥) = 0.73𝑒−0.69𝑥 + 1.065 (Fig. 8.7), which was calculated by 
running a least square regression analysis on Excel. 
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Figure 8.7: Mean value of the normalized ratios of trans-stilbene Raman signal 
intensity with diode over signal without the diode as a function of the phantom 
depth, in the data sets of the first three phantoms with exponential fitting: 𝑓(𝑥) =
0.73𝑒−0.69𝑥 + 1.065. 
 
  The depth values for the fourth data set have been predicted using the equation 
of the calibration curve: 𝑓(𝑥) = 0.73𝑒−0.69𝑥 + 1.065. The predicted depth values 
versus the actual ones were plotted against each other, exhibiting a low prediction 
potential (Fig. 8.8), with RMSEP to be 4.9 mm. For predicted depths where values 
could not be defined from the equation, we assumed the maximum depth value 
(20 mm). 
 
180 
 
 
 
 
Figure 8.8: Prediction of depth derived from the normalized ratios of trans-
stilbene Raman intensity with beam enhancer over intensity without beam 
enhancer. 
 
  From the prediction curve above, we can observe that although the depth values 
can accurately be predicted when the inclusion is located at the front of the 
phantom (0-4 mm), the prediction capability is lost when we are moving towards 
the middle and back of the sample. This is also suggested by Figure 8.7, where 
the intensity values of the exponential fitting drop very slowly in relation to the 
depth, as we move towards the main phantom volume. Therefore, a very high 
precision and reproducibility between the measurements and the different 
phantoms would be required in order to successfully predict the depth values in 
this area. Due to the liquid nature of phantoms and the instability in optical 
properties of scattering agent (Intralipid), in both stock solution and phantoms, 
such a high reproducibility could not be achieved and consequently our model 
fails to accurately predict the middle and back areas.    
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8.4 Depth prediction in tissue sections 
 
  Similar measurements were performed on chicken tissue sections. As tissue 
has both absorption and scattering properties, it was expected to provide similar 
results to those of combined tissue phantoms.  
  In order to test the feasibility of depth prediction through tissue, transmission 
measurements were recorded while a calcification standard (hydroxyapatite-
HAP) vial was placed between four different layers of chicken tissue (10 mm total 
thickness), in positions aligned with the laser beam axis (Fig. 8.9).  
 
Figure 8. 9: Transmission Raman measurements for depth prediction in 
chicken tissue. 
  
  A series of five measurements were recorded both with and without photon 
diode on five different blocks of chicken tissue sections. The intensity of the HAP 
Raman band at 960 cm-1 has been derived from each single measurement and 
the ratios of the intensity with photon diode at the same positions over the 
intensity without photon diode have been calculated for each single depth and 
group of tissue sections. The values were then normalized to the signal derived 
from the quartz set when the vial was at the back of the phantom ((Fig. 8.10). 
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Figure 8.10: Normalized ratios of HAP Raman signal intensity with diode over 
signal without the diode, as a function of the phantom depth for each individual 
set of measurements. 
 
  The mean values from four of the independent data sets were then used to 
create a calibration curve and fit an exponential line to the data which was 
calculated by running a least squares regression analysis (Figure 8.11). 
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Figure 8.11: Mean value of the normalized ratios of HAP Raman signal 
intensity with diode over signal without the diode as a function of the phantom 
depth, in the data sets of the first four sets with exponential fitting (𝑦 =
8.06𝑒−4.59𝑥 + 1.74). 
 
  Using the equation of the calibration curve above (𝑓(𝑥) = 8.06𝑒−4.59𝑥 + 1.74), 
we attempted to predict the depth values of the fifth data set. For predicted depths 
whose values could not be defined from the equation, we assumed the maximum 
depth value (10 mm). The predicted versus the actual depth values were plotted 
against each other (Fig. 8.12), confirming the very low correlation of collected 
Raman signal and tissue depth and highlighting the limitations of this attempt in 
tissue samples (RMSEP= 4.2 mm). Although the RMSEP is not higher compared 
to the one in combined tissue phantoms, the prediction model fails because most 
of the depth values have to be assumed, since they cannot be defined in an 
exponential scale and hence are not in the prediction range of the calibration 
curve. Although a number of different fittings have also been tested for calibration 
in this dataset, they resulted in worse prediction values. 
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Figure 8.12: Prediction of depth derived from the normalized ratios of HAP 
Raman intensity with beam enhancer over intensity without beam enhancer. 
 
  Similarly to the combined tissue phantoms, although the depth is predicted 
reasonably well when the calcification is at the front of the tissue block (0 mm), it 
fails in the middle and back. This can be attributed to a deviation between the 
independent sets of measurements (Fig. 8.10), which relates to the different 
optical properties (within a range) and slightly varying thicknesses of different 
tissue chicken sections and therefore lower reproducibility between the data sets. 
 
8.5 Discussion 
 
  In this experimental section, we attempted to predict the depth of a high Raman 
cross-section scatterer (inclusion) buried in different positions in a turbid matrix 
by using enhancement ratios achieved with photon diode in a transmission 
Raman geometry. This prediction has shown to be successful across the whole 
sample depth when no absorber agent was present, but not when absorption is 
either physically introduced (liquid tissue phantoms) or endogenous (chicken 
tissue). Similar studies on pharmaceutical tablets which also lack any distinct 
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absorption at visible-NIR wavelengths, confirm the strong dependence of signal 
as a function of sample depth by exhibiting a maximum enhancement when the 
inclusion is closest to the illumination side270. In the same study, numerical 
simulations also came to the conclusion that the introduction of absorption, which 
is equal for laser and Raman photons, reduces the enhancement levels through 
the sample depth, leading to a more symmetrical depth profile which does not 
favor the depth prediction.  
  This study demonstrates the limitations of the depth prediction on samples with 
absorption (tissue phantoms and tissue sections). In this case we are only able 
to accurately predict the depth when the inclusion is close to the front (illumination 
side), whereas the depth prediction is affected by a number of factors. The first 
one is the shape of the curve when absorption is introduced which exhibits an 
almost flat area in the middle volume and towards the back (Fig. 8.7). In order for 
the depth to be predicted through a calibration curve with such a shallow slope, 
a very high reproducibility between the independent samples and data sets is 
required. This is because depths which correspond to intensities very close to 
each other need higher precision in order to be predicted.  
  However, because of the liquid nature of the tissue phantoms and the reduced 
stability of higher concentration scattering agent over time especially in the 
presence of ink, it was not possible to achieve such a high reproducibility. 
Phantom stability has been already assessed in Chapter 4 (Fig. 4.3, 4.4, 4.5), 
showing that the 10% deviation observed in signal levels does not affect our 
results in the previous chapters. However, in this chapter, due to the very high 
precision required for the depth prediction in combined tissue phantoms, this 
deviation has a much more significant effect on our results. The tissue samples 
(chicken) also failed to provide high precision in measurements, since it is not 
possible to control precisely the optical properties or thicknesses of each different 
section of fresh tissue and therefore achieve a highly reproducible set of 
measurements.  
  In conclusion, this study exhibits the potential of predicting the depth of an 
inclusion in samples of significant thickness (10-30 mm) and zero or very low 
absorption. The limitations on the optical properties demonstrate that tissue is not 
the ideal medium for this depth prediction concept. In contrary, pharmaceutical 
tablets which bear typically no absorption, match the criteria for a promising 
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prediction model. The photon diode element has only been used on 
pharmaceutical tablets before in order to achieve a more efficient quantitative 
analysis of active pharmaceutical ingredients (API)234. The employment of the 
photon diode for predicting the depth of an API layer or even impurities in the 
tablet volume could be a new promising approach and would open the way to a 
number of different applications in the industrial pharmaceutical analysis. 
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9 Chapter 9: Bladder cancer and Raman 
spectroscopy 
   
  Much research has been done towards the improvement of the gold standard 
for bladder cancer diagnosis, which comprises cystoscopy and biopsy followed 
by histopathology. A number of optical techniques developed, such as 
fluorescence cystoscopy, electrical impedance spectroscopy286 and virtual 
spectroscopy with MRI and CT287, enhance the sensitivity of white light 
cystoscopy by improving the localization of the malignant areas288, 289. However, 
these techniques suffer from a low specificity290-292, are not able to accurately 
discriminate malignant from benign areas without these being assessed 
histochemically and come with the invasive nature of cystoscopy.   
   Attempts for a non-invasive approach rely on urine analysis rather than the 
study and sampling of the bladder wall. Non-invasive techniques which have 
been suggested include the detection of biomarkers, such as DNA and 
proteins293, 294. However, as mentioned more extensively in Chapter 2, despite 
their high sensitivity, these markers usually lack specificity116-118. 
  Raman spectroscopy has also been used for bladder cancer detection in 
different studies measuring either the bladder wall with a Raman probe in vivo206 
or excised tissue samples with Raman microscopy295, 296 or a confocal Raman 
probe297 ex vivo. The differences between benign and different malignant 
conditions are attributed to proteins, lipids and nucleic acids. More specifically, 
proteins, collagen and certain lipids are more abundant in healthy tissues 
whereas DNA, glycogen expression and certain amino acids are found to be 
increased in malignant tissues206, 295.  
  An alternative non-invasive approach for bladder cancer diagnosis described in 
this chapter, is the direct measurement of patients’ urine using Raman 
spectroscopy. Artificial urine samples have been generally measured with Raman 
spectroscopy in the past298. However due to the naturally low concentration of all 
urine components (uric acid, creatinine, etc.) except for urea, it has been shown 
that spontaneous Raman spectroscopy’s detection capability can be limited299. In 
one study conventional Raman spectroscopy, has been employed for measuring 
bladder tissue epithelial cells found in urine from patients with bladder cancer300, 
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but not in plain urine. In this chapter, we present the results of our study of the 
potential differences in urea’s distribution and interactions in urine from healthy 
individuals and patients with bladder cancer, using Raman microscopy.   
 
9.1 Raman signals of urine samples 
 
Raman spectra of urine samples were initially measured with three different 
excitation wavelengths in order to assess the most suitable one for subsequent 
measurements (Fig. 9.1). All of the Raman systems have been calibrated as 
described in section 4.2.2, except for the Witec system which contains a 
systematic error. Since the purpose of these measurements was the assessment 
of the quality of the Raman spectra rather than the exact position of the Raman 
bands, our results should not be affected. 
 
  
Figure 9.1: Urine Raman spectra recorded with different laser excitation 
wavelengths (532, 785 and 830 nm) on different Raman spectrometers. The 
spatial offset between the individual spectra has been adjusted for clarity. 
* 
*subject to calibration error  
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  As shown in the spectra above, urine samples exhibit fluorescence when 
measured with lower wavelengths (532 nm)301 but cells inside the urine are 
clearly detected300. At higher wavelengths (785 and 830 nm), plain urine does not 
exhibit any fluorescence and this is why these wavelengths were chosen for the 
urine analysis.  
  Spontaneous Raman microscopy has been shown not to be able to detect 
efficiently most of the urine components at their physiological values in human 
urine299 due to their low concentrations. Indeed, as shown in Figure 9.1, the only 
dominant peak in plain urine is attributed to the symmetric C–N stretching band 
of urea at 1003 cm-1. For this reason, the study was focused on the analysis of 
the urea peak position and its spatial distribution over the urea drop area in order 
to discriminate healthy from bladder cancer urine. 
 
9.2 Urea peak position analysis  
   
  During measurements in different urine samples, we noticed that the main peak 
of urea is adopting different positions between 995 and 1011 cm-1 (Fig. 9.2). A 
number of factors have been considered in order to find the reason behind this 
shift.  
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Figure 9.2: Peak shifts of the C-N stretching urea band in urine samples. 
 
Polarization 
  Initially, the urea peak shift in urine samples was studied under different types 
of polarization. The effect was tested on three different crystals of one urine 
sample by changing polarization of the collected light relative to the polarization 
of an 830 nm incident laser beam (parallel, perpendicular and no change of 
polarization) (Fig. 9.3). 
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Figure 9.3: Raman spectra under different types of polarization for the same 
urea crystal. Note that the peak at 325 cm-1 is attributed to the calcium fluoride 
substrate. 
  Different types of polarization (perpendicular and parallel to the laser) were 
found to have no effect on the C-N stretching urea band position in urine samples. 
 
Drying time 
  The effect of drying time on urine samples was also explored on fresh urine (one 
healthy and one malignant), measured as soon as they were collected and after 
a period of ten days. The measurements were recorded with a 785 nm laser and 
analysed with Principal Component Analysis (PCA) in order to assess the stability 
of the urine components over the drop area. The loading plots and score images 
are shown in the figures below. 
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Figure 9.4: Loadings comparison in a healthy urine sample which has been 
measured as soon as collected (time: 0 days – left) and ten days later (time: 10 
days -right). Loading plots are only shown for the first three principal 
components and the urea peak position is marked in each one of them. 
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Figure 9.5: Score images on PC1 (a), PC2 (b) and PC3 (c) of a healthy urine 
sample measured as soon as collected and 10 days later 
  In Figure 9.4 we can see that the spectral variation is explained by the same 
loading plots before and after the drying period. Spectral features of urea in the 
loading plots, such as the peak position, change between different loading plots 
for a specific time point (demonstrating the peak shift observed earlier), but is 
highly reproducible between the two different time points, proving that the urea 
peak shift does not depend on the drying time of the sample.  
  In Figure 9.5, where the distribution of the principal components over the drop 
area is shown, we observe a difference in the intensity of each component before 
and after the drying period. While the components at 0 time are of higher intensity 
compared to 10 days later (also reflected on the variance percentages of 
(a) 
(b) 
(c) 
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loadings), the distribution between the two time points remains similar. More 
specifically, the crystal shaped formations which are attributed to the higher urea 
shift (1002 cm-1 for time 0 and 1007 cm-1 for 10 days later), are concentrated in 
the middle of the drop and represent the greatest variance percentage over the 
drop area. A component-free ring which surrounds the urine drop also seems to 
retain its stability over time (Fig. 9.5b). These results demonstrate that the 
duration of Raman measurements should not impact on the components 
distribution in the droplet area or the PCA analysis conducted afterwards. 
Additionally, urine drops measured and left to dry over different periods of time 
should be safe to be compared with each other.  
  Similar trends are observed for the malignant urine drop below, where the high 
wavenumber urea shift is observed in crystal clusters concentrated in the middle 
of the drop (Fig. 9.7a, 9.7b). This spectral feature is constant both in terms of 
distribution and position of the urea band. The component-free ring is also 
present in the malignant urine (Fig, 9.7a). 
  
 
Figure 9.6: Loadings comparison in a malignant urine sample which has been 
measured as soon as collected (time: 0 days – left) and ten days later (time: 10 
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days – right). Loading plots are only shown for the first three components and 
the urea peak position is marked in each one of them. 
 
 
Figure 9.7: Score images on PC1 (a), PC2 (b) and PC3 (c) of a malignant urine 
sample measured as soon as collected and 10 days later. 
 
9.3 Urea vibrations in different environments 
   
  As stated in the literature before302, the urea peak shift can be attributed to urea 
molecule interactions in different environments. Frequency shifts of urea’s 
(a) 
(b) 
(c) 
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vibrational modes have also been recorded when urea state changes from liquid 
to solid (with IR)303 and from solid to gas304. It has also been shown that the 
position of the urea peak is shifting linearly with its concentration in an aqueous 
solution305. 
  In order to confirm that the position shift of urea band observed in the urine 
samples is connected to the change of environment and presence of different 
molecules, urea solid samples and aqueous solutions at physiological 
concentration306 were prepared, measured and analysed (Fig. 9.8).  
 
Figure 9.8: Raman spectra of solid urea crystals and aqueous urea solutions 
(9.3 g/L) measured with 830 nm laser for an acquisition time of 10 s. The 
Raman intensity of the spectra has been adjusted appropriately for comparison 
reasons. 
 
  Raman spectra recorded from 9.3 g/L urea aqueous solutions showed a urea 
band with a maximum at 1006 cm–1, whereas for the same band in solid urea 
spectra the maximum was located at 1013 cm–1, in agreement with earlier 
studies304. Comparison of the two urea bands demonstrates a peak shift similar 
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to the one observed in the urine samples earlier. However, it should be noted that 
the left shifted urea band in artificial urea solutions (1006 cm-1) did not match 
accurately the one in the urine samples (995 cm-1) and for this reason further 
investigation was needed. 
  The urea molecule is able to only bind strongly to one water molecule using two 
molecular bonds, by donating an electron from a nitrogen atom and accepting 
one onto the urea oxygen atom307. However, each urea molecule can also link up 
to five different water molecules more weakly through hydrogen bonding, or to 
cations through electrostatic forces via the electron-rich oxygen and nitrogen 
atoms (Fig. 9.9). In absence of sufficient water molecules, urea binds to itself 
through hydrogen bonds (a urea dimer is a particularly stable species) (Fig. 9.9c). 
 
 
 
Figure 9.9: Urea molecule in different environments can interact with water 
molecules (a), cations (b) or neighbouring urea molecules (c). 
 
  When urea molecules are connected to each other rather than to water 
molecules, the CN bond becomes shorter in the urea resonance forms304 and 
therefore its vibrational frequency increases. This is why the urea band position 
in Raman spectra is observed at higher wavenumbers (1011 cm-1). Conversely, 
when urea molecules are connected to the water, the CN bond remains single 
rather than double which is characterized by lower energy and lower frequency 
(1006 cm-1). When a urea molecule is connected to a salt cation, a stronger 
electrostatic bond is formed. This interaction makes the CN bond in urea 
molecule even weaker, causing a lower wavenumber shift to the Raman band 
(995 cm-1).     
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  Validating our hypothesis, recorded Raman spectra from aqueous urea 
solutions containing NaCl (0.18M), showed a urea band at 1005 cm-1. However, 
when a curve-fit analysis was applied to this band using OriginLab software, it 
revealed two different sub-bands: a ν(CN)s band component with a maximum at 
1008 cm–1 due to urea H-bonded to water and/or other urea molecules and a 
component at 995 cm–1 which can be assigned to urea interacting with Na+ 
cations through the carbonyl oxygen and the nitrogen atom (Fig. 9.10). 
 
Figure 9.10: Results of curve-fit analysis applied to the urea band of an 
aqueous urea solution containing NaCl (0.18M) recorded with 830 nm laser 
excitation wavelength (acquisition time: 10 s). 
 
  Based on this hypothesis, different urea peak positions in urine samples are a 
result of urea interactions with different molecules. Peak positions lower than 
1005 cm-1, such as 995 cm-1 and 998 cm-1, can be assigned to urea interactions 
with cations, whereas high wavenumber positions (1011 cm-1) are assigned to 
solid urea in which molecules are bound with each other (crystalline urea). In 
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between, the band with positions 1002 cm-1 and 1005 cm-1 can be assigned to 
partially hydrated states of urea.   
  After establishing the reasons behind the urea band shift, urine samples from 
21 healthy and patients with bladder cancer were studied using Raman 
microscopy. Initially, mean Raman spectra were recorded from each drop and 
analysed with Principal Component Analysis (PCA) and Linear Discriminant 
Analysis (LDA) using leave-one-out cross-validation, in order to explore the 
hypothesis that the urea peak shift – which depends on molecular interactions as 
described above – is related to the malignancy status. In a second round of 
measurements, a number of healthy and malignant urine samples were studied 
more extensively by recording Raman maps, in order to reveal any differences in 
the distribution of the different urea crystals over the droplet area. 
 
9.4 Analysis of urine samples using multivariate 
analysis  
 
  Raman spectra were recorded from 30 different positions on dried drops from 
21 urine samples (10 with bladder cancer and 11 healthy) by focusing a near 
infrared laser line (830nm) through a 50x objective lens of an optical microscope 
onto the surface of the drop (Fig. 9.11). 
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Figure 9.11: Urine drop under the white light of Raman microscope. The 
Raman spectra were recorded in the highlighted mapping area on a grid of 30 
points (scale in μm). 
 
  Single Raman spectra were pre-processed and mean Raman spectra were 
calculated for each sample (Fig. 9.12- A).  
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Figure 9.12: Mean Raman spectra of 21 urine samples over the whole spectral 
range (A) and in the urea peak region (B), as they were measured with 830 nm 
laser on a Raman microscope. 
 
202 
 
 
 
  As expected, the dominant peak in the spectra is the urea peak (around 1003 
cm-1) which shifts to different positions between different measurement points in 
different samples (Fig. 9.12- B).  
 
 
Figure 9.13: Urea peak on mean Raman spectra of healthy (green plot at 1000 
cm-1) and malignant (red plot at 1003 cm-1) urine samples. 
  This urea position change could be potentially related to the sample malignancy 
as indicated by the mean healthy and malignant spectra (Fig. 9.13). In order to 
explore the differences between the two groups further, multivariate analysis 
(PCA, LDA) was carried out on the dataset. PCA, which is further described in 
Chapter 4, is an unsupervised multivariate technique used to analyse the inherent 
structure of the data. In our case, PCA transforms a set of Raman spectra into a 
number of uncorrelated (orthogonal) variables (principal components) which 
describe the spectral variance of the dataset.  
  Initially, spectral features which are not related to the samples, such as the 
Raman peak attributed to the atmospheric oxygen at 1542 cm-1 308, were 
eliminated (Fig. 9.14). After the Raman spectra were processed (scaled 0-1, 
normalized, mean centred), they were analysed with PCA in order to reveal the 
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most significant diagnostic variables (PC-loadings) related to the spectral 
differences found in the dataset (Fig. 9.14). 
 
 
Figure 9.14: The first six most significant principal components as they resulted 
from PCA analysis. 
 
  The six first loadings resulting from PCA describe ~83% of the total spectral 
variance in our samples. The most prominent feature (loading 1- 69.63%) 
describes the intensity variation of urea peak, whereas the different position of 
the band through the different loadings shows the variation of the peak position. 
The first two loadings, which correspond to PC1 and PC2, clearly show the main 
feature of urea band located at 1000 cm-1, a hydrated urea state. PC4, PC5 and 
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PC6 loadings describe a shift of the urea peak towards lower (991 and 994 cm-1) 
and higher (1005 cm-1) wavenumbers.  
  The first three principal components (PC1, PC2 and PC3), which represent the 
80.48% of the total spectral variance across the urine samples, were plotted 
against each other in different combinations, in order to reveal discriminative 
relationships between healthy and malignant urine samples (Fig. 9.15). 
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Figure 9.15: Two dimensional PCA scores plots of the urine Raman spectra, 
with PC1, PC2 and PC3 plotted against each other, showing healthy (green) 
and malignant (pink) urine samples. 
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  In order to explore further the possible discrimination between the two groups 
(healthy and malignant), LDA was also performed, based on the first 15 PCs 
resulted from the PCA, and followed by a leave-one-out cross-validation. The 
number of principal components used in LDA was decided based on the presence 
of spectral features rather than plain noise background, in the corresponding 
loadings. LDA is a supervised model which optimally classifies the data into two 
classes and during the cross-validation. All mean spectra except one were used 
to build an LDA model and then to classify the left out spectrum. This process 
was repeated so that each spectrum is predicted once. The training model 
demonstrated a 73% sensitivity and 80% specificity, and a clear discrimination 
was shown between the two distributions (Fig. 9.16). 
 
 
Figure 9.16: Histogram of healthy group (green) against the malignant (red) 
showing the frequency of values with particular linear discrimination function 
scores. 
 
  It should be mentioned that the discrimination was based on the LD function 
(shown in Fig. 9.17) which, despite the noisy background, clearly demonstrates 
that the urea shift is the dominant discriminant factor between the two groups.  
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Figure 9. 17: The LDA discriminant function used from the LDA model for the 
optimum discrimination between the healthy and the bladder cancer urine 
group. 
 
9.5 Mapping of healthy and bladder cancer urine 
drops using Raman microscopy 
 
  After it was established that the main discriminant factor between the two groups 
is the urea peak shift, Raman maps were recorded in greater detail for two healthy 
and three malignant urine samples. The purpose was not only to detect where 
the urea shifts are localized but also to explore the distribution of the main 
spectral features over the drop area. The detailed Raman maps were run both 
with 785 nm and 830 nm laser excitation wavelengths and processed using PCA 
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analysis. As expected, most of the principal components revealed during the PCA 
analysis, are related to urea peak shifts in the samples. High density Raman 
maps reveal that healthy and malignant drops exhibit certain distinct 
characteristics in the distribution of the two main types of crystals: urea interacting 
with cations at 992 cm-1 and hydrated urea at 1005 cm-1. 
  Looking at the principal components in the Raman maps measured, it appears 
that healthy urine drops generally show the same distribution of hydrated urea 
molecules in the centre (1005 cm-1) and mostly the absence of urea···cations 
clusters over the whole drop area (992 cm-1) (Fig. 9.18). In comparison with the 
malignant urine samples, it is also obvious that the urea–cation band at 995 cm-
1 is not as abundant in the healthy as in the malignant samples (Fig. 9.19). 
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Figure 9.18: Distribution of 1005 cm-1 (a) and 992 cm-1 (b) component 
eigenvalues in healthy urine samples, as revealed from PCA analysis (loadings 
and score images on the correspondent Principal Components). 
 
 In malignant samples (Fig. 9.19), the distribution based on the band at 995 cm-1 
which indicates the presence of urea···cation clusters is more dominant and 
tends to be located all over the droplet area. This is obvious in the score images 
which correspond to loadings with a dominant spectral feature around 995 cm-1 
(990.4 cm-1, 993.8 cm-1, 993.8 cm-1) (Fig. 9.18b). It should be also noted that the 
urea···cation clusters in malignant samples are smaller and scattered in a larger 
drop area compared to the ones in healthy samples. The centre of the droplet in 
malignant samples is characterised by large clusters of hydrated urea, showing 
according to the loadings, a band around 1005 cm–1 (1010 cm-1, 1005 cm-1, 1007 
cm-1), leaving the periphery of the drop component-free (Fig. 9.19a). 
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Figure 9.19: Distribution of 1005 cm-1 (a) and 992 cm-1 (b) band in malignant 
urine samples, as revealed from PCA analysis (loadings and score images on 
the correspondent Principal Components) 
 
  Another general difference observed between the two types of samples is that 
the dried urine drops from the healthy group are generally more transparent, and 
hence of lower concentration in urea, than the drops from the malignant group. 
On the other hand, malignant samples are generally richer in urea and more 
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abundant in the different clusters that it might form. The observed distributions of 
urine components sometimes called ‘coffee ring’ effect309.  
  It has been mentioned before that when urea is interacting with water, a small 
fraction of the water molecules is strongly immobilized by urea307. Hence, when 
the urine samples are drying, they trap predominantly the intermediate hydrated 
states of urea rather than the fully dried form303. In this way, the urea···urea 
interaction which produces the dry state phase is prevented and this is why shifts 
corresponding to the dry phase (1013 cm-1) are not observed in the urine 
samples, even after they have dried out. 
 
9.6 Discussion 
 
  In this chapter, healthy and bladder cancer urine samples were studied by the 
means of Raman microscopy. As demonstrated by previous studies299, the 
majority of the components in urine cannot be detected using spontaneous 
Raman, due to their low concentration. Cells found in urine have been used in 
the past to detect bladder cancer. However, since cells are something uncommon 
to be found in urine samples, especially with the second urine of the day as used 
here, our analysis could not be based on them. This is why our study focused on 
the spectral features and spatial distribution of urea molecules in the urine 
droplets.  
  The main distinguishing spectral feature explored was the peak shift of the urea 
symmetric C–N stretching band. After eliminating a number of possible factors 
and demonstrating that the stability of urine drops over time only slightly affects 
urea distribution, it was shown that the main contribution to this shift derives from 
the different interactions between urea and its surrounding molecules. These 
interactions are promoted to different extent not only between different urine 
samples but also between different areas of the same sample depending on how 
the drop dries.    
  Detailed Raman maps on a number of healthy and malignant urine samples 
confirmed the different urea species distribution on different types of drops. The 
urea···cation was found to be more abundant in malignant urine, with the 
hydrated urea to be concentrated mainly in the centre of the drops.  
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  Linear discriminant analysis including all of the urine samples, made use of the 
15 first principal components as they resulted from previous PCA, in order to 
establish a linear discriminant function. This function revealed the urea peak shift 
as the main discriminant feature that leads to the optimum discrimination between 
the two groups. Employing this function to discriminate between the two groups 
of our dataset, a sensitivity of 73% and a specificity of 80% was achieved, with a 
clear separation of the two groups shown in the histogram. Although our 
observations cannot be conclusive due to the small number of urine samples 
available, this feasibility study demonstrates significant potential in bladder 
cancer non-invasive diagnosis. Based on the potential discrimination indicated 
through this study, further measurements and a bigger number of samples are 
required in order to establish higher statistical values for the performance of this 
promising non-invasive approach.      
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10 Chapter 10: Discussions 
   
10.1 Assessment of deep Raman application in 
breast and prostate cancer diagnosis 
 
  In the main part of this thesis we explored the feasibility of applying deep Raman 
spectroscopy for cancer, and specifically prostate and breast cancer diagnosis. 
As Raman spectroscopy is a chemically specific, non-invasive technique which 
can scan a significant volume of tissue, it could provide a promising alternative to 
the current diagnosis.  
  In the first stage, liquid tissue phantoms were employed in order to assess the 
feasibility of measurements on samples with optical properties and size 
comparable to those of breast and prostate. Similar studies on tissue and 
phantoms for diagnosis149, 155, 214, 249, 250 and surgical margins assessment212 have 
been reported in the literature. However, in these studies the Raman signal was 
only explored in terms of sample thickness, whereas aspects such as its spatial 
distribution throughout the sample volume and its dependence on the optical 
properties were unexplored. In addition, the spatial distribution of the Raman 
signal of potentially malignant features (calcifications) has been studied in 
different phantoms, assessing the signal origin and detection limits of Raman 
scattering in prostate and breast tissue of specific optical properties and 
dimensions.  
  In terms of the detection limits, which are different for each system and tissue 
environment, it was shown that if the measurement parameters (tissue optical 
properties, Raman profile of the malignant area/lesion, laser spot diameter) are 
known, it is possible to assess the characteristic distance from the beam axis 
from which the signal can be detected. In the case of our study the effective 
measurement area would be an area of 30 mm x 30 mm from the illumination 
point for both prostate and breast tissue. Assuming a 45 mm x 30 mm mean 
dimension human prostate gland, it would be possible to cover its entire volume 
using only a couple of transmission measurements in a potential scanning for 
prostate cancer (Chapter 5- Fig. 5.19). 
  In terms of the Raman signal origin, it has been clearly shown how the 
distribution of the collected Raman scattering signals changes under different 
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values of absorption and scattering coefficients of the phantom and hence in 
different types of tissues. It has been demonstrated that the highest signals are 
likely to be obtained from nearer surface lesions (either on collection or 
illumination side) than those at depth using transmission Raman spectroscopy. 
Even in this case though, relative signals are likely to be as high as 40–60% for 
‘lesions’ found in the centre of organs compared to those found towards the 
edges. This is in contrast to previous experimental252 and theoretical studies253, 
254 in powders and pharmaceutical tablets with minimal or no absorption on layers 
of infinite lateral dimensions, which indicate that the maximum Raman signal 
originates from objects buried in the centre of the tablets rather than towards its 
edges. 
  Another aspect of the study was to assess the feasibility of the measurements 
in terms of tissue content. Numerous studies using conventional Raman 
spectroscopy have proven not only the potential of acquiring Raman signal from 
human prostate and breast tissue, but also of discriminating between different 
pathologies of prostate tissue168, 193, 256, 257 and breast cancer196, 197, respectively. 
As a part of this thesis, different types of human prostate tissue acquired from the 
local tissue bank have been assessed in terms of Raman signal collection, using 
deep Raman spectroscopy. In order to explore the potential of the deep Raman 
technique as an approach to the clinical practice, the samples have been 
measured across the whole volume in a transmission mode and not sectioned as 
in earlier studies213. This attempt revealed the limitations of the deep Raman 
application on small samples of prostate tissue, which includes the presence of 
fluorescence (TURP samples) and the need for a sufficient sample volume 
(prostate biopsies). Measurements of prostate samples’ individual components 
(fat, muscle tissue) and sections of TURPs, confirmed the possibility of collecting 
Raman photons from samples which lack the limitations above, by proving that 
the prostate gland is not intrinsically fluorescent and hence a sufficient volume of 
it can be efficiently studied by means of deep Raman spectroscopy.  
  Our results demonstrate that failure of acquiring deep Raman signals from 
prostate tissue was due to the properties of the samples used rather than the 
actual technique. For that reason, we suggest that measurements of whole 
prostate glands (potentially removed after prostatectomy) would prove feasibility 
of the concept. If this is the case, we can set the basis for a non-invasive, real 
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time prostate cancer diagnosis, where the illumination fibre could be inserted 
transurethrally and the collection fibre transrectally or the other way round (Fig. 
10.1b). The deployment of transmission Raman geometry for this clinical 
application would be even more obvious in the case of breast, as it is an external 
and more accessible organ (Fig. 10.1a). In both of the cases, the transmission 
Raman mode is applicable and provide the advantage of high penetration depth, 
since both of the glands are accessible from both sides.   
 
 
Figure 10.1: Potential transmission Raman geometry applied to (a) breast95 
and (b) prostate cancer (recreated from248). 
 
  We should point out that diagnosing cancer with Raman fibre optic probes, 
mainly in the form of endoscopes, has been studied and experimentally applied 
for pathology discrimination168, 170, 203-210 throughout various studies. In the case 
of the deployment of fibre optic probes in a transmission mode, our study would 
contribute to increasing the efficiency of this approach by identifying areas with a 
maximum distribution of Raman signal. Although the tissue phantoms we 
employed might be different from tissues in terms of heterogeneity of the content, 
our results would still be applicable since we took into consideration the relative 
signals of the samples. However, being aware of the Raman signal distribution, 
would also apply to a more significant parameter: the detection limits. Being able 
to evaluate the effective volume of where Raman signal can be collected from, 
would increase the efficiency and sensitivity of the measurements.  
 
(a) (b) 
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10.2 Application of photon diode for signal 
enhancement and depth prediction 
 
  In order to improve the Raman signal and achieve the maximum possible 
efficiency in signal collection, a ‘’photon diode’’ element was introduced in our 
measurements and its effect has been studied in terms of ‘’calcification’’ depth in 
the sample and optical properties. This concept has been applied mainly in 
previous studies to pharmaceutical tablets159, 269 and to limited extent to biological 
tissue149, 235 but without exploring the parameters mentioned above. Because of 
important differences in the optical properties between tablets and tissues, such 
as the lack of significant absorption in tablets and considerably longer mean free 
scattering path lengths in tissues (at least by an order of magnitude) due to the 
difference in spatial scales, one cannot assume identical behavior and 
enhancement. The signal enhancement exhibited by the employment of photon 
diode in a wide range of phantom optical properties was between ×1 and ×2.4. 
Our results are in broad agreement with observations from similar studies which 
demonstrate a signal enhancement of 1.6 and 1.5 in chicken235 and porcine 
tissue149 respectively, which were performed without assessing the signal 
enhancement in terms of specific tissue optical properties. 
  Our measurements would contribute in a potential application of the photon 
diode element in transmission probe measurements as they indicate the types of 
tissues which are more likely to benefit from such a concept. From our results, 
tissues with high scattering and low absorption coefficients, such as fat, bone and 
skin (all layers) would benefit the most in terms of signal enhancement (Chapter 
7). In these types of tissues, a signal enhancement of at least 1.4- 2.2 at the 
front and 1.2-1.7 in the bulk volume can be achieved. Tissues with lower 
scattering and moderate absorption, such as breast, brain, muscle and small 
bowel can also benefit from a significant diode signal enhancement of 1.8-2.2 
at the front and 1-1.5 at the middle of the sample. Tissues with even lower 
scattering coefficient but considerable absorption, such as prostate, white matter 
brain and liver would still benefit from a photon diode but mainly in regions near 
the illumination side, with a signal enhancement of around 1.8. Finally, there are 
certain types of tissues such as dermis, stomach wall and aorta which would not 
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see any benefit due to their high optical absorption and high scattering properties.  
However, even in the case where certain types of tissue do not seem to benefit 
from a diode signal enhancement, there is still potential for signal to noise ratio 
improvement, with the use of additional enhancers/mirrors on the remaining 
tissue/phantom sides (right, left, top, bottom and the collection sides), as has 
been proven in the past159. 
  The photon diode approach can be beneficial when traditional setup parameters 
(laser power, collection time, collection efficiency) have been maximized. This 
can prove beneficial in the case of an in vivo real time measurement with a 
Raman probe, where after an assessment of the optical properties of the tissue 
measured, a simple introduction of a photon diode filter on the front of the Raman 
probe (Fig. 10.2) can enhance the signal by a considerable amount, increasing 
in this way the detection sensitivity and penetration depth of the measurements.   
 
 
Figure 10.2: Schematic diagram of photon diode element implemented in 
clinical practice. 
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  Apart from significantly enhancing the Raman signals on the phantoms, the 
photon diode has also been employed to predict the depth of a chemically distinct 
object buried within a turbid matrix. This novel approach for depth prediction could 
address the localization of certain suspicious lesions in tissues, a significant 
clinical feature in breast cancer diagnosis which is currently only available 
through mammography. The advantage of this potential approach lies in its 
simplicity, since it only requires two measurements in an identical sample 
orientation, with and without the photon diode.  Earlier studies have attempted 
depth prediction of layers283 or inclusions in animal tissue and tissue phantoms216. 
Raman tomography with SORS has also been employed in order to assess the 
location of an inclusion inside tissue phantoms. This concept however involves a 
large number of collection fibres in different orientations around the sample, 
additional use of an imaging technique (e.g. MRI, CT) and complex algorithms in 
order to reconstruct the 3D image214, 284, 285. That makes the technique less 
flexible and not easy to implement in the clinical practice.   
  The depth prediction has shown to be successful across the whole sample depth 
when no absorber agent was present, but not in samples where absorption is 
either endogenous or physically introduced (exogenous). Similar studies on 
pharmaceutical tablets which lack any distinct absorption at visible-NIR 
wavelengths, confirm the strong dependence of signal as a function of sample 
depth by exhibiting a maximum enhancement when the inclusion is closest to the 
illumination side270. In the same study, numerical simulations also evidence that 
the introduction of absorption reduces the enhancement levels through the 
sample depth, leading to a symmetrical depth profile which is not amenable to 
depth prediction. That demonstrates the limitations of the concept in media with 
inherent absorption such as tissue phantoms and tissue samples. In this case we 
were only able to accurately predict the depth when the inclusion was close to 
the front of the sample (illumination side). 
  However, the prediction depth concept was very promising for samples with little 
absorption and a thickness of up to 10-30 mm. That would render this application 
ideal for pharmaceutical tablets where minimum absorption is present. To date, 
the photon diode concept has only been used on pharmaceutical tablets in order 
to achieve a more efficient quantitative analysis of active pharmaceutical 
ingredients (API)234. The employment of this concept for predicting the depth of 
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an API layer or even impurities in the tablet volume could be a promising 
approach and open the way to a number of different applications in the industrial 
pharmaceutical analysis. 
   
10.3 Assessment of Raman microscopy in bladder 
cancer diagnosis 
 
  In the final experimental chapter of the thesis, we explored the potential of 
diagnosing bladder cancer by means of conventional Raman microscopy on urine 
samples. Raman spectroscopy has been employed for bladder cancer diagnosis 
in earlier studies by either measuring the bladder wall with a Raman probe in 
vivo206 or excised tissue samples with Raman microscopy295, 296 or a confocal 
Raman probe297 ex vivo. In contrary, our study involved direct and completely 
non-invasive measurements on patients’ urine samples. From our results, the 
main discriminant feature was indicated to be the urea Raman peak shift which 
depends on the interactions between urea and the surrounding molecules. These 
interactions are promoted to a different extent not only between different urine 
samples but also between different areas of the same sample. Based on this 
spectral feature, multivariate analysis on the urine measurements has indicated 
a sensitivity of 73% and a specificity of 80% in the discrimination between the 
two pathology groups. In similar studies of bladder epithelial cells in urine 
samples with Raman spectroscopy, sensitivity and specificity was 92% and 91% 
respectively, involving however a higher number of samples.300 Further in vivo 
and ex vivo measurements of the bladder wall of patients with bladder cancer 
have demonstrated a sensitivity and specificity range of 85-96% and 79-100% 
respectively.206, 295-297 A number of commercially available urine-based markers 
for bladder cancer tests have also exhibited a maximum sensitivity and specificity 
value of 83% and 86% respectively310. Although our observations in this study 
cannot be conclusive due to the small number of the urine samples available, 
these feasibility measurements demonstrate significant potential in non-invasive 
bladder cancer diagnosis. Further measurements on a bigger number of samples 
would potentially establish higher statistical values for the performance of this 
promising Raman approach.      
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Future work 
 
  There are a number of interesting research directions raised from this study 
which would be worth following up with future work.  
  In terms of prostate and breast cancer diagnostics, the efficiency of deep Raman 
has been shown for the respective optical properties. Specifically for prostate, it 
has also been shown that fluorescence would not inhibit measurements in tissues 
(unless they had been cut with a hot loop), and consequently in vivo analysis of 
whole prostate glands may be viable. The latter case would be quite interesting 
to explore in the operating theatre, since we have additionally shown that the 
whole prostate volume can be potentially scanned by a couple of transmission 
Raman measurements.  
  For this purpose, prostate glands removed through prostatectomies and just 
before being examined with histopathology for assessing cancer metastasis, 
could be potentially scanned in a transmission Raman setup on site. A number 
of measurements mainly around the peripheral zone where most of the 
carcinomas are diagnosed, would possibly detect calcifications or even 
suspicious areas with different Raman signal from the rest of the surrounding 
tissue in the gland. In a next step, the spectroscopical results can be correlated 
to the histopathological analysis on the same gland and identify signals 
corresponding to healthy or malignant prostate areas. 
  If this approach is successful, the next stage would be the real-time, non-
invasive scanning of prostate gland using fibre optics for illumination and 
collection through urethra and rectum, as described in Chapter 3. This concept 
would have the advantage of being minimally invasive compared to the current 
standard of biopsy, as no tissue would need to be removed from the gland. 
Additionally, the tissue volume scanned would exceed those in core biopsy 
samples, which are usually only a few mm in thickness and length. The small 
prostate volume tested for cancer with biopsy frequently leads to low sensitivity 
of the technique as the malignant area might be missed. With a deep Raman 
approach, the whole gland and mainly the high risk areas (peripheral and 
transitional zone) which are located in proximity to the rectum and centrally to the 
gland respectively (Fig. 11.1), would be potentially assessed for malignancies in 
their whole volume, increasing in this way the sensitivity of diagnosis. The 
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application of deep Raman on prostate cancer is a part of this study which could 
not be completed since the ethical and trust approval for this work took longer 
than anticipated. However, this is likely to be achieved in the months following 
the end of this doctorate project. 
 
 
Figure 11.1: Potential transmission Raman geometry for prostate cancer 
detection in relation to the prostate zones (recreated from248) (A) and the side 
view diagram of the prostate showing the anterior fibromuscular stroma (FM), 
central zone (CZ), posterior zone (PZ), transition zone (TZ), prostatic urethra 
(PU), and a seminal vesicle (SV) (B)311. 
 
  A similar approach would also be viable in the case of the breast cancer where 
the relationship between calcifications and disease is more well-established. In 
that case, transmission Raman which is particularly sensitive to calcifications due 
to their high Raman cross-section, would detect the nature of the calcified 
formations in the breast glad in transmission mode, without the need of tissue 
removal for a biopsy. As there are types of calcifications (type I, calcium oxalate) 
which are benign and do not provide any risk for the patient, Raman spectroscopy 
which is sensitive to the molecule vibrations of calcifications, would easily rule 
these cases out of the need for biopsies. That would reduce the number of 
women (around 22%) who are unnecessarily going through the stress and the 
clinical procedure of cancer diagnosis. The research group in Exeter University 
takes significant steps towards this direction by optimizing the transmission deep 
A B 
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Raman system (for wavelength, etc) which will be used on scanning human 
breast samples in collaboration with Royal Devon & Exeter Hospital. 
  The application of transmission Raman spectroscopy on both breast and 
prostate cancer, can benefit from the work presented in this thesis on photon 
diode signal enhancement. With the application of the ‘’photon diode’’ element at 
the front of the illumination fibre optic probe, we can double the signal 
enhancement of tissue in close proximity with the excitation side and the rest of 
the area up to ×1.5. This application can potentially show benefit with similar 
enhancement for fibre optic probes used alone or inserted though endoscopes 
on a range of tissues such as small bowel, skin and bone.  
  Another interesting work to follow up would be the inclusion depth prediction in 
diffusely scattering samples, using the ‘’photon diode’’ element. Although the 
results were not encouraging for tissue media which include absorbing agents, 
this concept would ideally work for pharmaceutical tablets, where much work has 
be done with the ‘’photon diode’’ effect on signal enhancement, but no depth 
prediction of any inclusion in their volume has been attempted yet. Potential 
applications in this field can include the depth prediction of one or multiple API 
layers in a pharmaceutical tablet, detection of impurities or contamination and 
their depth in the tablet volume.  
  Finally, the study on bladder cancer urine samples using Raman microscopy, 
demonstrated significant potential in non-invasive diagnosis. However, that was 
a feasibility study and our observations cannot be conclusive due to the small 
number of the urine samples studied. Based on the promising specificity (80%) 
and sensitivity (73%) achieved through our study, further measurements and a 
bigger number of samples would be required in order to establish higher statistical 
values for the application of this non-invasive approach. In a potential 
continuation of the study, a suggestion would be to collect the first urine of the 
day instead of the second one from the patients. In this way, more proteins would 
be detected in the urine volume, providing a greater potential for spectral 
discrimination between the two pathology groups. If this is the case, spectral 
features which are different between healthy and malignant samples could be 
attributed to molecular vibrations deriving from specific biomarkers in bladder 
cancer. That would provide an entirely non-invasive approach which would be 
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also possible to use as a screening test on patients’ urine samples for bladder 
cancer diagnosis.   
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Conclusions  
 
  The aim of this thesis was to explore minimally invasive approaches to cancer 
diagnosis, using conventional and deep Raman spectroscopy. The application of 
spectroscopic techniques and the advancing of individual parameters of their 
development have been assessed for three different cancer types, prostate, 
breast and bladder cancer. 
  In the case of prostate and breast cancer, we studied: 
 the Raman signal spatial distribution of potentially malignant features 
(calcifications)  in different phantoms 
 the origin and detection limits of Raman scattering of the calcifications in 
prostate and breast phantoms   
 
  In terms of detection limits, our results confirmed the feasibility of acquiring 
sufficient signal to detect malignancy over the volume of an average prostate 
gland, using only a couple of transmission measurements. In terms of Raman 
signal origin, it has been demonstrated that the highest signals are likely to be 
obtained from nearer surface lesions (either on collection or illumination side) 
than those at middle depth. However, relative signals can be still as high as 40-
60% for ‘’lesions’’ found in the centre of organs, compared to those found towards 
the edges.  
  During the measurements of human tissue (TURPs, biopsies) acquired from the 
local tissue bank, the limitations of deep Raman spectroscopy on prostate tissue 
were highlighted. These included: 
 the presence of fluorescence (TURP samples) 
 the need for a sufficient sample volume (prostate biopsies).  
 
  At the same time, we demonstrated the feasibility of collecting Raman photons 
from samples which lack the limitations above, by proving that prostate gland is 
not intrinsically fluorescent at 830 nm and hence a sufficient volume of it can 
be efficiently studied by means of deep Raman spectroscopy. 
  Further improvement of the deep Raman approach was explored in terms of 
signal enhancement, by introducing the ‘’photon diode’’ element. The effect of the 
photon diode has been studied in a wide range of optical properties, showing: 
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 a signal enhancement between ×1 and ×2.4 
 considerable signal enhancement for high scattering and low 
absorption levels  
 certain types of tissue (fat, bone) benefit more compared to other types 
(stomach, aorta) 
 the signal enhancement levels attenuate as the location (depth) of artificial 
‘’malignant lesions’’ in the phantoms increases.  
  The same ‘’photon diode’’ concept has also been employed to study another 
important feature in clinical diagnosis, the inclusion (or calcification) depth. A 
novel approach for depth prediction was explored while the ‘’malignant feature’’ 
was buried in different depths of tissue phantoms and the signal enhancement 
ratios achieved with the photon diode were used to predict the depth of the 
‘’calcification’. The depth prediction has specifically shown to be successful in 
samples where no absorption is present, rendering this application suitable 
for pharmaceutical tablets were minimum absorption is present. 
  In the case of bladder cancer, potential diagnosis was also assessed by means 
of Raman microscopy in healthy and malignant urine samples. The main 
discriminant feature was found to be the urea Raman peak shift which depends 
on the interactions between urea and the surrounding molecules. Based on this 
spectral feature, multivariate analysis on the urine measurements have indicated 
a sensitivity of 73% and a specificity of 80% in the discrimination between the 
two pathology groups. 
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Appendix 1- Local ethical approval  
 
Local ethical approval for TURP chips 
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Local ethical approval for prostate biopsies 
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